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Abstract 
 
Cytosolic sensor proteins like NLRP1 (NOD-like receptor containing a pyrin 
domain 1) play a fundamental role in mediating innate immunity. Upon activation 
they form signalling hubs that recruit the adaptor protein ASC (apoptosis-
associated speck-like protein containing a CARD) and procaspase-1 to form an 
inflammasome. Procaspase-1 is in turn activated and processes the cytokines 
pro-IL-1b and pro-IL-18 as well as the pore-forming protein GSDMD (Gasdermin 
D) into their mature forms, resulting in inflammation and pyroptosis. When 
dysregulated, inflammasomes are often involved in the development of 
autoinflammatory diseases. Therefore, it is of major interest to understand the 
molecular mechanisms underlying the regulation of inflammasome sensors. 
A biochemical approach was taken to investigate the structural basis of 
inflammasome formation. Producing and characterizing recombinant protein of 
separate domains of NLRP1 demonstrated that NLRP1 autoinhibition is not 
mediated by direct intramolecular interaction of the N-terminal PYD with other 
domains. Additionally, the full-length NLRP1 protein was characterized by 
biochemical and structural means. Size exclusion chromatography indicated that 
recombinant NLRP1 forms oligomers in solution. Small-angle X-ray scattering 
confirmed this observation and further allowed the calculation of a molecular 
envelope of the NLRP1 oligomer. The oligomeric state of the protein was 
estimated to be hexameric, based on the particle volume derived from the 
molecular envelope. 
Furthermore, a highly sensitive reversed-phase HPLC assay was employed to 
measure the ATP hydrolysis activity of recombinant full-length NLRP1. In contrast 
to previous reports, we found that NLRP1 hydrolyses ATP at a low rate. The 
physiological relevance of this activity was investigated by taking a mutational 
approach in functional assays in cells measuring inflammasome activation. 
Substitution of residues identified by computational analysis of the nucleotide 
binding site suggested that ATP hydrolysis is involved in maintaining NLRP1 in 
an autoinhibited state. 
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A similar approach was taken to investigate the involvement of direct 
modifications of the NLRP1 protein in regulating inflammasome activity. 
Functional effects of a single nucleotide polymorphism, which leads to the amino 
acid substitution M1184V in the NLRP1 protein and is described to increase 
autoproteolysis in the NLRP1 FIIND domain, were investigated. The results 
showed that increased cleavage can amplify or inhibited activation of NLRP1 in 
the context of different stimuli. Moreover, a potential phosphorylation within the 
CARD domain was identified as another essential modification regulating the 
activity of NLRP1. 
Overall, this work provides new insights into the role of structural mechanisms, 
ATP as a cofactor and posttranslational modifications in regulating NLRP1 
inflammasome activity. 
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1. Introduction 
 
1.1 The innate immune system 
 
Multicellular organisms have developed a multitude of mechanisms to defend 
themselves against infectious pathogens - the immune system. The immune 
system of vertebrates is commonly divided into the innate immune system and 
the adaptive immune system (Medzhitov and Janeway, 1997; Tosi, 2005). The 
innate immune system has developed earlier than the adaptive immune system 
and can therefore be regarded as phylogenetically primitive compared to the 
adaptive immune system. Nevertheless, the innate immune system plays an 
important role in defending the host against pathogens as it is required to trigger 
an immune response rapidly after infection. Furthermore, it is described to be 
involved in inducing adaptive immunity (Beutler, 2004; Tosi, 2005; Kumar et al., 
2011). 
Anatomical barriers like the skin, mucosal membranes and epithelial tissue 
form a first line of defence and are parts of the innate immune system (Carrillo et 
al., 2017). Pathogens that have passed this first line of defence and have invaded 
the host, can be detected and cleared by humoral and cellular mechanisms. Apart 
from pathogen-derived material, cell debris derived from damaged tissue can 
also be recognised and cleared by these mechanisms (Carrillo et al., 2017). 
Humoral components of the innate immune system include molecules that can 
sense and eliminate pathogens, like the complement proteins secreted in the liver 
and by local macrophages and monocytes (Ricklin et al., 2010). This humoral 
response can act cell-independent. However, it is often mediated in cooperation 
with a cellular innate immune response (Beutler, 2004; Bottazzi et al., 2010; 
Ricklin et al., 2010). Different cell types are part of the innate immune system and 
are typically derived of myeloid precursors. These cell types include granulocytes 
(eosinophils, neutrophils, basophils, mast cells), monocytes, macrophages and 
dendritic cells (DCs). These cell types commonly mediate an immune response 
through phagocytosis of pathogen- or damage-derived material and the secretion 
of chemokines and cytokines to attract and stimulate other immune cells (Lacy, 
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2015). Some lymphoid cells, such as natural killer cells (NK), natural killer T-cells 
(NKT) and innate lymphoid cells (ILCs) have roles in innate immunity as well 
(Carrillo et al., 2017). On a molecular level, germline-encoded receptors, termed 
pattern recognition receptors (PRR), are expressed on the surface or in the 
cytosol of these and other cells to facilitate the specific recognition of a broad 
range of pathogens. Thus, these receptors play an essential role in inducing an 
inflammatory innate immune response (Takeuchi and Akira, 2010; Kumar et al., 
2011). Taken together, the main goals of the innate immune system are to 
prevent infection through physical barriers, to sense and inhibit the spread of and 
eventually clear an infection or damaged tissue via a humoral and cellular 
immune response and to induce adaptive immunity by cytokine release and 
antigen presentation to T- and B-cells (Carrillo et al., 2017). 
In contrast to the innate immune system, adaptive immunity essentially relies 
on receptors that are generated in somatic mechanisms upon antigen 
presentation and thus possess a more diverse range of pathogen-specificity. This 
is because the specificity is not predetermined but evolved during the somatic 
maturation process according to the target (antigen) presented and can therefore 
be different for each individual organism. A consequence of somatic maturation 
of these receptors is a delayed response of the adaptive immune system 
compared to the innate immune system (Medzhitov and Janeway, 1997; Tosi, 
2005). Out of the different innate immune cell types, DCs are specialised in 
antigen-presentation and therefore form an important link between innate and 
adaptive immunity. As mentioned above, innate immune cells, like DCs, take up 
antigen by phagocytosis upon activation. Activated DCs can then migrate to 
lymph nodes to present antigen to T- and B-cells and induce adaptive immunity 
(Merad et al., 2013). 
 
1.2 Pattern recognition receptors (PRRs) 
 
Innate immune receptors have evolved to recognise conserved pathogenic 
patterns, also called pathogen-associated molecular patterns (PAMPs). These 
receptors are therefore referred to as pattern recognition receptors (PRRs). Apart 
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from PAMPs, PRRs are also reported to recognise molecular parts of cell debris 
derived from damaged tissue, which has been termed damage-associated 
molecular patterns (DAMPs) (Medzhitov and Janeway, 1997; Polly Matzinger, 
2002). More recently, it has been proposed that homeostasis-altering molecular 
processes (HAMPs) pose another pattern that can be recognised by the innate 
immune system (Liston and Masters, 2017). In the case of HAMPs, the innate 
immune receptor responds to an alteration in cellular homeostasis rather than a 
certain molecule or parts of a molecule. 
PRRs can be distinguished in regards to their cellular localization. C-type lectin 
receptors (CLRs) and Toll-like receptors (TLRs) reside in the cellular or in 
endolysosomal membranes. Retinoic acid inducible gene I (RIG-I) -like receptors 
(RLRs) and nucleotide-binding oligomerization domain-containing (NOD) -like 
receptors (NLRs) are localized in the cytoplasm of the cell (Takeuchi and Akira, 
2010). PRRs are typically expressed in innate immune cells like macrophages 
and DCs, but also in non-immune cells (Takeuchi and Akira, 2010; Carrillo et al., 
2017). Together, this broad range of receptors is able to detect a large and 
diverse set of molecular patterns and therefore form an essential part of the 
innate immune system (Bardoel and Van Strijp, 2011). Upon activation these 
receptors mainly induce the expression of key molecules such as tumour 
necrosis factor (TNF), interleukin-6 (IL-6), interleukin-1b (IL-1b), and type 1 
interferons (e.g. INFa, INFb), which in turn mediate an antimicrobial and 
inflammatory immune response (Takeuchi and Akira, 2010). 
 
1.2.1 Transmembrane PRRs 
 
1.2.1.1 C-type lectin receptors (CLRs) 
 
CLRs are part of the C-type lectin-like domain (CTLD) protein superfamily, which 
constitutes a diverse group of membrane proteins in multicellular organisms. 
CTLD proteins have been reported to have diverse functions (Zelensky and 
Gready, 2005). The term “C-type lectin” originates from the distinction between 
calcium dependent (C-type) and calcium independent carbohydrate binding 
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proteins (lectin) (Zelensky and Gready, 2005). CLRs are ubiquitously expressed 
and found in a diverse set of organisms like humans and sponges (Gundacker et 
al., 2001; Zelensky and Gready, 2005). 
Typically, CLRs are composed of an extracellular domain involved in 
carbohydrate binding, a transmembrane domain, and in some cases an 
intracellular domain involved in mediating downstream signalling (Kingeter and 
Lin, 2012). The extracellular domain consists of a stalk and a carbohydrate-
recognition domain (CRD). Structurally, the CRD is formed by two loops, which 
are stabilized through disulphide-bonds formed by highly conserved cysteines 
(Zelensky and Gready, 2005). Other conserved residues form the hydrophobic 
core of the domain fold and constitute the Ca2+ binding site (Drickamer and 
Taylor, 2015). 
The family of CLRs can be grouped into two distinct clusters, the Dectin-1 
cluster and the Dectin-2 cluster. This clustering is based on differences in the 
functionality of the extracellular and cytoplasmic domains and downstream 
signalling pathways (Kanazawa et al., 2004; Kanazawa, 2007; Huysamen and 
Brown, 2008; Graham and Brown, 2009). While members of the Dectin-1 cluster 
are described to bind mainly b-glucans with their CRD, members of the Dectin-2 
cluster are reported to bind a-mannans (Brown and Gordon, 2001; Brown et al., 
2002; McGreal et al., 2006). Dectin-1 molecules further contain a cytoplasmic 
signal transduction domain, harbouring immunoreceptor tyrosine-based 
activation motifs (ITAMs) or inhibitory motifs. Depending on the nature of the 
signal transduction motifs, ligand binding to the receptor results in activation or 
inhibition of transcription factors (Kingeter and Lin, 2012). A main difference 
between Dectin-1 and Dectin-2 molecules is that Dectin-2 molecules only contain 
a very short cytoplasmic domain uncapable of mediating signal transduction. To 
facilitate signal transduction, Dectin-2 receptors form heterodimers with the FcRg 
chain (Cao et al., 2007; Yamasaki et al., 2008). Binding of the two molecules is 
facilitated through a positively charged residue in the transmembrane domain of 
the Dectin-2 type receptor (Kingeter and Lin, 2012). Binding of pathogen 
carbohydrates has been shown to be dependent on homo-oligomer formation of 
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the CLRs. Hetero-oligomer formation as for the Dectin-2/FcRg chain dimer, adds 
to the complexity of CLR mediated signalling (Drickamer and Taylor, 2015). 
The involvement of CLRs in inducing an immune response has been discussed 
extensively in the literature. In this context they have been described to induce 
endocytosis, phagocytosis, anti-microbial as well as inflammatory and anti-
inflammatory responses (Hoving et al., 2014). Their ability to recognize different 
fungi is well characterized. However, CLRs are also described to recognise 
viruses, bacteria and parasites and have further been shown to be involved in 
autoimmunity, homeostasis and the recognition of dead and cancerous cells 
(Hoving et al., 2014; Dambuza and Brown, 2015). 
A key mediator in many downstream signalling pathways of Dectin-1 type and 
Dectin-2 type CLRs is spleen tyrosine kinase (SYK). SYK binds to the 
cytoplasmic signal transduction domains of the CLR or its interaction partner and 
orchestrates the formation of a complex of CARD9, B cell lymphoma 10 (Bcl10) 
and mucosa-associated lymphoid tissue lymphoma translocation protein 1 
(Malt1), ultimately resulting in activation of NF-kB and the expression of 
inflammatory cytokines (Kingeter and Lin, 2012; Hoving et al., 2014). Another 
common feature of PRR signalling is the cross-talk between different PRR 
pathways. For instance, functionality of the inflammasome adaptor protein 
apoptosis associated speck-like protein-containing a CARD (ASC) depends on 
tyrosine phosphorylation in a SYK dependent manner. As described above, SYK 
can be activated through CLRs, while ASC is an important factor in NLR signalling 
(Hara et al., 2013; Hoving et al., 2014). Moreover, the recognition and 
subsequent immune response to zymosan, a part of fungal cell wall components, 
has been shown to depend on the interplay of CLRs and TLRs (Gantner et al., 
2003). 
 
1.2.1.2 Toll-like receptors (TLRs) 
 
Out of the different groups of PRRs, TLRs are the most ancient ones and have 
the widest range of pathogen recognition (Nie et al., 2018). The term “Toll-like” 
was coined in accordance with the first Toll-gene identified in Drosophila 
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melanogaster. In 1985 Christiane Nüsslein-Volhard, a scientist at the Max Planck 
Institute in Tübingen (Germany), found that a mutation in this gene resulted in 
deformed fly larvae. When she first made this discovery she exclaimed “Das ist 
ja toll!” translating to “That’s great!” (Hansson and Edfeldt, 2005). It took 10 more 
years until the involvement of the Toll-gene in the immune response was 
identified (Hoffmann et al., 1996). 
Since then, 10 members of the Toll-like receptor family have been identified in 
humans and 13 members have been identified in mice (Kawai and Akira, 2007). 
TLRs are expressed in different cells like innate immune cells (e.g. macrophages, 
dendritic cells) or non-immune cells (e.g. fibroblasts, epithelial cells) and can be 
distinguished by their cellular localization. Some TLRs locate to the cell surface, 
like TLR1, TLR2, TLR4, TLR5, TLR6 and TLR10, while others are located in the 
endosome including TLR3, TLR7, TLR8, TLR9, TLR11, TLR12 and TLR13 
(Kawasaki and Kawai, 2014). 
Structurally, all TLRs share a similar modular domain architecture with an 
extracellular domain, a transmembrane domain and an intracellular domain. The 
extracellular portion of TLRs is comprised of 16-28 leucine-rich repeats (LRRs) 
(Matsushima et al., 2007). One LRR is comprised of about 24 amino acids in 
length and folds into a secondary structure element consisting of a short b-strand, 
a turn and a more variable region (Park et al., 2015). Multiple consecutive LRRs 
typically fold into a bent, horseshoe-like shape. Conserved hydrophobic amino 
acid residues within the b-sheet of each repeat form the concave inner core of 
the overall fold (Gay and Gangloff, 2007). In TLRs, the above mentioned more 
variable region of the LRR forms parallel 310 helices, which comprise the convex 
outer surface of the overall LRR fold (Jin and Lee, 2008). The transmembrane 
domain of TLRs is comprised of a single a-helix. The amino acid sequence of this 
helix does not show obvious sequence conservation between TLRs apart from 
hydrophobicity. Nevertheless, the transmembrane region as well as a small 
portion of the intracellular part of the protein, the juxtamembrane sequence, are 
thought to be critically involved in receptor activation (Jin and Lee, 2008). The 
intracellular domain shares significant homology with that of interleukin-1 
receptors and is therefore also referred to as Toll/interleukin-1 receptor (TIR) 
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domain. The cytoplasmic domain adapts an overall b/a-fold. Its core is comprised 
of a parallel b-sheet composed of five b-strands. This b-core is surrounded by 
five a-helices (Akira and Hemmi, 2003; Jin and Lee, 2008). 
Functionally, the extracellular LRR is required for the recognition of PAMPs or 
DAMPS by direct binding of pathogen or damage-derived molecules. The 
variable residues in the inner concave surface of the LRR determine the 
specificity of the corresponding receptor (Gay and Gangloff, 2007). Thus, not only 
the number of LRRs but also and more importantly the variable residues present 
in the b-sheet of each repeat can be varied and combined in sheer endless ways. 
This enables the formation of highly diverse receptors with specificity for different 
pathogenic molecules. Ligands of TLRs include bacterial lipopolysaccharide 
(LPS), glycolipids or lipoproteins (TLR1/TLR2/TLR4), fungal zymosan (TLR2), 
double stranded RNA (TLR3) or viral and bacterial DNA (TLR9), to only name a 
few (Akira and Hemmi, 2003). The cytoplasmic domain of TLRs is, similar to 
CLRs, involved in signal transduction via various pathways. Also similar to CLRs 
and receptor tyrosine kinases, efficient signalling through TLRs requires the 
dimerization or oligomerization after ligand recognition. This oligomerization is 
facilitated through the cytoplasmic TIRs and mainly mediated by electrostatic 
interaction between these domains (Gay and Gangloff, 2007; Jin and Lee, 2008). 
After oligomerization, TLR signalling is facilitated by a set of adapter proteins 
containing a TIR domain including MyD88 (Myeloid differentiation primary 
response 88), TRIF and TRAM. MyD88 signalling is utilised by all TLRs, except 
TLR3 which signals through TRIF and TLR4, which can signal through MyD88 
and TRIF (Medzhitov et al., 1998; Kawai and Akira, 2007). Ultimately, TLR 
signalling leads to the activation of the transcription factors NF-kB and AP-1 and 
mitogen-activated protein kinase (MAPK) pathways (Kawai and Akira, 2007; Lim 
et al., 2007; Kawasaki and Kawai, 2014). Activation of these pathways induces 
the expression of inflammatory cytokine genes. TRIF is an adaptor recruited by 
TLR3 and TLR4 to activate IRF3, NF-kB and MAPKs through an alternative 
pathway, again resulting in the induction of inflammatory cytokine genes and also 
type 1 interferon (IFN) genes (Kawasaki and Kawai, 2014). 
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1.2.2 Cytoplasmic PRRs 
 
1.2.2.1 RIG-I-like receptors (RLRs) 
 
RLRs were named after the retinoic-acid inducible gene I (RIG-I), the most 
extensively studied receptor in this group. Apart from RIG-I itself, the mammalian 
RLR family includes the receptors MDA5 (melanoma differentiation associated 
factor 5) and LGP2 (laboratory of genetics and physiology 2) (Loo and Gale, 
2011). RLRs are cytoplasmic DExD/H-box containing helicases, which detect 
patterns in viral RNA (Yoneyama et al., 2004; Loo and Gale, 2011). 
The modular domain architecture is similar for all three members of the RLR 
family and is typically composed of two N-terminal caspase activation and 
recruitment domains (CARD), central helicase domains (Hel1 and Hel2) and an 
insertion domain in helicase domain 2 (Hel2i), a bridging/pincer domain and a C-
terminal domain (CTD) (Loo and Gale, 2011; Yoneyama et al., 2015). CARDs 
are a subfamily of the death domain superfamily. These death domains typically 
form a six-helix bundle fold and are commonly involved in mediating protein-
protein interactions (Park, Lo, et al., 2007). Of note, LGP2 lacks both N-terminal 
CARD domains. 
The helicase domains Hel1, Hel2 as well as the helicase insertion domain in 
Hel2 and the CTD are involved in the recognition and binding of viral dsRNA. For 
RIG-I, a structure of the ligand-bound state showed that these domains 
completely surround the dsRNA. This fold is supported by a complex network of 
interactions. The elbow-shaped bridging domain is composed of an a-helix and 
constitutes an important mechanical connection between Hel1, Hel2, and the 
CTD (Luo et al., 2011; Kolakofsky et al., 2012). In the ligand-free state, Hel2i is 
involved in keeping the protein in an autoinhibited state by binding to one of the 
N-terminal CARD domains via hydrophobic and electrostatic interactions 
(Kolakofsky et al., 2012). Moreover, an ATP binding site is formed at the interface 
of Hel1 and Hel2 of RIG-I. Especially Hel1 harbours typical nucleotide binding 
and hydrolysis motifs like the Walker A and Walker B motifs (also see chapter 
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1.4) (Kolakofsky et al., 2012; Lässig et al., 2015). Nucleotide hydrolysis has been 
shown to determine dsRNA specificity of the receptor, preventing the recognition 
of self-RNA (Lässig et al., 2015; Baek et al., 2016).  
As mentioned above, RLRs are important factors in inducing an immune 
response to viral infections by sensing dsRNA of viral origin. Both, RIG-I and 
MDA5, have been described to differentially recognize and bind viral nucleic 
acids that are different in length and originate from different viruses. Thus, these 
receptors have evolved to detect a broad range of RNA and DNA viruses, like 
Paramyxoviridae, Picornaviridae and Flaviviridae (Kato et al., 2008; Loo and 
Gale, 2011). Upon binding of viral RNA, RIG-I and MDA5 recruit the adaptor 
protein mitochondrial antiviral signalling (MAVS) via CARD-CARD interactions. 
In turn, MAVS orchestrates the assembly of a large signalling complex, also 
referred to as the signalosome. This complex signals via multiple pathways to 
stimulate the expression of type I and type III IFN as well as ISGs (interferon 
stimulated genes). Expression of these genes ultimately results in an 
inflammatory immune response to control and eventually clear the viral infection 
(Loo and Gale, 2011; Yoneyama et al., 2015). 
 
1.2.2.2 NOD-like receptors (NLRs) 
 
The nucleotide-binding oligomerization domain (NOD) -like receptor family is 
comprised of 23 proteins in humans and at least 34 proteins in mice (Franchi et 
al., 2009). The common denominator of NLRs is the central NACHT (domain 
present in NAIP, CIITA, HET-E and TP-1) domain, also termed NOD/NBD 
(nucleotide-binding oligomerization domain). Most NLRs present with a tripartite 
domain architecture, with an effector domain located N-terminally of the NACHT 
domain and an LRR domain on the C-terminus (Shaw et al., 2008). 
The family of NLRs can be further divided into four subfamilies according to 
their N-terminal effector domain: NLRAs, NLRBs, NLRCs and NLRPs (Meunier 
and Broz, 2017). CIITA (class II, major histocompatibility complex, 
transactivator), belongs to the subfamily of NLRAs, which contain an N-terminal 
CARD domain and an acidic transactivation (AD) domain. NLRBs harbour a 
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baculo-virus inhibitor of apoptosis repeat (BIR)-like domain as their effector 
domain and are commonly referred to as NAIPs (neuronal apoptosis inhibitory 
proteins). While humans only have a single NAIP gene, mice have a total of seven 
NAIPs (Franchi et al., 2009). The subfamily of NLRCs includes NOD1, NOD2, 
NOD3, NLRC4, NLRC5 and NLRX1. Most NLRCs feature an N-terminal CARD 
domain as their effector domain (Meunier and Broz, 2017). The fourth subfamily, 
the NLRPs, is comprised of 14 proteins (NLRP1 - NLRP14), which all contain a 
pyrin domain (PYD) at their N-terminus (Tschopp et al., 2003). As CARD 
domains, PYD domains belong to the death domain superfamily, which 
commonly assemble into a six helix bundle fold and mediate protein-protein 
interactions via homotypic PYD-PYD or CARD-CARD interactions (Park, Lo, et 
al., 2007; Meunier and Broz, 2017). 
NLRs as well as other NACHT domain containing proteins are described to 
adapt an autorepressed, closed conformation in the cytoplasm of the cell. Upon 
ligand binding, a conformational change is induced, resulting in a transition to an 
open, active conformation and finally oligomerization of the protein. NLR 
oligomerization is described to be mainly facilitated by the NACHT domain (Danot 
et al., 2009). The NACHT domain can be divided into four subdomains, the 
nucleotide binding domain, two helical domains (HD1, HD2) and a so called 
winged helix domain (WHD), which is located in between the two helical domains. 
The NBD harbours conserved motifs for nucleotide binding, the Walker A and 
Walker B motifs. Other motifs involved in nucleotide binding and hydrolysis, the 
sensor 1 and sensor 2 motifs, are located in the HD1 and WHD subdomains 
(Macdonald et al., 2013). Containing these features, NLRs can be categorized as 
members of the STAND (signal transduction ATPases with numerous domains) 
clade of AAA+ ATPases (ATPases associated with various cellular activities) 
(Macdonald et al., 2013). The superfamily of AAA+ ATPases and the role of 
protein oligomerization in mediating activity will be described in more detail in 
Chapter 1.4. 
For mouse NLRC4, it has been shown by crystallographic structure analysis 
of the NACHT-LRR domains that in the closed, ADP-bound conformation, the 
LRR domain folds over the NACHT domain. Thereby, the LRR covers one side 
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of the NACHT domain, blocking oligomerization and keeping the protein in an 
autoinhibited state (Hu et al., 2013; Hu and Chai, 2016). However, a crystal 
structure of the rabbit NOD2 NACHT and LRR domains in the closed ADP-bound 
state revealed that NOD2 LRR is pointed outwards and therefore not blocking the 
NACHT domain. This shows that despite high similarities in their modular domain 
architecture, regulation of NLR activity is likely to be achieved through different 
mechanisms for different NLRs (Maekawa et al., 2016). 
LRR domains are commonly described to be involved in ligand recognition and 
binding for TLRs (see above) and also NLRs. For instance, murine NAIP5 directly 
recognizes and binds bacterial flagellin with parts of its LRR domain and also 
parts of the helical domain 2, a subdomain of the NACHT domain (Meunier and 
Broz, 2017; Tenthorey et al., 2017). Furthermore the LRR has been shown to aid 
in oligomer formation for NLRC4 (Moghaddas et al., 2018). The key domain for 
oligomerization and self-assembly however is the NACHT domain (Proell et al., 
2008; Maharana et al., 2018). 
As mentioned above, signalling occurs through the N-terminal effector 
domains and results in the activation of a multitude of pathways. Similar to TLRs, 
some NLRs, like NOD1 and NOD2, signal through pathways amounting in the 
induction of NF-kB and MAPK pathways, ultimately resulting in the expression of 
antimicrobial and inflammatory mediators like TNF, IL-6 and IL-1b (Chen et al., 
2009; Franchi et al., 2009). In contrast, another group of NLRs differs significantly 
from other PRRs in regards to their signalling and downstream targets. Among 
others, NLRP1, NLRP3 and NLRC4 are described to form large signalling 
platforms, termed inflammasomes (Martinon et al., 2002). In this signalling 
pathway the active, oligomerized NLR recruits the adaptor protein ASC through 
either PYD-PYD or CARD-CARD interactions. In turn, ASC assembles into large 
oligomeric filaments, so called specks, and recruits procaspase-1 (Dick et al., 
2016). Procaspase-1 is the inactive precursor of caspase-1 and needs to be 
proteolytically cleaved to become active. Through the accumulation of 
procaspase-1 molecules on ASC specks, procaspase-1 dimers are formed to 
allow intermolecular cleavage of the two associated molecules, finally resulting 
in the release of active caspase-1 (Elliott et al., 2009). Active caspase-1 is a key 
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inflammatory protein as it directly cleaves the inactive pro-forms of the 
inflammatory cytokines IL-1b and IL-18 into their mature forms and also cleaves 
gasdermin D (GSDMD). Cleaved GSDMD possesses pore-forming activity, and 
can induce a rapid form of cell-death, which was termed pyroptosis (Martinon and 
Tschopp, 2005; Place and Kanneganti, 2018). Interestingly, cleavage of IL-1b 
and IL-18 links NLR signalling to pathways similar to TLR signalling, since the 
respective transmembrane receptors for both cytokines (IL-1R, IL-18R) harbour 
an intracellular TIR domain, which upon ligand (i.e. cytokine) binding can recruit 
MyD88, ultimately resulting in the induction of NF-kB (Martinon and Tschopp, 
2005). 
 
1.2.2.3 Other cytosolic PRRs 
 
Other important intracellular PRRs that are not classified as RLRs or NLRs are 
AIM2 (absent in melanoma 2), Pyrin (encoded by the gene MEFV – 
Mediterranean fever), cGAS (cyclic GMP-AMP synthase) and STING (stimulator 
of interferon genes). Both, AIM2 and Pyrin, are reported to form inflammasomes 
similar to some NLRs (Guo et al., 2015). 
AIM2 has been shown to be involved in sensing pathogen-derived DNA or self-
DNA released into the cytosol from a disintegrated nucleus or mitochondria (Man 
et al., 2016). It consists of an N-terminal PYD and a C-terminal HIN 
(hematopoietic expression, interferon-inducible nature, and nuclear localization) 
domain. The HIN domain is involved in directly binding DNA, while the PYD is 
involved in inflammasome formation by facilitating protein-protein interactions 
with the adaptor protein ASC (Lugrin and Martinon, 2018). As for other (NLR) 
inflammasomes, binding of ASC induces speck formation and subsequent 
procaspase-1 activation, resulting in the cleavage of the proinflammatory 
cytokines pro-IL-1b and pro-IL-18 and the pore-forming protein GSDMD 
(Hornung et al., 2009; Fernandes-Alnemri et al., 2009; Liu et al., 2016). AIM2 has 
been shown to play a role in autoinflammatory diseases in the context of self-
DNA recognition (Jakobs et al., 2015). However, no gain-of-function mutations 
have been identified for AIM2 itself (Lugrin and Martinon, 2018). 
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Similar to AIM2, Pyrin is also described to form an inflammasome. The modular 
domain architecture of Pyrin presents with an N-terminal PYD, a central Bbox 
and coiled-coil domain and a C-terminal B30.2 domain. Interestingly, its domain 
architecture resembles that of E3 ligases, with the typical ring domain in ligases 
being switched for the PYD (Heilig and Broz, 2018). As for AIM2 and other NLR 
inflammasomes, the PYD is involved in ASC binding and inflammasome 
formation. While different functions have been proposed, the role of the B30.2 
domain has not been completely clarified yet (Heilig and Broz, 2018). Pyrin is 
described to indirectly sense pathogen-derived toxins that modulate the activity 
of the small GTPase RhoA (Ras homolog family member A) (Park et al., 2016). 
Inhibition of RhoA by bacterial toxins results in loss of PKN1/2 (protein kinase N) 
activity. These kinases directly phosphorylate pyrin, which is required to maintain 
pyrin autoinhibition. More precisely, phosphorylation mediates binding of 14-3-3 
proteins that keep pyrin in an autoinhibited conformation (Park et al., 2016; 
Masters et al., 2016). Activation of Pyrin results in inflammasome formation and 
release of mature IL-1b and IL-18 as well as GSDMD cleavage and pyroptosis 
(Broz and Dixit, 2016; Heilig and Broz, 2018). Multiple gain-of-function mutations 
have been reported for Pyrin, causing autoinflammatory diseases. Some of these 
mutations are reported to disrupt 14-3-3 binding, resulting in autoactivation of the 
protein and a disease pyrin-associated autoinflammation with neutrophilic 
dermatosis (PAAND) (Masters et al., 2016; Moghaddas et al., 2017). The 
mechanisms of other mutations involved in causing familial mediterranean fever 
(FMF) are not yet understood (Alghamdi, 2017). 
As AIM2, the cGAS protein has been shown to directly sense cytosolic dsDNA 
longer than 30 bp. cGAS consists of a poorly conserved and unstructured N-
terminus and a highly conserved C-terminus. The C-terminus is composed of an 
NTase (nucleotidyltransferase) core domain and a Mab21 domain. The Mab21 
domain further contains a zinc-ribbon domain (Wu et al., 2014). The NTase 
domain has enzymatic activity to synthesize the cyclic di-nucleotide (CDN) cyclic-
GMP-AMP (cGAMP). CDNs like cAMP can also be of direct pathogenic origin as 
they are secreted by certain pathogens like bacteria (e.g. Listeria 
monocytogenes) (Woodward et al., 2010; Lam et al., 2014). One CDN molecule, 
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which is either generated upon sensing of cytosolic dsDNA by cGAS or of 
pathogenic origin, can induce a complex trafficking event by directly binding to 
two molecules of STING (Gao et al., 2013; Gao et al., 2014). STING is anchored 
in the membrane of the endoplasmic reticulum with several transmembrane 
regions. The cyclic di-nucleotide binding site is located in the cytoplasm and is 
formed by a STING dimer (Wu et al., 2014). Binding of CDNs induces a structural 
change of the STING dimer, allowing for an interaction with TANK binding kinase 
1 (TBK1) (Ishikawa et al., 2009). The complex of STING and TBK1 is trafficked 
to the perinuclear Golgi via processes that resemble autophagy, relocating the 
complex to endolysosomal compartments of the cell (Ishikawa et al., 2009). Here, 
TBK1 activates the transcription factors IRF3 and NF-kB. Activation of these 
transcription factors induces the expression of cytokines and proteins belonging 
to the type-1 INF family, resulting in an inflammatory immune response (Shu et 
al., 2014; Barber, 2015). In the cGAS/STING pathway, two different sensing 
mechanisms converge. cGAS can induce an immune response through STING 
upon dsDNA binding, which can be self-DNA or pathogen-derived DNA. As 
mentioned above, STING can further sense CDNs directly derived from 
pathogens. Interestingly, the cGAS/STING pathway is described to be 
independent of other PRRs activated by dsDNA, like TLR9 and AIM2 (Barber, 
2015). This highlights the diversity of mechanisms used by the innate immune 
system to recognize PAMPs and DAMPs. As for other innate immune sensors, 
dysregulation of cGAS/STING leads to autoinflammatory disease. For instance, 
activating variants of STING are reported to cause an autoinflammatory disease 
called STING-associated vasculopathy with onset in infancy (SAVI) (Liu et al., 
2014). 
 
1.3 The current model of inflammasome activation 
 
Inflammasomes are large signalling platforms comprised of oligomerized PRRs, 
the adaptor protein ASC and caspase-1. NLR proteins (NLRP1, NLRP2, NLRP3, 
NLRP6, NLRP12, NLRC4) as well as non-NLR proteins (AIM2, IFI16, Pyrin) have 
been shown to be involved in the formation of these signalling complexes 
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(Rathinam et al., 2012; Walsh et al., 2014). The common model of how 
inflammasome activation occurs is described as a two-checkpoint mechanism 
(Figure 1.1). In a first step, also referred to as signal 1 or priming, microbial TLR 
ligands induce the activation of NF-kB, resulting in the transcription and 
translation of the cytokine pro-IL-1b and the inflammasome sensor itself 
(Bauernfeind et al., 2010; Walsh et al., 2014). The second step, termed signal 2, 
refers to the specific recognition of PAMPs, DAMPs or HAMPs through the 
respective inflammasome sensor molecule (Walsh et al., 2014). Activation by 
signal 2 results in oligomerization of the sensor molecule, providing a recruitment 
hub for the adaptor protein ASC and finally procaspase-1 (Martinon and Tschopp, 
2005). Active caspase-1 is described to induce an inflammatory immune 
response by processing pro-IL-1b and pro-IL-18 into their active forms by 
proteolytic cleavage. Moreover, caspase-1 cleaves GSDMD, which can in turn 
induce pyroptosis, a rapid inflammatory form of cell death (Sollberger et al., 2014; 
Liu et al., 2016). 
The ability of inflammasomes to trigger the release of cytokines also links this 
pathway to other parts of the immune system. For instance, IL-1b has a role in 
tumor metastasis and blood vessel formation. Furthermore, it potently induces IL-
6 production, which is directly involved in linking innate and adaptive immunity. 
IL-18 can act on different cells of the immune system, namely Th1 and Th2 cells, 
depending on the presence or absence of other cytokines, particularly IL-12 
(Dinarello, 2009). 
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Figure 1.1: Current model of inflammasome activation 
Schematic depiction of the current model of inflammasome activation. Upon 
activation of TLR signalling, which can be induced by pathogen-derived stimuli 
like bacterial LPS (Signal 1), NF-kB induces the expression of inflammasome 
sensor molecules (e.g. NLRP1, NLRP3, NLRC4, AIM2) and the pro-forms of IL-
1b and IL-18. The sensor molecules are localized in the cytosol as autoinhibited 
monomers. A conformational change is induced by a sensor-specific stimulus 
(e.g. bacterial flagellin for NLRC4), allowing the sensor molecules to oligomerize 
(Signal 2). The oligomerized sensors provide a platform to recruit the adapter 
protein ASC and procaspase-1 and form the inflammasome complex. In this 
complex, procaspase-1 becomes active through proteolytic cleavage. Active 
caspase-1 can process pro-IL-1b and pro-IL-18 into their mature forms. 
Furthermore, GSDMD is cleaved, resulting in the release of the pore-forming N-
terminus of the protein, inducing pyroptosis. Pyroptosis and the release of mature 
IL-1b and IL-18 stimulate an inflammatory immune response. Note the depicted 
stimulus for NLRP1, anthrax lethal toxin (LT), only activates certain variants of 
rodent but not human NLRP1. Adapted from Walsh et al. 2014. 
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In recent years, a different mechanism, termed the non-canonical inflammasome 
pathway, was described to induce pyroptosis and NLRP3 inflammasome 
formation. In this pathway, the human inflammatory caspases 4 and 5 as well as 
murine caspase-11 directly sense pathogen-derived cytosolic LPS, resulting in 
the cleavage of GSDMD and pyroptosis (Shi et al., 2014; Russo et al., 2018). 
Another effect of activation by LPS is activation of the NLRP3 inflammasome, 
again leading to activation of caspase-1 and the release of IL-1b and IL-18 
(Russo et al., 2018). 
 
1.3.1 The pro-inflammatory cytokines IL-1b and IL-18 
 
The family of IL-1 ligands includes a total of eleven molecules. Seven of these 
have receptor agonist activity, including IL-1b and IL-18, three have receptor 
antagonist activity and one, IL-37, is an anti-inflammatory cytokine (Dinarello, 
2009; Garlanda et al., 2013). Sensing of these cytokines is facilitated through IL-
1 receptors (IL-1R). The IL-1R family also consists of 11 members. These 
receptors are commonly composed of an extracellular domain consisting of three 
immunoglobulin (Ig)-like domains. Only the receptors TIR8 and IL-18BP (IL-18 
binding protein) have just one extracellular Ig-like domain. Similar to TLRs, an 
intracellular TIR domain is responsible for downstream signalling by binding the 
MyD88 adaptor. A functional receptor is formed by dimerization of two molecules 
of the IL-1R family. The IL-1 receptor is formed by the molecules IL1-R1 and IL-
1RAcP (IL-1 receptor accessory protein). The IL-18 receptor is formed by IL-
18Ra and IL-18Rb (Garlanda et al., 2013). 
IL-1b is produced mainly by monocytes, macrophages and dendritic cells. As 
described above, expression of the inactive precursor pro-IL-1b is potently 
induced upon activation of TLRs by bacterial LPS. However, active IL-1b can also 
stimulate the expression of more pro-IL-1b by binding to its receptor. Stimulation 
of expression by IL-1b itself is significantly prolonged compared to stimulation 
through products like bacterial LPS (Schindler et al., 1990; Dinarello, 2009; 
Dinarello, 2018). To unfold its inflammatory functions, IL-1b needs to be cleaved 
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by caspase-1. One mechanism by which IL-1b induces an inflammatory immune 
response, is to induce the expression of cyclooxygenase type 2 (COX-2) and 
inducible nitric oxide synthase (iNOS). These enzymes catalyse the production 
of prostaglandins and nitric oxide, inducing classic inflammatory symptoms like 
fever, vasodilatation and hypotension. Furthermore, secreted IL-1b induces the 
expression of chemokines and adhesion molecules which are both important for 
the infiltration of immune cells into the inflamed tissue (Dinarello, 2009).  
IL-18 was initially found in the serum of mice and named “IFNg- inducing 
factor”. In many ways IL-18 is similar to IL-1b. IL-18 is synthesized as an inactive 
precursor protein, pro-IL-18, which needs to be cleaved by caspase-1 to become 
active. Moreover, it shares significant structural similarities with IL-1b, despite 
having only 15 % sequence identity (Okamura et al., 1995; Dinarello, 1999). 
Nevertheless, the biology of these two cytokines is different. IL-18 is constitutively 
present in monocytes, macrophages and DCs of healthy individuals, which are 
the primary source for the production of this cytokine. It contains less mRNA 
destabilizing elements compared to other cytokines, resulting in a stable 
expression. Transcription of IL-18 is induced by NF-kB upon TLR stimulation. 
Interestingly, IL-18 is constitutively expressed in endothelial cells, keratinocytes 
and intestinal epithelial cells (Kaplanski, 2018). Similar to IL-1b, active IL-18 
induces inflammation by inducing the production of adhesion molecules, 
chemokines and nitric oxide. However, significantly higher concentrations of IL-
18 are required to induce an inflammatory response in cells compared to IL-1b 
(Kaplanski, 2018). IL-18 is well-described to also act cooperatively with other 
cytokines. Together with either IL-12 or IL-15 it can induce expression of INFg 
(Dinarello et al., 2013). The activity of IL-18 can be regulated by the soluble single 
Ig-like domain containing protein IL-18BP (IL-18 binding protein). It has an 
extraordinarily high affinity to IL-18 and can therefore inhibit its function (Dinarello 
et al., 2013). Apart from their pro-inflammatory functions both, IL-1b and IL-18, 
play a key role in the differentiation of innate and adaptive lymphoid cells 
(Garlanda et al., 2013). For instance, IL-18 is directly involved in regulating the 
immune response by Th1 and Th2 cells (Nakanishi et al., 2001). 
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Dysregulation of IL-1b and IL-18 has been described to be the cause of or 
involved in the development of several autoinflammatory diseases, such as 
rheumatoid arthritis, neurogenerative diseases including Alzheimer’s and 
Parkinson’s, type 2 diabetes and multiple sclerosis. Discovery of the involvement 
of these two cytokines in multiple autoinflammatory diseases has led to the 
development of drugs that specifically inhibit the signalling pathways triggered by 
them. For instance, IL-1R blockade has become a successful treatment for type 
2 diabetes (Volin and Koch, 2011; Lukens et al., 2012; Giacomelli et al., 2016). 
 
1.3.2 Pyroptosis – an inflammatory form of cell death 
 
Pyroptosis is a regulated form of cell death, which can be induced by a 
disturbance of extra- or intracellular homeostasis. It is directly linked to innate 
immunity and distinct from other forms of regulated cell death, like apoptosis or 
necroptosis, by certain characteristics such as a specific morphotype (Miao, 
2015; Galluzzi et al., 2018). The pyroptotic morphotype shows an atypical form 
of chromatin condensation and DNA damage. In contrast to apoptosis, the 
nucleus of cells undergoing pyroptosis remains intact (Fink and Cookson, 2006). 
Moreover, pyroptotic cell death features rapid swelling and osmotic lysis through 
ruptures of the plasma membrane (Jorgensen and Miao, 2015). This results in 
the uncontrolled release of proinflammatory cell contents, which is again different 
from the packaging of cell contents that occurs during apoptosis (Jorgensen and 
Miao, 2015; Galluzzi et al., 2018). 
The rapidly induced rupture of the cell membrane during pyroptosis is 
described to be mainly dependent on the pore-forming proteins of the gasdermin 
(GSDM) family. Members of the gasdermin family include GSDMA, GSDMB, 
GSDMC, GSDMD, GSDME and Pejvakin (PJVK). Expression of these proteins 
is tissue dependent in mice and humans. For example, GSDMD is mainly 
expressed in the skin, oesophagus, stomach and placenta in humans (Feng et 
al., 2018). With the exception of PJVK, all GSDMs contain an N-terminal domain 
that has pore-forming activity and can induce pyroptosis-like cell death in 
overexpression systems (Ding et al., 2016; Feng et al., 2018). GSDMD is 
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expressed as an autoinhibited precursor protein, in which the pore-forming N-
terminus is structurally inhibited by the C-terminus (Liu et al., 2019). After 
proteolytic cleavage by inflammatory caspases (caspase-1, caspase-4/5 or the 
mouse homolog of caspase-4, caspase-11) its N-terminal fragment is released 
from the inhibitory C-terminal fragment and can form membrane pores to induce 
pyroptosis (He et al., 2015; Shi et al., 2015). However, pyroptosis has been 
shown to be not solely dependent on GSDMD. This was demonstrated by 
stimulating BMDMs lacking the GSDMD gene with canonical inflammasome 
activators. These cells were still able to undergo pyroptosis, even though the 
process was significantly delayed (Kayagaki et al., 2015). 
Different mutations in members of the gasdermin family have been shown to 
be the cause of or involved in causing different diseases like alopecia, asthma or 
gastric cancer (Feng et al., 2018). Thus, gasdermin proteins have become a 
focus in research to better understand the mechanistic basis of their function and 
enable the design of drugs specifically inhibiting their pore-forming activity and 
consequently the induction of pyroptosis (Hu et al., 2018; Pandeya et al., 2019). 
 
1.4 ATPases associated with diverse cellular activities (AAA+ ATPase) 
 
1.4.1 What are AAA+ ATPases? Classification of P-loop NTPases 
 
A common approach to understanding the nature of how the biology of different 
organisms works on a molecular level, is to organise molecules with similarities 
in their sequences, their structure or their function into different classes. Finding 
these similarities (and differences) as part of this classification, helps to find 
patterns in regards to their functionality and therefore improves the understanding 
of yet to be characterised members of these classes. This further enables the 
prediction of the function a protein might have (to a limited extent) and allows for 
the design of targeted experiments. A very good example of such a classification 
is the organisation of the class of P-loop NTPases, which comprises an estimated 
5-10 % of the (in 2004) fully sequenced genomes of prokaryotic and eukaryotic 
genomes (Koonin et al., 2004; Snider and Houry, 2008). These proteins contain 
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a shared aba core domain with a parallel b-sheet centred between two sets of a-
helices (James Milner-White et al., 1991). On the sequence level, P-loop proteins 
commonly contain conserved motifs, the Walker A and Walker B motif. These 
motifs were named after John E. Walker, who first described these conserved 
sequences (Walker et al., 1982). The Walker A motif was initially identified to 
contain a set of conserved residues following the pattern GxxxxGK(T)xxxxxxI/V 
(x denotes any of the proteinogenic amino acids). The Walker B motif was 
described to be located downstream of the Walker A motif and was described to 
follow the pattern R/KxxxGxxxLhhhhD (h denotes any hydrophobic amino acid) 
(Walker et al., 1982). Originally, the Walker A motif was referred to as the 
phosphate-binding loop or P-loop, hence the name P-loop NTPases (Saraste et 
al., 1990). Both, the Walker A and Walker B motifs, play an important role in 
protein function, as they contain conserved residues involved in nucleotide 
binding and hydrolysis (Walker et al., 1982; Saraste et al., 1990). 
P-loop NTPases can be further subdivided into two major groups, the kinase-
GTPase (KG) group and the additional strand catalytic E (ASCE) group (Figure 
1.2A). KG group members present with a strand order of 5-4-1-3-2 in the core b-
sheet, with the Walker B strand and the strand connected to the Walker A (P-
loop) being adjacent to each other. Indicated by the name, members of the ASCE 
group contain a strand between the Walker B strand (strand 3, which commonly 
contains the catalytic glutamate (E)) and the strand connected to Walker A 
(strand 1), resulting a strand order of 5-1-4-3-2 (Figure 1.2B) (Snider and Houry, 
2008). ASCE proteins are again divided into different families of proteins, 
including the ATPases with diverse cellular activities (AAA+ ATPases) (Figure 
1.2A) (Snider and Houry, 2008). The key element that defines ASCE proteins as 
members of the AAA+ ATPase superfamily is the so called C-domain, an a-
helical domain C-terminal of the ATPase domain (Ammelburg et al., 2006).  
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Figure 1.2: Classification of P-loop NTPases and structural 
characteristics of the nucleotide binding site 
(A) Classification of P-loop NTPases into the two major subgroups, the kinase-
GTPase (KG) group and the additional strand catalytic E (ASCE) group. Several 
subfamilies of the KG and ASCE groups are denoted below, including the 
superfamily of AAA+ ATPases as part of the ASCE group. The structural of 
elements containing comprising the catalytic domain are depicted. The strand 
order, which distinguishes the two groups of P-loop NTPases, are noted in the b-
strands of the structures. (B) Secondary structure elements of the nucleotide 
binding site of AAA+ ATPases are numbered as they occur according to the 
primary sequence of the proteins (top left). For the classification of P-loop 
NTPases the organization of secondary structure elements as they occur in the 
nucleotide binding site fold is compared (right). The organization of the b-sheet 
in AAA+ ATPases follows the 5-1-4-3-2 pattern, which is typical for members of 
the ASCE group. Key elements of AAA+ ATPases involved in nucleotide binding 
and hydrolysis including the Walker A, Walker B, Sensor 1 and Sensor 2 motif, 
are denoted in the schematic at the bottom left as they occur in the primary 
sequence of the proteins. (Adapted from Snider et al. 2008; Hanson and 
Whiteheart 2005). 
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Some AAA+ proteins such as plant resistance (R) proteins and their human AP 
ATPase homologs like Apaf-1 (apoptotic protease activating factor 1) and CED-
4 (cell death protein 4) were originally classified into a separate subgroup of P-
loop NTPases, the signal transduction ATPases with numerous domains 
(STAND) (Leipe et al., 2004). This subgroup has subsequently been described 
to be part of the ASCE/AAA+ ATPase superfamily (Ammelburg et al., 2006). As 
the name implies, AAA+ proteins are involved in a vast number of different 
cellular functions, including protein unfolding and degradation, fusion and fission 
of membranes and transcriptional activation (Snider et al., 2008; Sysoeva, 2017). 
The Walker A and Walker B motifs of AAA+ ATPases were redefined to follow 
the pattern GxxxxGK(T/S) and hhhhDE, respectively. Furthermore, additional 
motifs involved in nucleotide binding and hydrolysis were identified, such as the 
Sensor 1 and Sensor 2 motif (Figure 1.2B) (Hanson and Whiteheart, 2005). 
Proteins involved in regulating different forms of cell death, like the above 
mentioned Apaf-1 or inflammasome forming NLRs contain these motifs and are 
thus consequently categorized as members of the STAND clade of the AAA+ 
ATPase superfamily (Ogura and Wilkinson, 2001; Leipe et al., 2004; Danot et al., 
2009). 
 
1.4.2 The role of self-assembly in AAA+ activity 
 
As mentioned above (Chapter 1.3), oligomerization of the sensor protein is a 
central event in the assembly of inflammasomes. Members of the AAA+ ATPase 
superfamily are well-described to form biologically active, ring-like oligomeric 
complexes (Ogura and Wilkinson, 2001; Hanson and Whiteheart, 2005; Sysoeva, 
2017). The oligomeric state is described to range from pentamers to octamers, 
with hexamers being the most prevalent form among AAA+ proteins. Oligomers 
can be homooligomers or heterooligomers (Hanson and Whiteheart, 2005; 
Sysoeva, 2017). A common model described for AAA+ oligomer activity, is that 
the energy of nucleotide hydrolysis events within the subunits of the oligomer are 
converted into mechanical energy in form of conformational changes. 
Consequently, these molecules are known to adapt different conformations in 
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their active and inactive state (Sysoeva, 2017). Different mechanisms for the 
sequence of hydrolysis events in the single subunits of one oligomer have been 
proposed. The concerted hydrolysis model suggests that all hydrolysis events 
and the coupled conformational changes occur simultaneously. Other hydrolysis 
models include the rotary, the sequential and the stochastic model, all of which 
propose different sequences of hydrolysis events (Ogura and Wilkinson, 2001; 
Sysoeva, 2017). 
A well-described example for a functional hexamer is the AAA+ ATPase p97, 
which is involved in a variety of biological mechanisms like the ubiquitin 
proteasome system (Meyer et al., 2012). Crystal structures of p97 in the apo state 
or bound to different nucleotides revealed that ATP binding and hydrolysis 
induces significant conformational changes in the p97 hexamer (Hänzelmann 
and Schindelin, 2016). Similar observations were made for the NtrC1 AAA+ 
ATPase by structural analysis of the heptameric protein in the apo state or bound 
to different nucleotides (Chen et al., 2010). A conserved arginine residue, also 
referred to as the arginine finger (Figure 1.2B), is crucial in transmitting 
conformational changes between the subunits of the oligomeric AAA+ ATPase 
complex. Typically, this arginine is located at the interface between two subunits 
of the oligomer and has been shown to participate in formation of the nucleotide 
binding site of the neighbouring molecule (Hanson and Whiteheart, 2005; Chen 
et al., 2010; Hänzelmann and Schindelin, 2016). This arginine residue is not 
found in members of the STAND group of AAA+ ATPases, to which Apaf-1, MalT 
and also NLRs belong (Leipe et al., 2004). Interestingly, in the model of activation 
for Apaf-1 and MalT these proteins are monomeric in their inactive conformation 
and only oligomerize upon activation (Danot et al., 2009). Structural data for both 
proteins in their monomeric and oligomeric forms supports this model. For MalT, 
binding of its ligand maltotriose and ATP as a cofactor was required to induce 
oligomerization of the protein (Acehan et al., 2004; Larquet et al., 2004). 
However, ATP hydrolysis was not required for oligomerization, as the non-
hydrolysable AMP-PNP was sufficient to induce oligomerization in combination 
with maltotriose (Larquet et al., 2004). In contrast, Apaf-1 needs both ATP binding 
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and hydrolysis upon activation by binding of mitochondrial Cytochrome C to form 
an active apoptosome (Kim et al., 2005). 
A similar activation model is described for inflammasome forming NLRs. For 
the NLRC4 inflammasome this model is supported by high resolution structural 
information on the active and inactive conformation. A crystal structure of an 
ADP-bound murine NLRC4 construct including its NACHT and LRR domain 
revealed the monomeric, autoinhibited conformation of NLRC4 (Hu et al., 2013). 
More recent studies unveiled the structure of the active NLRC4 oligomer, which 
requires a NAIP molecule as nucleation factor. A single NAIP molecule is 
described to undergo conformational changes upon binding of its ligand, bacterial 
flagellin. Subsequently it can recruit an NLRC4 molecule and thereby induce 
NLRC4 oligomerization (Diebolder et al., 2015; Zhang et al., 2015; Tenthorey et 
al., 2017). The role of nucleotides in NLRC4 inflammasome activity has not yet 
been clarified. 
Negative-stain electron microscopy of full-length NLRP1 showed monomers 
as well as pentameric and heptameric oligomers (Faustin et al., 2007). However, 
no high resolution structural information for active or inactive NLRP1 is available 
yet. Thus, the mechanism of NLRP1 oligomerization, its oligomeric state and the 
role of nucleotide binding in mediating inflammasome assembly remain to be 
clarified. 
 
1.5 The NLRP1 inflammasome 
 
1.5.1 Differences between rodent and human NLRP1 
 
Human NLRP1 is encoded by a single gene, located on chromosome 17 (Gene 
ID: 22861). It encodes 18 exons and is described to be transcribed and translated 
into seven isoforms produced by alternative splicing. NLRP1 expression was 
detected in multiple tissues such as heart, thymus spleen and intestine and in 
different immune cells including macrophages and neutrophils (Kummer et al., 
2007). The protein described as canonical isoform 1 in the protein database 
UniProt contains 1473 amino acids and has a calculated molecular weight of 166 
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kDa (UniProt ID: Q9C000). In contrast, there are three paralogs described for 
murine NLRP1, namely NLRP1a, NLRP1b and NLRP1c, which are likely the 
result of evolutionary gene duplication events (Chavarria-Smith and Vance, 
2015). Furthermore, the existence of five highly polymorphic alleles is reported 
for the NLRP1b paralog (Boyden and Dietrich, 2006). 
Human and murine NLRP1 further differ on the protein level in regards to their 
modular domain architecture (Figure 1.3) (Yu et al., 2018). Human NLRP1 is 
composed of an N-terminal PYD, a central NACHT and LRR domain, followed by 
a FIIND (domain with “function to find”) domain and a C-terminal CARD. Both the 
PYD and the CARD domain belong to the family of death domains. Members of 
this family are typically involved in mediating protein-protein interaction via 
homotypic interactions (Weber and Vincenz, 2001). While the PYD of NLRP1 is 
involved in keeping the protein in an autoinhibited conformation, the C-terminal 
CARD domain is the effector domain required for downstream signalling (Finger 
et al., 2012; Zhong et al., 2016). NACHT domains are described to be involved 
in nucleotide binding and oligomerization of NLR proteins (Proell et al., 2008). 
The FIIND domain consists of a ZU5-UPA domain tandem also present in non-
NLR proteins like PIDD and Unc5b (Tinel et al., 2007; Wang et al., 2009). It is 
described to undergo autolytic cleavage, which is required but not sufficient for 
NLRP1 activation (D’Osualdo et al., 2011; Finger et al., 2012). 
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Figure 1.3: Comparison of the human and murine NLRP1 proteins 
Modular domain architecture of human and murine NLRP1 proteins. Human 
NLRP1 contains an N-terminal PYD, a central NACHT and LRR domain, a FIIND 
and C-terminal CARD. The domain boundaries and positions are drawn to scale 
(based on the human NLRP1 protein). Murine NLRP1 contains an NR100 domain 
instead of the PYD found in human NLRP1 and a significantly shorter linker 
between the N-terminal NR100 domain and the NACHT domain. Furthermore, a 
truncation of the second and third LRR is found in murine NLRP1 compared to 
human NLRP1. Autolytic cleavage within the FIIND is depicted with a star (*) and 
proteolytic cleavage by anthrax lethal toxin in the murine NR100 domain with a 
circle (°). Protein sequences were obtained from the UniProt database and from 
NCBI. Accession codes were as follows: for NLRP1 human, Q9C000; NLRP1A 
mouse, Q2LKU9; NLRP1B1 mouse, Q2LKW6; NLRP1B2 mouse, A1Z198; 
NLRP1B3 mouse, Q2LKV5; NLRP1B4 mouse, Q2LKV2; NLRP1B5 mouse, 
Q0GKD5; NLRP1C mouse, AAI41385.1. (Adapted from Yu, Moecking et al. 
2018). 
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All mouse NLRP1 paralogs lack the N-terminal PYD and instead contain a region 
of roughly 100 amino acids, which was termed NR100 domain (Figure 1.3) 
(Moayeri et al., 2012). Moreover, the linker connecting the N-terminal domain and 
the NACHT domain in human NLRP1 is missing in the mouse variants (Yu et al., 
2018). Mouse NLRP1b allele 1 and 5 are described to be susceptible to cleavage 
by anthrax lethal toxin, resulting in inflammasome activation. The cleavage site 
is located in the NR100 domain. Neither human NLRP1 nor mouse NLRP1a, 
NLRP1b allele 2, 3 and 4 or NLRP1c contain this cleavage site (also see chapter 
1.5.2) (Yu et al., 2018). NLRP1b allele 3 is further not cleaved within its FIIND 
domain, rendering this variant inactive. NLRP1b allele 4 and NLRP1c lack the 
entire C-terminal CARD domain and part of the FIIND domain and are therefore 
also completely inactive variants. NLRP1c further lacks part of the NR100 domain 
(Yu et al., 2018). The physiological role of the constitutively inactive mouse 
variants of NLRP1 has not yet been elucidated. 
The human genome further encodes a protein called CARD8, which is 
composed only of a FIIND and a CARD domain. According to the UniProt 
database 5 isoforms of CARD8 exist, which are produced by alternative splicing. 
Canonical isoform 1 consists of 431 amino acids and has a molecular weight of 
49 kDa (UniProt ID: Q9Y2G2). In a pairwise sequence alignment CARD8 showed 
38 % sequence identity and 53 % sequence similarity to the NLRP1 FIIND and 
CARD domains (amino acids 991-1473; Clustal Needle Tool, default settings). 
As for NLRP1, the CARD8 FIIND domain is reported to undergo autoproteolysis 
(D’Osualdo et al., 2011). The mouse genome does not encode a CARD8 protein. 
 
1.5.2 Mechanisms of NLRP1 activation 
 
Although no pathogenic ligand is described that directly binds to and activates 
NLRP1 (as bacterial flagellin for NLRC4), several pathogenic and non-pathogenic 
stimuli have been reported to specifically induce NLRP1 inflammasome formation 
(Tenthorey et al., 2017). Some of these stimuli activate both human and rodent 
NLRP1, while others are specific for certain rodent NLRP1 variants. 
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In particular, anthrax toxin from Bacillus anthracis is shown to only activate a few 
variants of NLRP1 in mice and certain rat strains (Yu et al., 2018). Anthrax toxin 
is an exotoxin composed of the three proteins protective antigen (PA), oedema 
factor (EF), and lethal factor (LF) (Smith and Keppie, 1954; Turk, 2007). PA 
facilitates the entry of EF and LF into the cytosol of host cells via endosomes. 
Inside the cell, EF and LF act on intracellular signalling pathways to disrupt and 
inhibit an efficient immune response. The combination of PA and LF is also 
referred to as LeTx (lethal toxin). LF is a metalloproteinase that directly cleaves 
mitogen-activated protein kinase kinases (MKKs), ultimately resulting in the 
down-regulation of the MAPK pathway and an impaired immune response (Dong 
et al., 2002; Turk, 2007). The first connection between anthrax toxin and NLRP1 
was made when LeTx susceptibility of mouse macrophages was shown to be 
dependent on NLRP1b (Boyden and Dietrich, 2006; Liao and Mogridge, 2009). 
However, only macrophages of certain mouse strains tested in these studies 
showed susceptibility to LeTx, which was attributed to the highly polymorphic 
nature of the NLRP1b paralog (Boyden and Dietrich, 2006). Further studies 
showed that LF directly cleaves the murine NLRP1b protein (allele 1 and allele 
5) as well as the NLRP1 protein of certain rat strains within the N-terminal NR100 
domain (Hellmich et al., 2012; Levinsohn et al., 2012). This cleavage event was 
later on confirmed to be sufficient to induce NLRP1 inflammasome activation 
(Chavarría-Smith and Vance, 2013). 
Human NLRP1 and other murine and rat NLRP1 variants (e.g. murine 
NLRP1a) are not direct substrates of LF and thus not activated when exposed to 
this protease. Nevertheless, proteolytic cleavage within the linker region 
connecting the N-terminal PYD or NR100 domain to the NACHT domain was 
shown to induce inflammasome activation in a reconstituted overexpression 
system in HEK293T cells. Proteolytic cleavage was achieved by introducing a 
TEV cleavage site in the aforementioned linker region and treating the cells with 
TEV protease (Chavarría-Smith et al., 2016). Interestingly, when the N-terminal 
PYD was replaced by a GFP (green fluorescent protein) molecule, NLRP1 
retained its autoinhibited conformation and could still be activated by TEV 
cleavage. Thus, it was concluded that the autoinhibitory effect of NLRP1 PYD is 
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mediated through steric hindrance rather than a specific intramolecular 
interaction (Chavarría-Smith et al., 2016). 
Consistent with the above mentioned finding that cleavage of the N-terminal 
PYD (or NR100 domain in rodents) results in activation of NLRP1, a deletion 
variant of NLRP1 lacking the N-terminal PYD was found to be constitutively active 
in overexpression system in 293T cells (Zhong et al., 2016). Similarly, deletion of 
the LRR domain leads to constitutive activation of the NLRP1 inflammasome in 
both humans and mice (Liao and Mogridge, 2009; Chavarría-Smith et al., 2016). 
Thus, the PYD and LRR of human NLRP1 are assumed to be involved in keeping 
the protein in an autoinhibited conformation. An activating effect of LRR deletion 
mutants has been reported for other NLR family members like NLRC4 and NOD2 
(Ogura et al., 2001; Kofoed and Vance, 2011). In contrast, an activating effect of 
a PYD deletion mutant has only been reported in the context of NLRP1. In other 
NLRP proteins, such as NLRP3, the N-terminal PYD is required for binding of the 
adaptor protein ASC and therefore essential in downstream signalling (Vajjhala 
et al., 2012; Swanson et al., 2019). 
Toxoplasma gondii is a parasitic pathogen shown to induce NLRP1-dependent 
pyroptosis and IL-1b release in rodents. As for LeTx, sensitivity to Toxoplasma 
gondii is highly variable for different mouse and rat strains carrying different 
NLRP1 variants (Cavailles et al., 2006; Ewald et al., 2014; Cirelli et al., 2014; 
Cavailles et al., 2014). For instance, rat strains carrying allele 1 or 2 of NLRP1 
are significantly more sensitive to T. gondii infection compared to rat strains 
carrying allele 5. Consistent with this finding, rat macrophages infected with T. 
gondii exhibited reduced pyroptosis and IL-1b release when carrying allele 1 or 2 
of NLRP1 compared to macrophages carrying allele 5 (Ewald et al., 2014; Cirelli 
et al., 2014). Similarly, BMDMs expressing NLRP1a or NLRP1b allele 2 undergo 
T. gondii induced pyroptosis. In contrast to LeTx, activation of murine NLRP1 
variants was shown to be independent of a cleavage event in the N-terminus of 
the protein, suggesting a different underlying activation mechanism (Ewald et al., 
2014). In another study the role of NLRP1 in resistance to T. gondii was 
confirmed, as NLRP1-/- mice exhibited increased parasite load (Gorfu et al., 
2014). Three dense granule proteins were identified to be required to induce 
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pyroptosis in rat macrophages (Wang et al., 2019). However, the exact 
mechanism by which T. gondii activates NLRP1 in mice and rats is still unknown. 
NLRP1 might also play a role mediating resistance to T. gondii infection in 
humans, as polymorphisms in NLRP1 are linked to increased susceptibility to 
congenital toxoplasmosis (Witola et al., 2011). Furthermore, human innate 
immunity to T. gondii was shown to depend on ASC and caspase-1, as treatment 
with a caspase-1 inhibitor reduced IL-1b release of monocytes. This was 
confirmed by performing shRNA knockdown experiments of caspase-1 and ASC 
(Gov et al., 2013). However, the direct involvement of NLRP1 in sensing T. gondii 
and the underlying mechanisms have yet to be elucidated. 
Apart from LeTx and T. gondii, other pathogens, namely the bacteria Shigella 
flexneri and Listeria monocytogenes, have recently been demonstrated to 
activate the NLRP1b inflammasome in mice (Neiman-Zenevich et al., 2017). 
However, the molecular basis of inflammasome activation by these bacteria has 
not been clarified. 
Another mechanism described to induce NLRP1 activation in mice and 
humans is inhibition of dipeptidyl peptidase 9 (DPP9) (Okondo et al., 2018; Zhong 
et al., 2018; de Vasconcelos et al., 2019). Dipeptidyl peptidases are involved in 
multiple physiological processes and associated with immune pathologies 
(Waumans et al., 2015). For instance, DPP9 has been reported to regulate the 
protein turnover of spleen tyrosine kinase (SYK) by directly cleaving a dipeptide 
at its N-terminus and thereby directing it to the N-end rule pathway (Justa-Schuch 
et al., 2016). DPP9 forms functional dimers and specifically cleaves off dipeptides 
from proteins with a proline in the second position from the N-terminus (Zhang et 
al., 2013; Ross et al., 2018). It shares 77 % sequence similarity and 57 % 
sequence identity to DPP8, increasing to 100 % and 90 %, respectively, when 
only taking the catalytic domain into account (Van Goethem et al., 2011). 
Inhibition of DPP8/9 was first shown to activate NLRP1b in mice by treating cells 
with the DPP8/9 inhibitor Talabostat. Interestingly, this activation mechanism was 
reported to be independent of the adaptor protein ASC (Okondo et al., 2018). 
Inflammasome activation independent of ASC was previously reported for other 
stimuli of murine NLRP1b, for instance, when activated by LeTx, but not for 
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human NLRP1 (Van Opdenbosch et al., 2014). Consistent with these findings, 
human NLRP1 activation by inhibition of DPP9 was shown to be dependent on 
ASC in immortalized keratinocytes (Zhong et al., 2018). Furthermore, 
experiments in BMDMs revealed that ASC amplifies signalling of the active 
inflammasome, as measured by release of IL-1b (Zhong et al., 2018). The 
inhibitory mechanism of DPP9 was identified to be mediated by direct binding of 
DPP9 to the FIIND domain of NLRP1 by immunoprecipitation experiments with 
DPP9 and NLRP1 overexpressed in HEK293T cells. Treatment with Talabostat 
impairs binding of DPP9 to NLRP1, resulting in inflammasome activation. 
Furthermore, DPP9 requires its catalytic activity to unfold its inhibitory effect on 
NLRP1, as a catalytically inactive mutant (DPP9 S759A) was still able to bind 
NLRP1 but unable to rescue ASC speck formation in DPP8/9 double KO 293T 
cells (Zhong et al., 2018). In contrast to LeTx, DPP8/9 inhibition induces 
inflammasome activation for all functional rodent NLRP1 variants. Moreover, 
comparing the activation pattern of DPP8/9 inhibition with that of T. gondii 
showed that both stimulate rodent NLRP1 variants in a very similar pattern. Thus, 
it was concluded that T. gondii activation mimics DPP8/9 inhibition, or at least 
activates NLRP1 by a similar mechanism (Gai et al., 2019). Importantly, DPP8/9 
inhibition was also reported to induce pyroptosis by activating the CARD8 protein 
in two human NLRP1-/- cell lines. It was therefore suggested that depending on 
the cell type DPP8/9 inhibitor induced pyroptosis can be independent of NLRP1 
(Johnson et al., 2018). This has to be considered when using DPP8/9 inhibitors 
as activating stimuli for NLRP1. 
Very recently, two independent studies described a mechanism that could 
serve as universal model for NLRP1 activation (Chui et al., 2019; Sandstrom et 
al., 2019). One study identified genes required for NLRP1b dependent pyroptosis 
in a genome-wide CRISPR-Cas9 knockout screen. Several components of the 
N-end rule pathway were identified in this screen, like Ubr2, Ubr4 or Uba6 (Chui 
et al., 2019). Indeed, NLRP1b activation by LT or Talabostat induced degradation 
of the N-terminal cleavage fragment of NLRP1, which was shown by western blot. 
Double knockout of Ubr2/Ubr4 completely abrogated LT induced pyroptosis and 
NLRP1b degradation, as measured by LDH release or western blot analysis, 
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respectively (Chui et al., 2019). Moreover, inhibitors of the N-end rule degradation 
pathway and proteasome inhibitors efficiently rescued cells from LT or Talabostat 
induced pyroptosis (Chui et al., 2019). Specific degradation of the NLRP1b N-
terminal cleavage fragment upon cleavage by LT and the rescuing effect of 
proteasome inhibitors were confirmed in another study (Sandstrom et al., 2019). 
Furthermore, the C-terminal cleavage fragment of NLRP1b was shown to be 
sufficient to oligomerize and form a functional inflammasome. The Shigella 
flexneri E3 ubiquitin ligase IpaH7.8 was demonstrated to directly activate NLRP1 
by ubiquitination of the NLRP1 N-terminal fragment (Sandstrom et al., 2019). 
Ubiquitination is commonly described to direct proteins to proteasomal 
degradation (Ciechanover, 1994). The proposed model for inflammasome 
activation derived from these results suggests that NLRP1b poses an integrated 
decoy target to pathogen enzymes. These enzymes induce degradation of the N-
terminal cleavage fragment containing the NR100, NACHT, LRR and part of the 
FIIND domain of NLRP1b. Consequently, the C-terminal cleavage fragment, 
composed of part of the FIIND domain and the CARD domain, would be released 
and could assemble into an active inflammasome (Chui et al., 2019; Sandstrom 
et al., 2019). Similar mechanisms were previously described for the NLR-related 
plant resistance proteins (Jones et al., 2016). 
Bacterial muramyl dipeptide (MDP) was initially described to enhance NLRP1 
inflammasome activation in a cell-free system and was considered a direct 
pathogen-derived ligand for NLRP1 (Faustin et al., 2007; Bruey et al., 2007). 
MDP is part of the bacterial cell wall of gram negative and gram positive bacteria. 
Later studies found that MDP does not directly bind the NLRP1 LRR or NACHT-
LRR domains in an in vitro cell-free system (Reubold et al., 2014; Martino et al., 
2016). Moreover, BMDMs from NLRP1b-/- mice exhibited unchanged IL-1b levels 
when activated with MDP (Kovarova et al., 2012). Other studies reported that 
MDP is a direct ligand of NOD2 and NLRP3 (Inohara et al., 2003; Girardin et al., 
2003; Martinon et al., 2004). Thus, it has to be concluded that MDP is not a direct 
activator of the NLRP1 inflammasome. 
Another controversy regarding mechanisms underlying NLRP1 activation is 
the role of ATP. As for MDP, ATP was described to enhance NLRP1 
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oligomerization in a cell-free system (Faustin et al., 2007). In this context, the 
proteins Bcl-2 and Bcl-XL were reported to inhibit NLRP1 activation by blocking 
ATP binding and thereby prevent NLRP1 oligomerization (Bruey et al., 2007; 
Faustin et al., 2009). Both proteins belong to the group of Bcl-2 family proteins, 
which is known to be involved in regulating cell death (Kale et al., 2018). 
However, in another study it was found that a reduction of cytosolic ATP resulted 
in specific activation of NLRP1b (Liao and Mogridge, 2013). Additionally, Walker 
A mutation variants of mouse NLRP1b or human NLRP1 are shown to exhibit 
increased or constitutive inflammasome activity, respectively (Liao and Mogridge, 
2013; Chavarría-Smith et al., 2016). Walker A mutations typically impair 
nucleotide binding, which has been shown for recombinant human NLRP1 in a 
Scintillation Proximity Assay with radiolabelled, non-hydrolysable [35S]-g-ATP 
(Harris et al., 2015). Moreover, screening for ATP-competitive inhibitors did not 
lead to the identification of a specific inhibitor for NLRP1, however assays for 
NLRP1 activation were not well developed at this time (Harris et al., 2015). A 
recombinant protein construct containing the NACHT and LRR domains of 
NLRP1 was shown to be constitutively bound to ATP in an open, active though 
monomeric conformation. However, no hydrolysis activity was detected when 
incubating this protein with ATP and Mg2+ (Martino et al., 2016). Taken together, 
NLRP1 does bind ATP, however oligomerization and inflammasome activity do 
not seem to depend on ATP binding. Thus, the role of nucleotide binding in the 
NACHT domain for regulating NLRP1 activity remains to be elucidated. 
 
1.5.3 NLRP1-associated autoinflammatory diseases 
 
A number of missense mutations in the NLRP1 gene locus have been identified 
to directly cause constitutive inflammasome activation, resulting in 
autoinflammatory disease. These mutations are located within different domains 
of NLRP1 and contributed in the understanding of the molecular mechanisms 
governing NLRP1 regulation. Mutations found in the PYD (A54T, A66V, M77T) 
were described induce dyskeratosis and multiple self-healing palmoplantar 
carcinoma (MSPC) in patients (Soler et al., 2013; Zhong et al., 2016). 
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Mechanistically, these mutations disrupt the fold of the PYD since they disturb 
the hydrophobic core of the domain (Soler et al., 2013; Zhong et al., 2016). These 
mutations confirmed the identification of the NLRP1 PYD as an autoinhibitory 
rather than an effector domain. A homozygous mutation in the HD2-LRR 
transition region (R726W) and a de novo mutation in the FIIND domain of NLRP1 
were reported to induce an autoinflammatory phenotype with arthritis and 
dyskeratosis (NAIAD - NLRP1-associated autoinflammation with arthritis and 
dyskeratosis) (Grandemange et al., 2017). A deletion of exon five (amino acids 
F787-R843) was shown to cause familial keratosis lichenoides chronica (FKLC) 
in patients (Zhong et al., 2016). Interestingly, all mutations reported for NLRP1 to 
cause the systemic autoinflammatory syndromes MSPC, FKLC and NAIAD, are 
associated with skin inflammation. This is consistent with the finding that NLRP1 
is strongly expressed in keratinocytes and epithelial cells. In addition to the above 
mentioned mutations, a rare genetic variant within the NACHT domain of NLRP1 
(G578S) was found to be potentially involved in the development of sporadic 
multiple sclerosis and concomitant malignant melanoma (Maver et al., 2017). 
Multiple common single nucleotide polymorphisms (SNPs) are described for 
NLRP1 that are associated with autoinflammatory diseases. Different SNPs in 
NLRP1 are reported to be involved in vitiligo and associated autoimmunity by 
causing increased IL-1b processing (Y. Jin et al., 2007; Levandowski et al., 2013). 
Other autoinflammatory disorders associated with NLRP1 polymorphisms 
include type 1 diabetes, diabetic kidney disease, asthma and Crohn’s disease 
(Cummings et al., 2010; Leal et al., 2018; Soares et al., 2018; Sun et al., 2019). 
NLRP1 variants are also described to increase susceptibility for congenital 
toxoplasmosis, bacterial meningitis, HPV infection and associated cervical 
cancer, infection with the malaria parasite Plasmodium vivax and Trypanosoma 
cruzi associated Chagas cardiomyopathy (Witola et al., 2011; Geldhoff et al., 
2013; Santos et al., 2016; Pontillo et al., 2016; Clipman et al., 2018). Furthermore, 
NLRP1 was identified as a potential risk locus for the development of breast 
cancer (Gao et al., 2012).  
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1.6 Thesis aims 
 
The increasing number of autoinflammatory diseases associated with or directly 
linked to a dysregulated NLRP1 inflammasome, made it a conceivable drug 
development target. As mentioned above, a screening for ATP competitive 
inhibitors did not reveal specific NLRP1 inhibitors (Harris et al., 2015). Apart from 
that, no other drugs or screenings for drugs directly inhibiting the NLRP1 
inflammasome have been reported yet. Identification of the activation mechanism 
by N-terminal degradation demonstrated that proteasome and N-end rule 
pathway inhibitors could pose a new treatment strategy for NLRP1 related 
diseases (Chui et al., 2019; Sandstrom et al., 2019). Indeed, proteasome 
inhibitors like Bortezomib are already clinically used in the therapy of multiple 
myeloma. However, the proteasome is involved in regulating protein turnover of 
many proteins and inhibition can therefore have adverse effects in patients 
(Curran and McKeage, 2009). Thus, more specific inhibitors for NLRP1 would 
greatly improve disease management options in patients suffering from NLRP1-
associated autoinflammatory disease. A better understanding of the molecular 
mechanisms would aid in the development of assays for NLRP1 specific drug 
screenings. Therefore, the aims of this thesis were defined to: 
 
1. Improve the understanding of NLRP1 autoinhibition and activation by 
biochemical analysis and generating structural data. 
 
2. Gain insight into the mechanisms underlying nucleotide binding and the 
requirement of nucleotides for NLRP1 activation. 
 
3. Identify and understand molecular mechanisms regulating NLRP1 activity. 
 
To achieve these aims, a combination of a computational analysis of sequence 
and structural features of NLRP1, biochemical and structural experimental 
approaches and in vitro cell culture assays measuring inflammasome activation 
were used. This work was focused entirely on the human NLRP1 inflammasome. 
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2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 Reagents and consumables 
 
Table 2.1: DNA and Protein molecular weight marker 
 
Marker Supplier 
DNA Ladder 1 kb CarlRoth, Karlsruhe, Germany 
DNA Ladder 100 bp CarlRoth, Karlsruhe, Germany 
Gel filtration standard Bio-Rad, Munich, Germany 
Low molecular weight (LMW) marker GE Healthcare (Munich, Germany) 
Page Ruler Prestained Plus Thermo Fisher Scientific, Waltham, USA 
Precision Plus ProteinTM All Blue 
Prestained Protein Standards Bio-Rad, Munich, Germany 
 
Table 2.2: Kits 
 
Kit Supplier 
ExtractMe Plasmid Mini Kit Blirt, Gdańsk, Poland 
ExtractMe DNA Clean-Up & Gel-Out 
Kit Blirt, Gdańsk, Poland 
GeneJET Plasmid Maxiprep Kit Thermo Fisher Scientific, Waltham, USA 
QuikChange Mutagenesis PCR Agilent, Santa Clara, USA 
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Table 2.3: Primer sequences 
 
Construct/Mutation Sequence (5’-3’) 
Amplification  
NLRP1-A fwd CATGCCATGGCTGGTGGTGCTTGGG 
NLRP1-A rev CGGAATTCAGGAGGACAGGGGCAGCAGG 
NLRP1-B fwd CATGCCATGGGACCCGTGACCGACGCTTACTGGC 
NLRP1-B rev CGGAATTCAGGAGGGCTTGCGACGGCTG 
NLRP1-C fwd CGCGGATCCGGTCCCGTGGCTACTGAGGTGG 
NLRP1-C rev CGGAATTCAGCCCTTCTTGGAACCCTTCTCCCAC 
NLRP1-D fwd CGCGGATCCCCTCTGGACGCTCCTCAGCTG 
NLRP1-D rev CGGAATTCAGCCCTTCTTGGAACCCTTCTCCCAC 
NLRP1-E fwd CGCGGATCCGGTCCCGTGGCTACTGAGGTGG 
NLRP1-E rev CGGAATTCAAGGAGCGTCCAGAGGAGAGGGC 
NLRP1-F fwd CATGCCATGGCTGGTGGTGCTTGGG 
NLRP1-F rev CGGAATTCAGGAGTGACCAGCACCCTCTTGAGC 
  
Mutagenesis Template pCIG2-NLRP1 
K340A fwd GCTGGAATTGGGGCGTCAACACTGGC 
K340A rev GCCAGTGTTGACGCCCCAATTCCAGC 
S341A fwd GGAATTGGGAAGGCAACACTGGCCAGG 
S341A rev CCTGGCCAGTGTTGCCTTCCCAATTCC 
E414Q fwd GATGGTGTAGATCAGCCAGGATGGGTC 
E414Q rev GACCCATCCTGGCTGATCTACACCATC 
T389A fwd GCCGGAGTGGCTGCCCCATCTTTTCCG 
T389A rev CGGAAAAGATGGGGCAGCCACTCCGGC 
H623A fwd GCTACAGCTTCATTGCCCTCTGTTTCCAAG 
H623A rev CTTGGAAACAGAGGGCAATGAAGCTGTAGC 
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P1214R fwd GAGGACTCCCAAGGTCTAGAAGCTGGGGTTTTCCAGAACTATGT 
P1214R rev ACATAGTTCTGGAAAACCCCAGCTTCTAGACCTTGGGAGTCCTC 
Y1413F fwd GCTGAGCCAGGAGCAGTTCGAGAGGGT 
Y1413F rev ACCCTCTCGAACTGCTCCTGGCTCAGC 
Y1413E fwd GCCAGCACCCTCTCTTCCTGCTCCTGGCTCA 
Y1413E rev TGAGCCAGGAGCAGGAAGAGAGGGTGCTGGC 
Y1413Q fwd TGAGCCAGGAGCAGCAAGAGAGGGTGCTGGC 
Y1413Q rev GCCAGCACCCTCTCTTGCTGCTCCTGGCTCA 
  
Mutagenesis Template pACE-Bac1-MBPtev-NLRP1 
M1184V fwd CTGTTCCAGGTGGCTCACTTCAAGGAAGAG 
M1184V rev GAAGTGAGCCACCTGGAACAGGGAGGTGTC 
S1213A fwd GAACCCCTCCTTCGCCCCCCTGGGTGTC 
S1213A rev GACACCCAGGGGGGCGAAGGAGGGGTTC 
K340A fwd GTATCGGCGCGTCCACCCTGGCTCGTCAAG 
K340A rev CAGGGTGGACGCGCCGATACCAGCAGCAC 
  
Primers were purchased from Metabion International AG (Bonn) or from 
Integrated DNA Technologies (Melbourne). (fwd: forward; rev: reverse) 
 
2.1.2 Cell culture and bacterial culture media 
 
All cell culture and bacterial culture media were prepared and used under sterile 
conditions. Bacterial culture media was prepared from powder with Milli-Q® water 
(Bonn, Germany) or supplied by the WEHI media kitchen (Melbourne, Australia). 
Foetal Bovine Serum (FBS) for mammalian cell culture was heat inactivated at   
55 °C for 30 min before adding it to cell culture media. 
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Table 2.4: Cell culture and bacterial culture media 
 
Chemical/Reagent Supplier 
Dulbecco’s Modified Eagle’s Medium 
(DMEM) 
Thermo Fisher Scientific, Waltham, 
USA 
Foetal Bovine Serum (FBS) Sigma-Aldrich, USA 
Insect-XPRESSTM Lonza, Basel, Switzerland 
Luria Broth (LB) 
CarlRoth, Karlsruhe, Germany/ 
WEHI Media Kitchen, Melbourne, 
Australia 
OptiMEM Thermo Fisher Scientific, Waltham, USA 
Roswell Park Memorial 
Institute medium 1640 
(RPMI) 
WEHI Media Kitchen 
Sf-900TM III SFM 1x Invitrogen, Karlsruhe, Germany 
Super-Optimal Broth (SOB) WEHI Media Kitchen, Melbourne, Australia 
 
2.1.3 Equipment 
 
Table 2.5: Equipment 
 
Device Supplier 
Agarose gel chamber, DNA-SUB-Cell Bio-Rad, Munich, Germany 
Autoclave 5075 EL Systec, Linden, Germany 
Biophotometer Eppendorf, Munich, Germany 
Centrifuge, Avanti J265 XP Beckman and Coulter, Brea, California, USA 
Centrifuge, Eppendorf 5810 Eppendorf, Munich, Germany 
Centrifuge, Eppendorf 5810R Eppendorf, Munich, Germany 
ChemiDoc™ Touch Imaging System Bio-Rad, Munich, Germany 
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Electroporator, Eporator Eppendorf, Munich, Germany 
FPLC-System Äkta micro GE Healthcare, Munich, Germany 
FPLC-System Äkta prime plus GE Healthcare, Munich, Germany 
FPLC-System Äkta Pure GE Healthcare, Munich, Germany 
FPLC-System Äkta Start GE Healthcare, Munich, Germany 
Freezer (-80 °C) Thermo Scientific, Corston, UK 
HPLC system, Agilent 1260 Infinity II Agilent, Stevens Creek, USA 
Incubator Heratherm Thermo Scientific, Waltham, USA 
Incubator Innova 40 New Brunswick Scientific, Jersey, USA 
Incubator Multitron pro Infors HAT, Bottmingen, Switzerland 
Incubator, Heraeus CO2 Auto zero Heraeus Instruments, Hanau, Germany 
LSR Fortessa X-20 BD, Australia 
Magnetic stirrer MR 2000 Heidolph, Schwabach, Germany 
Mastercycler nexus SX1 Eppendorf, Munich, Germany 
Microbalance CPA324S Sartorius, Göttingen, Germany 
Microscope Axiolab Carl Zeiss, Jena, Germany 
Mini protean Tetra Cell Bio-Rad, Munich, Germany 
Nanodrop 2000/c UV-Spectrometer Thermo Scientific, Waltham, USA 
Odyssey, gel documentation system Li-Cor Biosciences, Bad Homburg, Germany 
pH meter lab 850 Schott Instruments, Mainz, Germany 
Sonifier Vibra cell Sonics, Newton, USA 
Sonifier W-250 Branson, Danbury, USA 
Tabletop centrifuge Eppendorf 3424 Eppendorf, Munich, Germany 
Thermomixer comfort Eppendorf, Munich, Germany 
Vortexer Vortex Genie 2 Bender & Hobein, Bruchsal, Germany 
Water bath Julabo 5 Julabo, Seelbach, Germany 
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2.1.4 Cell lines and bacterial strains 
 
Table 2.6: Cell lines 
 
Cell line Supplier 
Sf9 insect cells (clonal isolates 
derived from Spodoptera frugiperda 
cell line IPLB-Sf21-AE) 
Thermo Fisher Scientific, Waltham, 
USA 
Sf21 insect cells (clonal isolates 
derived from Spodoptera frugiperda 
cell line IPLB-Sf21-AE) 
Thermo Fisher Scientific, Waltham, 
USA 
Human embryonic kidney (HEK) 
293T cells ATCC Australia 
Human embryonic kidney (HEK) 
293T cells (ASC-RFP) Dr. Dominic De Nardo 
 
2.1.5 Buffers for protein purification 
 
Table 2.7: Buffers for protein purification (affinity chromatography) 
 
Construct Buffer/Application Composition 
NLRP1-A 
 
Lysis/Wash buffer 
20 mM Tris/HCl (pH 8.0), 
150 mM NaCl, 
5 mM b-ME 
Elution buffer 
20 mM Tris/HCl (pH 8.0), 
150 mM NaCl, 
10 mM maltose, 
5 mM b-ME, 
NLRP1-C 
NLRP1-D 
NLRP1-E 
Lysis buffer 
20 mM Tris/HCl (pH 7.0), 
150 mM NaCl, 
5 mM b-ME 
Wash buffer 
20 mM Tris/HCl (pH 7.0), 
500 mM NaCl, 
5 mM b-ME 
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Elution buffer 
20 mM Tris/HCl (pH 7.0), 
150 mM NaCl, 
10 mM maltose, 
5 mM b-ME 
NLRP1-B 
Lysis buffer 
50 mM MES/NaOH (pH 6.5), 
500 mM NaCl, 
1 % (v/v) NP-40, 
5 mM b-ME 
Wash buffer 
50 mM MES/NaOH (pH 6.5), 
100 mM NaCl, 
5 mM b-ME 
Elution buffer (GST) 
50 mM MES/NaOH (pH 6.5), 
500 mM NaCl, 
30 mM GSH (reduced), 
5 mM b-ME 
Elution buffer (IEC) 
50 mM MES/NaOH (pH 6.5), 
1000 mM NaCl, 
5 mM b-ME 
NLRP1-F 
Lysis buffer 
20 mM Tris/HCl (pH 7.0), 
150 mM NaCl, 
5 mM b-ME 
Wash buffer 
20 mM Tris/HCl (pH 7.0), 
500 mM NaCl, 
5 mM b-ME 
Elution buffer 
20 mM Tris/HCl (pH 7.0), 
150 mM NaCl, 
30 mM GSH (reduced), 
5 mM b-ME 
 
Table 2.8: Buffers for protein purification (size exclusion chromatography) 
 
Construct/Application Composition 
NLRP1-A 
20 mM HEPES/NaOH (pH 8.0), 
150 mM NaCl, 
1 mM TCEP 
NLRP1-B 
50 mM MES/NaOH (pH 6.5), 
100 mM NaCl, 
1 mM TCEP 
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NLRP1-C 
NLRP1-D 
NLRP1-E 
NLRP1-F 
20 mM HEPES/NaOH (pH 7.2), 
100 mM NaCl, 
1 mM TCEP 
Analytical SEC 
20 mM HEPES/NaOH (pH 7.2), 
100 mM NaCl, 
1 mM TCEP 
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2.2 Methods – Molecular Biology 
 
2.2.1 Polymerase Chain Reaction (PCR) 
 
PCR was used to specifically amplify fragments from a DNA template or to mutate 
a gene of interest into a DNA plasmid. Furthermore, a PCR was carried out on 
cell lysates (e.g. from HEK293T cells) to test these cells for contamination with 
mycobacteria. 
For the amplification of DNA fragments for cloning, either a Phusion 
Polymerase or Q5 Polymerase (New England Biolabs), was used. In these 
reactions, the annealing temperature and elongation time were adjusted to the 
primer melting temperatures and length of the DNA fragment as recommended 
by the manufacturer. Mutagenesis PCR was carried out using the QuikChange 
Lightning Site-Directed Mutagenesis Kit (Agilent) following the instructions 
described in the manual of the manufacturer. 
To test cell lysates for contamination with mycobacteria by PCR, a GoTaq-Mix 
was used. 1 x 106 cells were spun down and resuspended in 100 µL tail lysis 
buffer (Viagen) supplemented with 1 x Proteinase K (Sigma Aldrich) to degrade 
DNases. Lysis was performed at 55 °C o/n. Afterwards, Proteinase K was heat 
inactivated by incubating at 80 °C for 10 min. 1 µL of the lysate served as template 
in the PCR reaction. A set of primers designed to identify a contamination was 
applied, resulting in a DNA fragment of about 350 bp for contaminated samples. 
A positive and negative control were run alongside the samples. 
 
2.2.2 Agarose gel electrophoresis 
 
DNA fragments from PCR reactions were separated according to their size by 
running them on a 1 % agarose gel in 1 x TAE buffer (40 mM Tris base, 20 mM 
acetic acid, 1 mM EDTA sodium salt dihydrate). Gels were typically run at 100 V 
for at least 30 min. Before applying samples to a gel, the appropriate amount of 
6 x loading buffer was added to each sample. Additionally, a DNA marker was 
run on the gel, to confirm the size of the fragments produced by PCR. If the DNA 
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fragments were to be used in cloning procedures afterwards, they were purified 
from the gel using the ExtractMe DNA Clean-Up & Gel-Out Kit (Blirt) following the 
instructions of the supplied manual. 
 
2.2.3 Restriction digest 
 
Restriction endonucleases are a class of enzymes described to be responsible 
for the sequence-specific recognition and cleavage of foreign double stranded 
DNA. Prokaryotes distinguish foreign from self-DNA, by making use of a specific 
methylation pattern. Type II restriction endonucleases recognize both asymmetric 
or symmetric patterns, so called palindromic, DNA sequence motifs and cleave 
the covalent phosphodiester bond within these sequences producing a break in 
the DNA strand. The resulting either sticky or blunt ends can be further ligated 
according to the cohesive ends. 
Restriction enzymes were primarily utilized to produce compatible overhangs 
(sticky ends) on DNA fragments produced in PCR and target vectors, making 
them accessible to ligation. All restriction enzymes were purchased from New 
England Biolabs and reactions were set up as recommended by the 
manufacturer. Digested fragments and vectors were purified by gel extraction 
(ExtractMe DNA Clean-Up & Gel-Out Kit, Blirt) to remove enzymes and 
unneeded fragments resulting from the digest. Analytical restriction digest was 
performed after ligation (Chapter 2.2.4) and transformation (Chapter 2.2.5), to 
confirm that the vector contains the correct insert. In these reactions 0.2 µL per 
enzyme were used in a total reaction volume of 20 µL. 
 
2.2.4 Ligation 
 
To insert a DNA fragment into a vector with compatible sticky ends, T4 DNA 
ligase (New England Biolabs) was used. Reactions were set up to contain 50 ng 
of digested and purified vector DNA and three times as much digested and 
purified insert DNA (molar ratio). The total reaction volume of a ligation was 20 
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µL, containing 1 µL of ligase and 2 µL of 10 x T4-DNA Ligase Buffer (New 
England Biolabs). Reactions were incubated for 2 h at RT or o/n at 4 °C. 
 
2.2.5 Transformation of bacteria 
 
A volume of 50 µL of chemically competent E. coli DH10b was mixed with 100 ng 
plasmid DNA or 10 µL of a ligation and incubated on ice for 15 min. 
Transformation was carried out by applying a heat shock (42 °C, 30 s). 
Subsequently, the bacteria were recovered by immediately placing them on ice 
for 2 min. Afterwards 900 µL of Super-Optimal Broth (SOB) medium were added 
and the transformed bacteria were incubated at 37 °C for at least 1 h. 
Transformed and recovered bacteria were streaked out on an LB-agarose plate 
containing the appropriate antibiotics. Typically, Ampicillin (100 µg/mL), 
Kanamycin (50 µg/mL), Gentamycin or Tetracyclin (both 10 µg/mL) served as 
selection antibiotics. 
For the production of Bacmids (Chapter 2.2.8), 25 µL of E. coli DH10 
MultiBacTurbo (electrocompetent or chemically competent) were mixed with 100 
ng of the according plasmid and transformed in a cuvette by electroporation (2 
kV) or by applying a heat shock (42 °C, 30 s). Immediately after electroporation, 
900 µL of SOB medium were added. The transformed cells were incubated at 37 
°C for at least 3 h and then streaked on an LB-agarose plate containing Ampicillin, 
Kanamycin, Tetracyclin and Gentamycin at the concentrations described above. 
Additionally, these plates contained IPTG (40 µg/mL) and BluoGal (100 µg/mL) 
to enable a blue-white screening. In this screening, positive clones (containing 
the insert) appear white while negative clones (not containing the insert) appear 
blue. 
 
2.2.6 Sequencing 
 
Plasmids identified to contain the desired insert after ligation or purified from E. 
coli after mutagenesis, were analysed by Sanger sequencing. Sequencing was 
carried out by external services (GATC/Bonn; AGRF/Melbourne). Sequencing 
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samples were prepared according to the requirements of the respective 
sequencing service supplier. Sequencing results were analysed using ApE and 
Serial Cloner (2-6-1) software. 
 
2.2.7 Preparation of amplified plasmids from E. coli 
 
To amplify ligated plasmids or plasmids that had the correct sequence insert or 
mutation, 100 ng of the according plasmid DNA were transformed into E. coli as 
described in 2.2.5. From the transformation plates a single colony was picked 
with a pipette tip, which was then dropped into LB media containing the 
appropriate antibiotics. For a large-scale plasmid purification (Maxiprep), 300 mL 
of LB were used. Plasmids intended for use in human cell lines were always 
purified by Maxiprep to ensure the removal of endotoxins. The GeneJET Plasmid 
Maxiprep Kit (Thermo Fisher Scientific) was used and the Maxiprep performed 
following the instructions given in the manual. For a small-scale purification 
(Miniprep), 4 mL of LB were inoculated with a single colony of transformed 
bacteria as described above. The purification was carried out with the ExtractMe 
Miniprep Kit (Blirt) or the Promega™ Wizard™ PlusSV Minipreps DNA 
Purification System (Promega) according to the manufacturer’s protocol. In both, 
Mini- and Maxipreps, nuclease-free water was used instead of the provided 
elution buffer to elute the purified DNA from the columns. The concentration of 
the eluted DNA was determined by measuring the absorbance at 260 nm using 
a Nanodrop spectrophotometer. The 260/230 nm and 260/280 nm ratios were 
recorded to check for potential contaminants like proteins. 
 
2.2.8 Isolation of baculovirus shuttle vector (Bacmid) 
 
Bacmids are large shuttle vectors used to generate recombinant baculoviruses. 
Due to their size they cannot be purified using a Miniprep Kit, since the shearing 
forces caused by spinning the DNA onto DNA-binding columns could potentially 
damage the Bacmid. 
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From the blue-white screening plates (Chapter 2.2.5) a single white colony was 
picked with a pipette-tip and transferred to 4 mL LB media containing Ampicillin, 
Kanamycin, Gentamycin and Tetracycline at the concentrations previously 
described (2.2.5). The bacteria were grown at 37 °C for 48 h and harvested 
according to the protocol of the Miniprep Kit mentioned above. The protocol was 
followed up to the step where the lysate is clarified by centrifugation. The cleared 
lysate was then transferred to a fresh tube containing 800 µL of ice-cold 
isopropanol to precipitate the bacmid. Precipitated bacmids were spun down at 
maximum speed in a microcentrifuge at 4 °C for 30 min. After removing the 
supernatant, 800 µL of ice-cold 70 % ethanol were added to wash the bacmid 
pellet followed by another centrifugation step (4 °C, 15 min). The washing step 
with cold ethanol was repeated twice. Before removing the ethanol after the 
second wash, the tube was placed in a class 2 biosafety cabinet. After removing 
the ethanol, the lid of tube was left open to air-dry any residual ethanol for about 
15 min. Afterwards, the bacmid was resuspended in 22 µL nuclease-free water 
and immediately used for transfection of Sf9 or Sf21 cells as described in Chapter 
2.3.2. 
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2.3 Methods – Cell Biology 
 
Work with cells (insect or human) was conducted within a class 2 biosafety 
cabinet. Materials used inside the biosafety cabinet were sterilized using 80 % 
ethanol before placing them in the biosafety cabinet. If cells were removed from 
the biosafety cabinet to transfer them to an incubator or for centrifugation, they 
were kept in a sealed, sterile container (e.g. cell culture flask, falcon tube). 
 
2.3.1 Sf9 and Sf21 cell culture 
 
Generally, Sf9 cells (Bonn, Germany) were cultured in Sf-900TM SFM III 
(Invitrogen) in a shaking incubator at 27 °C. Sf21 cells (Melbourne, Australia) 
were grown in Insect-XPRESSTM media (Lonza) under the same conditions. 
Culture growth and cell size was monitored every third day to ensure a cell 
density not exceeding 5 x 106 cells per mL. For cell counting and size 
measurements an automatic cell counter (EVE™ Automated Cell Counter, 
NanoEnTek) was used. Cells were mixed 1:1 with 0.4 % trypan blue to stain dead 
cells. 10 µL of the mix were applied to a counting slide. Viability and size of 
uninfected cells was typically between 90-99 % and between 11-13 µM, 
respectively. Infected cells increased in size to about 14-15 µM and had a viability 
of at least 80 %. 
 
2.3.2 Transfection of Sf9 and Sf21 cells 
 
Recombinant baculovirus is used as a vector for heterologous gene expression 
in Sf9 and Sf21 cells. For recombinant virus production, bacmids purified as 
described in Chapter 2.2.8 need to be transfected into the insect cells. 
A culture of Sf9 or Sf21 cells was diluted to a cell density of 0.7 x 106 cells per 
mL and 2 mL of the suspension were transferred to each well of a 6 well cell 
culture plate. Cells were allowed to settle for 30 min at RT inside the biosafety 
cabinet. Purified bacmids were resuspended in nuclease-free water as described 
in 2.2.8. Additionally, 100 µL medium were added to each bacmid. In a different 
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tube, 8 µL of Cellfectin™ II Reagent (Thermo Fisher Scientific) and 100 µL of 
insect cell media were mixed. To achieve transfection of the insect cells by 
lipofection, the Cellfectin™ mix was added to the bacmids and incubated at RT 
for 15-30 min. Subsequently, 200 µL of the bacmids incubated with Cellfectin™ 
was added to the according well. As a negative control, only Cellfectin™ and 
medium were used. Cells were incubated with the transfection mix for 5 h at 27 
°C. Afterwards, the supernatant was removed and 3 mL of fresh medium were 
added to each well following further incubation for 72 h at 27 °C. Transfection 
plates were kept in a humidified stationary incubator to prevent the cells from 
drying out. The produced virus (V0) was harvested by collecting the supernatant. 
To ensure the supernatant was sterile and did not contain any residual insect 
cells or debris, it was passed through a 0.22 µM sterile filter. The filtered V0 was 
used for further virus amplification and excess of virus was stored at 4 °C. 
 
2.3.3 Virus amplification (V1 and V2) 
 
For a large-scale culture used for recombinant protein expression in insect cells, 
a high titre virus stock is needed to efficiently infect a large number of cells. 
Therefore, the V0 virus was expanded in two steps. First, a small culture (25-50 
mL, 0.6 x 106 cells/mL) of Sf9 or Sf21 cells was infected with 3 mL of V0. Cell 
growth was monitored every day using a cell counter and the cell density was 
adjusted to 0.6 x 106 cells/mL until the cells stopped growing. Then the culture 
was collected in a 50 mL falcon tube and spun down at 45 x g for 20 min. The 
supernatant was filtered through a 0.22 µM sterile filter and the virus stock (V1) 
was stored at 4 °C. For the second step of virus amplification, a culture of 100-
250 mL at 1 x 106 cells/mL was infected with 1 % (v/v) of V1. As for the first virus 
amplification, cell growth was monitored every day and the cell density adjusted 
to 1 x 106 cells/mL until the cells stopped dividing. The culture was collected as 
described for V1 and the resulting viral stock (V2) stored at 4 °C until it was used 
to infect cultures for protein expression (Chapter 2.4.2). 
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2.3.4 Cell culture of human cell lines 
 
HEK293T cells were cultured in complete Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 100 U/mL Penicillin and 0.1 % (w/v) Streptomycin (supplied 
by WEHI Media Kitchen, Melbourne) supplemented with 10 % foetal bovine 
serum (FBS). A continuous culture was monitored every second or third day. 
Cells were harvested and counted using a haemocytometer. To harvest the cells, 
all medium was taken off and the cells were washed once with 10 mL 1 x DPBS 
at RT. Then 5 mL of Trypsin/ethylenediaminetetraacetic acid (EDTA) were added 
to the cells, followed by 5 min of incubation at 37 °C. After adding 5 mL of DMEM 
the cells were resuspended and counted. A continuous culture was prepared at 
a 1:10 dilution. 
Murine primary bone marrow was cultured in complete DMEM containing 
Penicillin and Streptomycin at the concentrations described above and 
supplemented with 10 % FBS. Macrophages were differentiated from murine 
bone marrow by supplementation with 10 % L292 conditioned media (L292 
contains Macrophage Colony Stimulating Factor (M-CSF), WEHI Media Kitchen) 
for 6 days. Apart from that, isolation and differentiation of murine primary bone 
marrow was carried out as described previously (Gloria et al., 2018). All cells 
were cultured at 37 °C and 10 % CO2 in a stationary incubator. 
 
2.3.5 Transfection of HEK293T cells 
 
A culture of HEK293T cells was harvested and counted as described in Chapter 
2.3.4. For an ASC speck (Chapter 2.3.6) assay, 0.5 x 106 cells per well were 
seeded in a 24 well plate. For immunoprecipitation and western blot experiments, 
2.5 x 106 cells per well were seeded in a 6 well plate. Cells were incubated at 37 
°C and 10 % CO2 for 24 h before transfection. For the transfection, two separate 
tubes were prepared. In one tube an appropriate amount of OptiMEM was mixed 
with the required amount of DNA (50 ng/well for a 24 well plate, 2.5 µg/well for a 
6-well plate). The other tube contained OptiMEM and the required amount of 
Lipofectamine transfection reagent (1 µL/well for a 24 well plate, 3.25 µL/well for 
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a 6-well plate). Both, the DNA and Lipofectamine solutions, were incubated 
separately for 5 min at RT and then mixed and incubated for another 25 min at 
RT. This transfection mix was added to each well of the according plate and 
incubated with the cells for 18 h at 37 °C and 10 % CO2. 
 
2.3.6 ASC speck formation assay 
 
This assay was performed according to a technique described previously by 
Sester and colleagues (Sester et al., 2015). It was used to quantitively determine 
ASC speck formation, which can be used as a measure for inflammasome 
activation. HEK293T cells stably expressing an ASC protein fused to a red 
fluorescent protein (RFP) were transfected with either a plasmid encoding for 
human NLRP1 or a DNA control vector. The plasmid also encoded for a green 
fluorescent protein (GFP), which was expressed from an internal ribosomal entry 
site to enable gating for cells that are positive for NLRP1. The assay was 
performed in a 24 well plate and the transfection was carried out as described in 
Chapter 2.3.5. 50 ng of plasmid DNA were used per transfection per well. If the 
cells were to be treated with Talabostat, the medium was replaced with fresh 
medium containing 2 µM Talabostat or an equivalent amount of DMSO as a 
control, 18 h after transfection. After incubation for an additional 6 h (first time 
point) or 24 h (second time point) the cells were harvested for FACS analysis. To 
this end, the medium was removed from the cells and the cells washed once with 
1 x DPBS. Afterwards 100 µL Trypsin/EDTA was added to each well of the plate 
and the cells were incubated for 5 min at 37 °C. After adding 100 µL of DMEM to 
each well, cells were resuspended and transferred to a round bottom 96 well plate 
and then centrifuged for 5 min at 400 x g. The supernatant was discarded and 
the cells resuspended in 100 µL FACS buffer. FACS measurements were carried 
out with a Fortessa X20 (BD) using a High Throughput System. 80 µL of each 
well were analysed at a flow rate of 3 µL/s. The gating strategy used for FACS 
analysis and a representative fluorescence microscopy image of HEK293T cells 
with and without specks is visualized in Figure 2.1. 
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Figure 2.1: Gating strategy used in ASC speck assay 
(A) Representative dot plots and gating strategy of an ASC speck assay. In the 
first three graphs, the gating for single cells is displayed. The last two graphs 
show the gating for ASC+ cells (i.e. RFP+) and the gating for NLRP1+ cells (i.e. 
GFP+). Note that the cells were gated for low expression levels of GFP to reduce 
the influence of background activation from NLRP1 activated by high levels 
overexpression. (B) Dot plot representing the gating strategy to distinguish cells 
containing ASC specks from cells not containing ASC specks. Included are 
representative images of untransfected cells not showing any specks and cells 
transfected with NLRP1 and subsequently activated and thus showing ASC 
specks. Fluorescence microscopy was performed in assistance with Dr. Dominic 
de Nardo (Abbreviations: SSC: Side Scatter; FSC: Forward Scatter; A: Area; H: 
Height; W: Width; YG585_15: Filter for RFP; B530_30: Filter for GFP). 
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2.3.7 Immunoprecipitation 
 
For immunoprecipitation experiments, HEK293T cells were transfected with a 
plasmid encoding for NLRP1 or with an empty vector as a control. 
Immunoprecipitation was performed in a 6 well plate and the transfection carried 
out as described in Chapter 2.3.5. Cells were harvested 24 h after transfection 
by removing the media, washing the cells with 1 mL cold DPBS per well and 
adding 500 µL of cold NP-40 lysis buffer (1 % NP40 (v/v), 10 % Glycerol (v/v), 20 
nM Tris-HCl, 150 mM NaCl, 1 mM EGTA, 10 mM NaPPi, 5 mM NaF, 1 mM 
Na3VO4, 1 mM PMSF) supplemented with 1 x protease inhibitor cocktail. The 
cells were incubated in lysis buffer for 30 min on ice, transferred to a 1.5 mL 
Eppendorf tube and spun down in a microcentrifuge at 4 °C and maximum speed 
for 15 min. 60 µL of the supernatant were added to a fresh tube containing 20 µL 
4 x SDS sample buffer (240 mM Tris pH 6.8, 8 % (w/v) SDS, 40 % (v/v) glycerol, 
0.04 % (w/v) bromophenol blue, 5% (v/v) β-ME) serving as whole cell lysate 
control samples. The remaining supernatant was then added to 40 µL of 50 % 
Anti-FLAG M2® beads, which were previously washed twice in NP-40 lysis buffer. 
After incubation o/n at 4 °C under rotation, the beads were spun down in a 
microcentrifuge at 4 °C and maximum speed for 20 s and the supernatant was 
removed using a vacuum pump. The beads were washed three times in lysis 
buffer, resuspended in 30 µL SDS sample buffer and boiled at 96 °C for 5 min. 
Afterwards the samples were centrifuged at maximum speed for 5 min and 
immediately loaded onto a polyacrylamide gel or stored at -20 °C. In these 
experiments, 15 µL of the immunoprecipitation samples and 30 µL of the whole 
cell lysate samples were loaded onto a gel. SDS-PAGE and western blot analysis 
were performed as described in Chapter 2.4.9 and Chapter 2.4.10, respectively. 
 
2.3.8 Enzyme-linked Immunosorbent Assay (ELISA) 
 
Enzyme-linked Immunosorbent Assay (ELISA) was used to determine cytokine 
levels in supernatants of BMDM cultures. Culture supernatants were used neat 
or diluted 1 in 4 if required. A commercial ELISA kit was used to detect mouse or 
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human IL-1β (R&D Systems). ELISA plates were washed 4 times with 1 x PBS 
supplemented with 0.05 % Tween 20 between the single steps and developed 
using a 3,3’,5,5’-Tetramethylbenzidine (TMB) peroxidase substrate kit (VWR) 
and the reaction was stopped using 1 M H2SO4 (Thermo Fisher Scientific). 
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2.4 Methods – Protein biochemistry 
 
2.4.1 Expression of recombinant protein in bacteria 
 
For the expression of recombinant proteins in bacteria, E. coli BL21 (DE3) pLysS 
were used. After transformation of chemically competent E. coli BL21 with the 
plasmid containing the gene encoding the protein of interest, pre-cultures were 
grown in a shaking incubator o/n at 37 °C in 100 mL LB media supplemented with 
the appropriate antibiotics. Optical density of the pre-culture was determined the 
next day by measurement of the absorbance at 600 nm (OD600nm). An amount of 
pre-culture was used to inoculate the expression culture to reach a final OD600nm 
of 0.1. Expression cultures were grown at 37 °C and at a shaking frequency of 
110 rpm in 5 L flasks with baffles. OD600nm was determined every hour until the 
culture reached an optical density of 0.4-0.6. Protein expression was induced by 
adding isopropyl-β-D-thiogalactopyranoside (IPTG) at a final concentration of 0.3 
mM and the cultures were incubated for another 4 h at 30 °C or o/n at 20 °C. 
Cultures were harvested in 1 L buckets by centrifugation at 6229 x g at 4 °C 
for 20 min. The supernatant was discarded and the cell pellets were washed once 
in 1 x PBS and then transferred to 50 mL Falcon tubes. After another 
centrifugation step at 4501 x g and at 4 °C for 15 min, the cell pellets were either 
snap-frozen in liquid nitrogen and then stored at -20 °C or directly subjected to 
cell lysis and protein purification procedures. 
 
2.4.2 Expression of recombinant protein in Sf9 or Sf21 cells 
 
A culture of insect cells was diluted to a density of 1.5 x 106 cells/mL and then 5 
% (v/v) of V2 were added. The infected insect cells were grown in Fernbach flasks 
(max. culture volume 750 mL) or in 5 L Erlenmeyer flasks (max. culture volume 
1.5 L) at 27 °C. After 72 h the culture was checked for growth, vitality and average 
cell diameter using the EVE™ cell counter. If all of the parameters were as 
expected (decreased cell growth; viability > 80 %; average diameter > 13 µM) the 
culture was harvested at 1125 x g in 1 L buckets at 4 °C for 20 min. Afterwards, 
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the cell pellets were washed once in 1 x PBS, centrifuged again at 1125 x g at 4 
°C for 20 min and then snap-frozen in liquid nitrogen and stored at -20 °C or 
subjected to lysis and subsequent protein purification procedures. 
 
2.4.3 Cell lysis – Sonication 
 
Both, bacterial and insect cells, were lysed by sonication. The pellets were 
resuspended in 3 mL lysis buffer per gram cell pellet using a magnetic stirrer. The 
lysis buffer was supplemented with fresh phenylmethylsulfonylfluorid (PMFS) to 
a final concentration of 1 mM. The completely resuspended cell-suspension was 
sonicated with an amplitude of 30 % on ice. Bacterial cells were sonicated on ice 
4 x for 30 s with a break of 30 s between each sonication step. Insect cells were 
sonicated on ice 4 x for 15 s with a break of 15 s between each sonication step. 
Lysates were clarified by centrifugation in an Avanti J-26S XP centrifuge 
(Beckman Coulter) with a JA 25.50 rotor at 75481 x g at 4 °C for 30 min (bacterial 
lysates) or 1 h (insect cell lysates). Clarified lysates were further processed 
through a 0.45 µM filter to remove residual cell debris. Finally, the filtered lysates 
were used for affinity chromatography. For affinity chromatography performed 
according to the batch protocol, lysates were used unfiltered. 
 
2.4.4 Protein purification – Affinity chromatography 
 
Affinity chromatography is used to separate the protein of interest from 
contaminations like other proteins and nucleic acids present in the cell lysate. 
This is achieved by expressing the protein of interest as a fusion with an affinity 
tag. The tags used in this project include a Histidine6 tag (His6-tag), a glutathione 
S-transferase tag (GST-tag) and a maltose binding protein tag (MBP-tag). The 
affinity tags can specifically bind to ligands immobilized on a stationary phase, 
contaminants can be washed away and subsequently the protein of interest can 
be eluted from the stationary phase. The separation was carried out using either 
His-Trap FF, GSTrap FF or MBPTrap HP columns (GE Healthcare) attached to 
an FPLC (Äkta prime plus, GE Healthcare) or in a “batch” procedure using 
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Amylose Resin (New England Biolabs, for MBP-tagged proteins) or cOmplete 
His-Tag Purification Resin (Roche). All purification steps were carried out on ice 
or at 4 °C. 
FPLCs were run at a flow rate of 1 mL/min when applying the lysate to the 
column. To reduce the amount of non-specifically bound protein, columns were 
washed with at least 10 column volumes (CV) of buffer. Afterwards another 
washing step was carried out with 5 CV lysis buffer to reduce the salt 
concentration. In purifications with His-tagged proteins only one wash step with 
at least 10 CV lysis buffer was carried out. All washing steps were carried out 
using a flow rate of 3 mL/min. Finally, the specifically bound protein was eluted 
at a flow rate of 1 mL/min using a buffer containing 250 mM Imidazole, 30 mM 
reduced glutathione, or 10 mM maltose for His6-tagged, GST-tagged or MBP-
tagged proteins, respectively. Eluate was collected by an automated fractionator. 
For the batch protocol, clarified lysates were incubated with the according resin 
in 50 mL falcon tubes for at least 2 h at 4 °C under constant rotation. Washing 
steps were carried out similar to the FPLC protocol with the resin incubating in 
10 x resin volume of wash buffer for 10 min. The washing procedure was 
repeated three times. Elution was carried out by incubating the resin with 1 x resin 
volume elution buffer for 30 min at 4 °C. Elution procedure was repeated three 
times. In between wash and elution steps the beads were collected by 
centrifugation at 405 x g. During all purification steps the flow-through and wash 
fractions were collected and analysed by SDS-PAGE. 
 
2.4.5 Concentration of protein samples 
 
Protein samples were concentrated using Amicon Ultra Centrifugal Filter Units 
(Merck Millipore). In this application protein solution is filtered through an 
Ultracel® regenerated cellulose membrane. Proteins of larger size than the pore 
size of the membrane are retained, while the buffer and proteins of smaller size 
than the pore size pass through the membrane. Thereby, a concentration of the 
purified protein can be achieved. Filtration was carried out by centrifugation at 4 
°C until the desired volume or protein concentration was reached. 
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2.4.6 Determination of protein sample concentration 
 
A Nanodrop spectrophotometer was used to determine the protein concentration 
by measuring absorbance at 280 nm. Absorption at 260 nm was measured to 
monitor potential nucleic acid contaminations. The protein concentration was 
calculated according to the Beer–Lambert law, using the molecular weight and 
specific absorption coefficient determined with the ExPASy ProtParam tool 
(https://web.expasy.org/protparam). 
 
2.4.7 Tobacco Etch Virus (TEV) protease digestion 
 
For most constructs, the affinity-tag was fused N-terminally to the protein of 
interest and a TEV-protease cleavage site (amino acid sequence: ENLYVQGS) 
was inserted between the protein of interest and the affinity tag. The cleavage 
site was inserted to enable specific removal of the tag by proteolytic cleavage 
after affinity chromatography. To cleave off the affinity tag, TEV protease was 
added to the concentrated fusion protein at a ratio of 1/100 (mg TEV/mg protein). 
The protein was incubated with TEV at 4 °C o/n. Afterwards, size exclusion 
chromatography was performed to separate the TEV protease from the protein 
of interest. If the TEV protease was too similar in size to be separated by size 
exclusion chromatography, an additional affinity step was carried out to remove 
His6-tagged TEV protease. TEV protease was produced at the laboratory in Bonn 
(Germany). 
 
2.4.8 Protein purification – Size exclusion chromatography (SEC) 
 
In SEC, proteins are separated by size by applying them to a column containing 
a porous matrix with various pore sizes. Larger proteins elute earlier as they 
cannot enter smaller pores and therefore take less time to pass through the 
column. The opposite is the case for small proteins. Different columns were used 
for proteins of different molecular weight. A Superdex75, a Superdex200 or a 
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Superose6 (GE Healthcare) connected to an FPLC (Äkta Primer or Äkta Pure, 
GE Healthcare) were used in this work. After equilibrating the column in at least 
one CV of the according SEC buffer, protein samples were applied by injecting 
them into a loop connected to the FLPC. The flow-through was collected by an 
automated fractionator in fraction volumes of 0.5-2 mL. Small samples of each 
fraction were taken to be analysed by SDS PAGE. Fractions containing the 
protein of interest were pooled and concentrated as described in Chapter 2.4.5 
and then used for further analysis or snap-frozen in liquid nitrogen and stored at 
-80 °C. 
For the calculation of molecular weight estimates from analytical SEC elution 
profiles, the following formula was applied to calculate the Kav value: 
 𝑉" −	𝑉%𝑉& −	𝑉% 	= 	𝐾)* 
 
Here, Ve, VC and V0 denote the elution volume of the analyte, the volume of the 
entire column and the void volume of the column, respectively. Kav is the partition 
coefficient and can be described as the proportion of pores available to the 
analyte. Since there is a linear relationship between the Kav of a molecule and 
the logarithm of its molecular weight, a calibration curve can be generated by 
running a molecular weight standard. This makes it possible to calculate an 
estimate of the molecular weight from the elution volume of a protein. Proteins of 
molecular weight standards eluting outside the separation range of a column 
were excluded from the calibration curve. 
 
2.4.9 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
 
Monitoring of protein purity and molecular weight was carried out by analysing 
chromatography fractions and concentrated protein samples by SDS-PAGE and 
subsequent Coomassie-staining. In SDS-PAGE the proteins are denatured by 
diluting them in Laemmli sample buffer containing sodium dodecyl sulphate 
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(SDS) and boiling the samples at 96 °C for 5-10 min. The SDS is negatively 
charged and therefore masks the charge of the protein itself. Because proteins 
are denatured and negatively charged, they are separated only according to their 
relative molecular weight when run on a polyacrylamide gel. Gels that were run 
to be stained with Coomassie were poured using the BioRad miniPROTEAN 
system. Different percentages of acrylamide (12-20 %) were used in separation 
gels to ensure sufficient protein separation. Electrophoresis was performed at a 
constant current of 30 mA in the BioRad miniPROTEAN system. Coomassie-
staining was performed by incubating gels in 0.1 % (w/v) Coomassie R250 diluted 
in 40 % (v/v) ethanol and 10 % (v/v) acetic acid for 1 h. Afterwards, gels were 
destained in 10 % (v/v) ethanol and 5 % (v/v) acetic acid 2-3 times for 1 h or o/n. 
Commercial 4-12 % gradient gels with a thickness of 1.5 mm (NuPAGE® Novex™, 
Thermo Fisher Scientific) were used if the samples were further analysed by 
western blotting. Gradient gels were run at a constant voltage of 120 V. Protein 
transfer and western blot analysis are described in detail in Chapter 2.4.10. 
Commercial Novex™ SimplyBlue SafeStain solution (Thermo Fisher Scientific) 
was used for staining and Milli-Q® water was used for destaining of SDS gels run 
for mass spectrometric analysis of proteins. 
 
2.4.10 Western blot 
 
For analysis by western blot, protein samples were first separated according to 
their size by SDS-PAGE as described in Chapter 2.4.9. Afterwards the protein 
was transferred from the gel onto a Polyvinylidenfluoride (PVDF) membrane. For 
the transfer, the gel was placed on two layers of filter paper and a sponge 
previously soaked in 1 x western transfer buffer. The PVDF membrane was 
activated in 100 % methanol before it was positioned directly on the gel and 
covered with two more layers of soaked filter paper and a sponge. The transfer 
was carried out at a constant voltage of 100 V at 4 °C for 90 min. Subsequently, 
the membrane was stained with Ponceau S solution to confirm the successful 
transfer of proteins. Then the membranes were destained in PBS supplemented 
with 1 % Tween 20 (PBS-T) and blocked for 1 h at RT in 5 % skim milk in PBS-
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T. The membranes were incubated with primary antibody o/n at 4 °C. Primary 
antibody incubation was followed by 3 washing steps in PBS-T for 10 min each 
and incubation with secondary antibody conjugated to horseradish peroxidase 
(HRP) at RT for 1 h. After incubation with secondary antibody the membranes 
were washed 3 times for 30 min in PBS-T. The membranes were then incubated 
with a solution containing substrate for HRP and directly exposed. Images were 
taken using a ChemiDoc™ Touch Imaging System (Bio-Rad). Antibodies: 
aNLRP1: AL176 (AdipoGen); aFLAG: 9H1 (WEHI protein facility); aActin: b-
Actin. 
 
2.4.11 Mass spectrometry 
 
To confirm the identity of recombinant proteins, several samples were analysed 
by peptide mass fingerprint. In this mass spectrometry approach, proteins are 
first digested using a protease (e.g. trypsin) and the resulting peptides are purified 
and applied to mass spectrometry. The peptide masses can then be compared 
to a database of peptides to identify the proteins that were subjected to enzymatic 
digestion. 
Protein that was intended to be analysed by mass spectrometry was separated 
by SDS-PAGE as described in Chapter 2.4.9 and then stained with SimplyBlue 
SafeStain (Thermo Fisher Scientific). Bands of interest were excised from the gel 
and transferred to a clean 1.5 mL polypropylene tube. Gel pieces were 
centrifuged to the bottom of the tube and then destained for 15 min at 37 °C while 
shaking in 100 µL of a 50 mM ammonium bicarbonate and 50 % acetonitrile 
solution. Destaining solution was removed by vacuum and the destaining step 
repeated until the gel pieces appeared clear. After removing the destaining 
solution 100 µL of 100 % acetonitrile were added, followed by 15 min incubation 
at RT. Proteins were then reduced in 10 mM dithiothreitol in 100 mM ammonium 
bicarbonate for 30 min at 37 °C while shaking. Excess DTT was removed using 
vacuum suction. Subsequently, proteins were alkylated in 100 µL of 55 mM 
iodoacetamide in 100 mM ammonium bicarbonate for 30 min at 37 °C (protected 
from light). Then the alkylation solution was removed, the gel slices washed twice 
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in destaining solution and dehydrated in 100 µL of 100 % acetonitrile for 15 min. 
After removing the acetonitrile, the gel slices were air dried and then rehydrated 
in 40 µL of trypsin solution (15 ng/µL) for 45 min on ice. When the slices were 
completely rehydrated, the trypsin solution was removed, the gel pieces covered 
in 40 µL of 25 mM ammonium bicarbonate and the samples wrapped in parafilm 
and incubated o/n at 37 °C. The next day samples were centrifuged before adding 
60 µL of extraction buffer (0.1 % formic acid in 60 % acetonitrile) to each tube. 
Samples were incubated for 30 min at RT with extraction buffer and the extracted 
peptides then transferred to a labelled microvial. The extraction procedure was 
repeated once. Samples were acidified by adding formic acid to a final 
concentration of 1 % (v/v). Prior to analysis samples were lyophilized to dryness 
and stored at -80 °C. Samples were reconstituted in 20 µL of 0.1 % formic acid 
and 2 % acetonitrile before measurements. Mass spectrometry samples were run 
and analysed by Dr. Jarred Sandow at the proteomics facility of the Walter and 
Eliza Hall Institute (Melbourne, Australia). 
 
2.4.12 Small-angle X-Ray scattering (SAXS) 
 
Protein of the second peak (Chapter 3.3.5 and 3.3.6) of a full length MBP-NLRP1 
(WT) purification was pooled and concentrated to the indicated concentrations. 
100 µL of protein sample was loaded onto a Superose 6 increase (5/150) column. 
The SEC run was performed at a flow rate of 0.4 mL/min. The column was 
connected to the SAXS capillary, ensuring that the protein enters the capillary 
directly after eluting from the SEC column. SAXS measurement was carried out 
at the Australian Synchrotron in Melbourne in assistance with Prof. James 
Murphy from the Walter and Eliza Hall Institute. 
 
2.4.13 Reversed-Phase High-Performance Liquid Chromatography (RP-
HPLC) based hydrolysis assay 
 
High-performance liquid chromatography (HPLC) is a technique used in 
analytical chemistry to separate, identify and quantify different chemicals 
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contained in a mixture. In Reversed-Phase (RP) applications of HPLC the 
stationary phase of the chromatography column is inverted compared to Normal-
Phase chromatography, as it is hydrophobic. This gave rise to the name 
Reversed-Phase Chromatography. RP-HPLC poses a highly sensitive technique 
to separate analytes. Adding ion pair reagent to the HPLC buffer, further allows 
the separation of partly ionized analytes. The nucleotides ATP, ADP and AMP all 
carry negative charges (ATP: 4-, ADP: 3-, AMP: 2-) at neutral pH and only differ 
slightly in size. Using ion pair RP-HPLC the three nucleotides can be separated. 
By determination of the area of the elution peaks in the according chromatogram, 
a quantification of the nucleotides is possible. With these properties ion pair RP-
HPLC is a suitable and highly sensitive technique to measure and characterise 
ATP hydrolysis reactions and was therefore used to determine the hydrolysis 
activity of MBP-NLRP1. 
Nucleotides were separated using a Chromolith Performance RP-18 100-4.6 
HPLC column and the corresponding guard cartridge Chromolith RP-18 (Merck, 
Darmstadt, Germany). The measurement was performed using an Agilent 1260 
infinity PSS bio-inert HPLC System (Agilent Technologies, Inc., Santa Clara, 
USA). The mobile phase was composed of 10 mM TBA-Br, 30 mM K2HPO4, 70 
mM KH2PO4, 0.2 mM sodium-azide, and 4 % acetonitrile. The pH of the mobile 
phase was adjusted to 6.5 and afterwards it was filtered through a 0.22 µm filter. 
Acetonitrile was added after adjusting the pH and filtering the mobile phase to 
avoid foaming during the filtration step. Reactions were set up to contain 3 µM 
MBP-NLRP1 Peak 1 protein and 100 µM ATP (or a different nucleotide as 
indicated) in a 10 x buffer containing 20 mM HEPES (pH 8.0), 150 mM sodium 
chloride and 5 mM MgCl2. Nucleotides were added last and reactions were 
placed in the autosampler of the HPLC immediately after addition of the 
nucleotides. Reactions were incubated and run at 25 °C and at a flow rate of 1 
mL/min. A sample was taken by the autosampler at the start of the measurement 
and every 10 minutes afterwards. Nucleotide elution was monitored at 254 nm 
and protein elution was monitored at 280 nm. Peaks were manually identified and 
automatically integrated. The sum of the peak integrals of one measurement was 
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normalized to 100 % to allow quantification and comparison of the nucleotide 
content in the reaction. 
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3. Biochemical and structural characterisation of 
recombinant NLRP1 
 
3.1 Introduction 
 
Seven isoforms of human NLRP1 are reported in the UniProt database 
(Accession Code: Q9C000). Isoform 1 of the human NLRP1 protein consists of 
1473 amino acids and has a theoretical molecular weight (MW) of 165.86 kDa. 
As other members of the NLRP protein family it harbours an N-terminal PYD 
(pyrin domain) and a central NACHT domain (found in NAIP, CIITA, HET-E and 
TEP1) followed by a domain composed of leucine rich repeats (LRR). 
Additionally, NLRP1 contains a FIIND (domain with “function to find”) located C-
terminal in respect to the LRR and a CARD (caspase activation and recruitment 
domain) on the very C-terminus. This unique feature makes NLRP1 stand out in 
the family of NLRP inflammasome proteins. Furthermore, with about 240 amino 
acids in length the linker region connecting the PYD and NACHT domain is by far 
the longest compared to that of other NLRPs. For instance, in the NLRP3 protein 
this linker region is comprised only of about 130 amino acids. 
Both, the PYD and the CARD domain, belong to the superfamily of death 
domains (DD), typically adapting a six helix bundle fold (Park, Lo, et al., 2007). 
Their 3D structures have been determined by solution NMR and X-ray 
crystallography, respectively (Hiller et al., 2003; Jin et al., 2013). Interestingly, the 
NMR structure of the NLRP1 PYD revealed a lack of alpha helix 3 (a3) and 
instead a flexible, unstructured loop between a2 and a4. Recent findings showed 
that for NLRP1 the PYD has an autoinhibitory function (Zhong et al., 2016). This 
is different compared to other NLRP proteins like NLRP3, where the PYD is 
directly involved in the activation of Caspase-1 by binding the adaptor protein 
apoptosis-associated speck-like protein containing a CARD (ASC) (Vajjhala et 
al., 2012). Furthermore, NMR studies of the PYD showed that a destabilization 
of the hydrophobic core by introducing point mutations results in autoactivation 
of the NLRP1 inflammasome (Zhong et al., 2016). The lack of a3 might explain 
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the difference in function of the NLRP1 PYD compared to other NLRP proteins. 
However, this aspect has never been investigated in depth. 
The NLRP1 CARD structure (PDB: 3KAT) presents as a typical six helix 
bundle fold. Since NLRP1 harbours a CARD domain, it was hypothesized that it 
could interact directly with Caspas-1 CARD. Electrostatic surface charge analysis 
of the NLRP1 CARD crystal structure and a Caspase-1 CARD homology model 
unveiled complementary charged surfaces, which could promote an interaction 
between the two domains (Jin et al., 2013). Indeed, it has been shown that under 
some conditions mouse NLRP1 variants can activate Caspase-1 independent of 
ASC (Masters et al., 2012; Van Opdenbosch et al., 2014). However, different 
functional studies have also shown that the CARD of NLRP1 can engage with 
the adaptor protein ASC to form a functional inflammasome (Faustin et al., 2007; 
Zhong et al., 2016). 
In addition, the NLRP1 LRR structure has been determined by X-ray 
crystallography, showing six consecutive repeats with an N-terminal capping 
helix and an additional C-terminal b-sheet (Reubold et al., 2014). Furthermore, a 
molecular envelope was calculated from SAXS data recorded for a construct 
spanning the NACHT and LRR domains. When fitting the closed (inhibited) and 
open (active) conformation of reported NLRC4 NACHT-LRR structures into this 
envelope, the open conformation was found to produce the better fit (Martino et 
al., 2016). Functionally, it was shown that the protein is constitutively active when 
the LRR is missing, indicating an autoinhibitory function of this domain 
(Chavarría-Smith et al., 2016). 
Using a bioinformatics approach it was found that the FIIND domain has high 
structural similarity to a ZU5 (initially found in ZO-1 and UNC5) and UPA 
(conserved in UNC5, PIDD and Ankyrins) domain tandem (D’Osualdo et al., 
2011). However, to date there is no high resolution structural information 
available for the NLRP1 FIIND domain. 
NLRPs are described to adapt a closed conformation in an autoinhibited state 
and undergo conformational changes to an open conformation when activated. 
After transition to the open, active state NLRPs assemble into oligomers. The N-
terminal part of NLRP1 has a similar modular domain architecture as other 
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NLRPs and would therefore be expected to adapt a similar oligomeric 
conformation. As mentioned above, NLRP1 has two additional domains (FIIND 
and CARD) compared to other NLRP proteins. Therefore, it is likely that its overall 
oligomeric fold is extended compared to other NLRP oligomers. The only 
structural information available on full-length NLRP1 is a negative stain electron 
microscopy (EM) study on recombinant protein purified from Sf9 cells. The EM 
analysis showed a mix of monomers and oligomers, where most oligomers 
presented as pentamers or heptamers (Faustin et al., 2007). 
Further structural information on the NLRP1 protein is of great interest to gain 
a better understanding of the molecular mechanisms underlying regulation and 
activation of this inflammasome.  
 Results 
72 
3.2 Results 
 
3.2.1 Sequence based analysis of NLRP1 domain architecture 
 
Improving the understanding of the molecular basis of NLRP1 inflammasome 
regulation and activation by gaining structural information was approached in two 
different ways. The gene encoding full-length human NLRP1 was cloned into a 
vector as an N-terminal maltose binding protein (MBP) fusion (full-length 
approach). Apart from that several constructs of separate domains of NLRP1 
were designed (domain-based approach). Analysis of the primary amino acid 
sequence of the canonical isoform 1 of human NLRP1 was performed, to get an 
understanding of its domain architecture. This is crucial to determine boundaries 
for constructs for recombinant protein expression. For a thorough analysis, a 
combination of sequence alignments with the known structures described in 
Chapter 3.1 and sequence analysis tools were applied. A detailed analysis of the 
primary sequence of the NLRP1 protein revealed several subdomains and 
conserved motifs and repeats. This analysis further allowed determination of 
domain boundaries, which are depicted in Figure 3.1A. For the PYD (1-93), 
NACHT-LRR (230-990), LRR (791-990) and CARD (1372-1467) domain 
containing constructs, the boundaries were mainly determined based on 
alignments with the sequence of the according published structures. Since there 
was no structure available for the FIIND domain, an alignment with a similar 
domain that has been structurally determined was performed. The protein Unc5b 
harbours a ZU5-UPA tandem as well, of which the structure has been determined 
by X-ray crystallography (PDB: 3G5B). Based on an alignment of the NLRP1 
FIIND with the ZU5-UPA sequence of Unc5b (Figure 3.1B) and considering the 
boundaries of the flanking domains, the FIIND domain containing construct was 
determined to span residues 1084-1376. A biochemical characterization and in-
depth structural analysis of selected constructs including the full-length NLRP1 
protein will be described in the following chapters. 
  
 Results 
73 
  
B 
1079 
1380 
A 
 Results 
74 
Figure 3.1: Domain and construct boundaries determined for NLRP1 
(A) Schematic diagram of the modular domain architecture of human NLRP1. 
Numbers indicate amino acid number according to the primary amino acid 
sequence. Numbers below the schematic represent domain boundaries 
determined from the primary amino acid sequence and used for the design of 
constructs for recombinant protein expression. Subdomains are depicted below 
the bar diagram. Conserved motifs and sequence elements are highlighted in 
different colours. (B) Sequence alignment of the sequence of the UNC5b 
cytoplasmic domain (taken from PDB: 3G5B) with NLRP1-FIIND domain (amino 
acid 1079-1380). Alignment: Clustal Omega (Madeira et al., 2019); Secondary 
structure assignment: ESPrit 3.0 (Robert and Gouet, 2014); Explanation of 
symbols: squiggles: helix, arrows: b-sheet, TT: b-turn, black empty arrows 
indicate domain boundaries chosen for FIIND domain construct. 
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3.2.2 Purification and characterization of NLRP1 PYD 
 
NLRP1-PYD was expressed in E. coli BL21 cells as an N-terminal GST-fusion 
protein (Figure 3.2A). It was purified to homogeneity as shown by analytical SEC 
and SDS-PAGE analysis (Figure 3.2B and C). Analytical SEC after removing the 
GST-tag by TEV cleavage showed that the PYD behaves as a monomer in 
solution. NLRP1 PYD elutes as a single peak with an apparent MW of 15.96 kDa 
as determined from the SEC elution profile. This is slightly higher than the 
calculated molecular weight of 10.37 kDa, based on the amino acid sequence. In 
SDS-PAGE analysis the PYD runs at the expected molecular weight below the 
14.4 kDa band of the marker. 
The structure of NLRP1 PYD has been determined previously by NMR 
spectroscopy (PDB: 1PN5) (Hiller et al., 2003). A computational structure function 
analysis was carried out, aiming to understand the difference in function between 
NLRP1 PYD and other PYDs in the NLRP protein family. In the NMR study the 
lack of a3 was already identified. This is a major difference to other PYDs. A 
sequence alignment with the NLRP3 PYD showed that NLRP1 has a proline 
(P45) residue in the centre of the region where a3 would be expected to form 
(Figure 3.2D). Proline residues are known to disrupt a-helices (Li et al., 2005). 
Alignment of the sequence of the first 120 amino acids (containing the PYD) of 
all NLRP proteins revealed that only NLRP1 harbours a proline in this position 
(Appendix, Figure A1). Thus, the presence of a proline residue in this position 
could prevent a3 formation in NLRP1 PYD. However, a comparison of the 
structure of NLRP1 and NLRP3 PYD showed that a lack of a3 in NLRP1 does 
not disrupt the overall fold (Figure 3.2E). In fact, it is comparable to NLRP3 PYD 
with some helices (a4, a5, a6) showing slightly different orientations. So far it is 
not clear, whether the lack of a3 is the reason for NLRP1 PYD being 
autoinhibitory rather than the effector domain and binding ASC like NLRP3 PYD. 
To further assess this, the surfaces of NLRP3 PYD required for its interaction with 
ASC PYD were investigated regarding conservation in NLRP1 PYD. In an NMR 
study two main interfaces were identified to facilitate the interaction of NLRP3 
and ASC PYD (Oroz et al., 2016). The according residues identified in these 
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interfaces are highlighted in Figure 3.2D. Interface 1 is mainly formed by a1 and 
a2. Residues Y12, E14 and L21 are identical to NLRP3 in regards to their relative 
positions. Residues E20 and E52 are charge conserved between NLRP3 and 
NLRP1. Interface 2 is located mainly in a5 and residues G62 and W67 are 
identical with NLRP3 PYD. L71 is hydrophobic in interface 2 of NLRP3 PYD and 
H92 is charge conserved between the two PYDs. For NLRP3, none of the 
residues directly involved in the interaction with ASC are located within a3. Thus, 
the structural difference of NLRP1 PYD compared to NLRP3 PYD does not 
directly indicate the difference in their function. Nevertheless, the a3 helix has 
been described to play an essential role in self-association and the formation of 
filaments for both ASC and NLRP3 PYD (Oroz et al., 2016). As such an important 
mediator of homotypic interactions between PYDs, a3 might still affect 
interactions of heterotypic interactions of PYDs of different proteins by allowing 
homotypic interactions. 
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Figure 3.2: Biochemical and computational characterization of NLRP1 
PYD 
(A) Schematic representation of the GST-PYD expression construct. (B) 
Analytical SEC of NLRP1 PYD (TEV cleaved). The protein sample was run on a 
Superdex 75 (3.2/300) column at a flow rate of 0.04 mL/min. (C) Coomassie-
stained SDS-PAGE of TEV-cleaved, purified NLRP1 PYD. 4 µg of the protein 
sample were run on a 20 % acrylamide gel. (D) Sequence alignment of NLRP3 
and NLRP1 PYD sequences. The position of Proline 45 of NLRP1 PYD located 
within the region where a3 would be expected is highlighted in blue. Alignment: 
Multalin Tool (Corpet, 1988); Secondary structure assignment: ESPrit 3.0 (Robert 
and Gouet, 2014); Explanation of symbols: squiggles: helix, filled arrows: 
residues identified for interface 1 required for ASC interaction of NLRP3 PYD, 
empty arrows: residues identified for interface 2 required for ASC interaction of 
NLRP3 PYD. (E) Structures of NLRP3 PYD (PDB: 2NAQ) and NLRP1 PYD (PDB: 
1PN5). Secondary structure elements are shown in cartoon representation. 
Proline 45 of NLRP1 PYD is shown in stick representation. Images were 
generated with PyMOL. 
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3.2.3 Purification and characterization of NLRP1 LRR 
 
The construct for recombinant protein expression of the NLRP1 LRR domain was 
designed as an N-terminal GST-fusion protein as shown in Figure 3.3A. It was 
expressed in E. coli BL21 cells and purity and homogeneity of the final TEV 
cleaved protein product were analysed by analytical SEC and SDS-PAGE. On 
the Coomassie-stained SDS-gel only minor impurities can be observed. NLRP1 
LRR, with a calculated molecular weight of 22.61 kDa, runs at the expected height 
just below the 25 kDa band of the marker (Figure 3.3B). In analytical SEC the 
TEV cleaved LRR elutes as a single peak species with an elution volume 
corresponding to an apparent molecular weight of 55 kDa (Figure 3.3C). 
Interestingly, this is more than twice as much as calculated for monomeric NLRP1 
LRR (22.61 kDa) from the amino acid sequence. This suggests that the LRR 
might form a dimer in solution. To further analyse the LRR, the protein was 
crystallized (Figure 3.3D) and the structure of the LRR determined to a resolution 
of 2.1 Å (Protein crystallization, X-ray diffraction measurement, density 
calculation and model building was performed by Dr. Kanchan Anand). The 
structure of one asymmetric unit is visualized in Figure 3.3E. Since there were 
two molecules per asymmetric unit and analysis by analytical SEC indicated a 
dimer, the structure was analysed for a potential interface that facilitates an 
interaction between LRR molecules. Only one potential interaction site was found 
located near the C-terminus of one molecule and the N-terminus of the other 
molecule within the asymmetric unit. Residues that are in close proximity at this 
site are shown in stick representation in Figure 3.3E. Distance measurements in 
PyMOL reveal that these residues are close enough to interact by ionic 
interactions or to form hydrogen bonds. However, no obvious complementary 
charges, hydrogen bond donors or acceptors or hydrophobic patches between 
the residues of the two molecules can be observed. Therefore, the dimer 
formation of the purified LRR is more likely to be an artefact of the purification or 
crystallization procedure and might not be of physiological relevance. 
The previously published structure of NLRP1 LRR was crystallized with one 
molecule per asymmetric unit (Reubold et al., 2014). An overlay of the structure 
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solved in this work and the published structure is shown in Figure 3.3F. Both 
structures display six consecutive repeats with an N-terminal capping helix and a 
C-terminal b-sheet. On the outside of both structures the a-helices form a convex 
surface and on the inside the b-sheets form a concave surface. The structures 
are well fitted with all a-helices and b-sheets adapting very similar orientations. 
The root-mean-square deviation (RMSD) calculated by PyMol was 0.622, further 
indicating a good fit of the two structures.  
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Figure 3.3: Biochemical characterization and crystal structure 
determination of NLRP1 LRR 
(A) Schematic representation of the GST-LRR expression construct. (B) 
Analytical SEC of NLRP1 LRR (TEV cleaved). The protein sample was run on a 
Superdex 75 (3.2/300) column at a flow rate of 0.04 mL/min. (C) Coomassie-
stained SDS-PAGE of purified NLRP1 PYD (TEV cleaved). 4 µg of the protein 
sample were run on a 15 % acrylamide gel. (D) Images of crystals of TEV cleaved 
NLRP1 LRR protein. (E) Crystal structure of NLRP1 LRR with two molecules 
(molecule one: grey, molecule two: wheat) in the asymmetric unit. Residues 
potentially involved in an interaction between LRR molecules are shown in stick 
representation and labelled with the respective one-letter code and number in the 
NLRP1 amino acid sequence. Numbers between residues depict distances (in Å) 
measured between atoms connected by dashed yellow line. (F) Overlay of the 
NLRP1 LRR structure determined in this work (blue) with the structure previously 
published for NLRP1 LRR (red, PDB: 4IM6) revealed an RMSD of 0.622. Images 
and distance measurements in E and F were generated with PyMOL. 
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3.2.4 Analysis of potential intramolecular interactions in NLRP1 
 
Since the domain architecture as well as the function of the PYD of NLRP1 differs 
from that of other members of the NLRP protein family, its overall conformation 
is likely to be different as well. NLRP1 PYD might fold back onto another domain, 
thereby keeping the protein in an autoinhibited conformation. To investigate if 
intramolecular interactions are involved in keeping the protein in an autoinhibited 
conformation, analytical SEC of different constructs spanning one or multiple 
domains of NLRP1 was performed. The constructs for NLRP1 PYD and LRR 
were the same as described in Chapters 3.2.2 and 3.2.3. Constructs spanning 
the NACHT-LRR domain as well as the FIIND, CARD or both the FIIND and 
CARD domains were designed as N-terminal MBP-fusion proteins (Figure 3.4A). 
All of the MBP-tagged constructs were purified to high purity and homogeneity as 
shown by SDS-PAGE analysis (Figure 3.4C) and used without the tag being 
cleaved off. Cleavage of the MBP led to aggregation and precipitation of the 
proteins, making them unusable for further experiments. 
In Figure 3.4B, analytical SEC elution profiles of the interaction studies are 
displayed. In analytical SEC runs, the MBP-CARD construct behaved as a 
monomer, eluting as a single peak at a volume corresponding to a molecular 
weight of 35.65 kDa. This is significantly lower than the expected molecular 
weight of 52.73 kDa, indicating that the MBP-CARD protein is tightly packed. Both 
constructs harbouring the FIIND domain eluted as a tailing peak in the void 
volume of the column. This indicates either a high degree of oligomerization or 
aggregation of the protein. The molecular weight of these constructs was 
therefore not determined. The MBP-NACHT-LRR construct eluted as a single 
peak at a volume corresponding to a molecular weight of 239.64 kDa. This is 
almost twice as much as the molecular weight calculated for the monomeric MBP-
NACHT-LRR construct of 126.68 kDa, indicating the possibility of dimer 
formation.  
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Figure 3.4: Interaction studies of NLRP1 PYD with other domains of 
NLRP1 
(A) Schematic representation of the expression constructs for the FIIND, FIIND-
CARD and NACHT-LRR domains used in interaction studies. (B) Analytical SEC 
of NLRP1 PYD with other domains of NLRP1. Proteins were mixed in a 1:1 molar 
ratio at a concentration of 10 µM in a total volume of 50 µL. The protein mix was 
incubated at RT for 30 min before loading into a 20 µL loop connected to an ÄKTA 
micro device. The PYD and LRR samples were run on a Superdex 75 (3.2/300) 
column. The PYD and MBP-NACHT-LRR, MBP-FIIND, MBP-FIIND-CARD and 
MBP-CARD samples were run on a Superose 6 (3.2/300) column. All SEC 
samples were run at a flow rate of 0.04 mL/min. Peaks of the molecular weight 
standard are 667 kDa, 158 kDa, 44 kDa, 17 kDa and 1.35 kDa (left to right). (C) 
Coomassie-stained SDS-PAGE of purified MBP-NACHT-LRR, MBP-FIIND, 
MBP-FIIND-CARD and MBP-CARD. 4 µg of the protein samples were run on a 
15 % acrylamide gel. 
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Whether NLRP1 PYD interacts intramolecularly with any of the other domains of 
NLRP1 was investigated by mixing TEV-cleaved NLRP1 PYD in a 1:1 molar ratio 
with one of the other domains. The protein mixture was incubated at RT for 30 
min before applying the sample to a SEC column. If the PYD would interact with 
any of the other domains, a new peak species eluting at a higher molecular weight 
than the peaks of the domains by themselves would be expected to appear in the 
according elution profile. However, no peaks corresponding to a complex formed 
between the PYD and another domain was found in these experiments (Figure 
3.4B). These results indicate that the NLRP1 PYD does not strongly interact with 
any of these domains under the experimental conditions tested. Nevertheless, 
this does not exclude the possibility of intramolecular interactions in the context 
of the full-length protein. 
As a positive control for the analytical SEC experiments, nanobodies specific 
for the NLRP1 PYD and CARD domain were applied (expression plasmids for 
nanobodies provided by Dr. Florian I. Schmidt). Nanobodies were purified to 
homogeneity as shown by SDS-PAGE and preparative (AF-F08, PYD specific 
nanobody) or analytical (Q2-G06, CARD-specific nanobody) SEC (Figure 3.5A, 
B and C). Both nanobodies elute as a single peak species with an apparent 
molecular weight of 9.42 kDa (AF-F08) and 14.67 kDa (Q2-G06). This is close to 
their calculated molecular weight of 14.61 kDa and 14.67 kDa, respectively. 
Interaction of the nanobodies with the respective interacting domain was first 
analysed by analytical SEC. For NLRP1 PYD and the according nanobody AF-
F08, complex formation is clearly visible in the SEC elution profile. A mixture of 
the two proteins (1:1 molar ratio), which was incubated at RT for 30 min, elutes 
as a higher molecular weight complex compared to the run of the PYD or the 
nanobody separately (Figure 3.5A). Samples of a preparative SEC run of the 
PYD/AF-F08 complex were analysed by SDS-PAGE, showing a 1:1 ratio of the 
two proteins. A sample containing 1:1 protein complex of PYD/AF-F08 was 
subjected to crystallization trials (carried out by Dr. Kanchan Anand). The 
complex grew into rod-shaped crystals (Figure 3.5D). However, when exposed 
to X-rays these crystals did not diffract. Binding of AF-F08 to NLRP1 PYD was 
further characterized by SPR (SPR measurement carried out by Dr. Karl 
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Gatterdam). The nanobody showed good binding to the immobilized GST-PYD 
in the SPR experiment and the kD was determined to 52.8 nM. 
Elution profiles recorded for the nanobody specific for NLRP1 CARD did not 
indicate complex formation, since no new peak species could be observed 
(Figure 3.5C). This implies that in solution, the surface of NLRP1 CARD required 
for the interaction with the nanobody might be blocked by the MBP-tag. 
Therefore, results obtained for the investigation of intramolecular interactions with 
MBP-fusion proteins have to be interpreted with care. 
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Figure 3.5: Interaction studies with NLRP1-specific nanobodies 
(A) Analytical SEC of NLRP1 PYD with a PYD specific nanobody (AF-F08). 
Nanobody and PYD were run separately and as a complex. For complex 
formation, proteins were mixed in a 1:2 molar ratio (PYD:nanobody) and 
incubated at RT for 30 min. All samples were run on a Superdex 75 (10/300 GL) 
column at a flow rate of 0.4 mL/min. (B) SDS-PAGE of PYD/AF-F08 complex 
after SEC (1), a 1:2 mix before SEC (2) and PYD (3) and AF-F08 (4) separately. 
Samples were run on a 20 % acrylamide gel. (C) Analytical SEC of NLRP1 CARD 
fused to MBP with a CARD specific nanobody (Q2-G06). Nanobody and Q2-G06 
were run separately and as a complex. For complex formation, proteins were 
mixed in a 1:1 molar ratio (MBP-CARD:nanobody) and incubated at RT for 30 
min. All samples were run on a Superose 6 (3.2/300) column at a flow rate of 
0.04 mL/min. (D) Crystals of the PYD/AF-F08 protein complex. (E) SPR 
measurement of GST-PYD (ligand) and AF-F08 (analyte) as well as of a GST 
only control. Concentrations: GST-PYD (25 nM); AF-F08 (32, 64, 128, 256, 512, 
1024, 2048, 4096 nM). 
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3.2.5 Recombinant full-length MBP-NLRP1 forms oligomers 
 
Structural information of full-length NLRP1 is required for a more detailed 
structure-function analysis. A high resolution structure could reveal 
intramolecular interactions and potential interaction interfaces. This information 
could further be used to map mutations involved in autoimmune disorders 
associated with NLRP1 and thus unveil the functional consequences that these 
mutations might have. Therefore, full-length human NLRP1 was expressed as an 
N-terminal MBP-fusion protein (Figure 3.6A) in baculo virus infected Sf9 and Sf21 
insect cells. The protein was processed to high purity, as shown by SDS-PAGE 
analysis in Figure 3.6B. In preparative SEC experiments the protein eluted as a 
single peak in the void volume of the chromatography column (Figure 3.6B). The 
peak showed a significant tail, running near the void volume. Since the main peak 
was eluting outside the separation range of the column, no molecular weight 
estimate could be determined by SEC for MBP-NLRP1. Elution in the void volume 
corresponds to a higher molecular weight than the column is able to separate. In 
the case of MBP-NLRP1 this means it elutes much bigger than its monomeric 
molecular weight of 207 kDa. This indicates that the protein is forming higher 
order oligomers or protein aggregates. 
To investigate this further, samples of the main peak as well as the tail were 
taken for analysis by negative stain electron microscopy (images recorded by Dr. 
Heide Behrmann). For the main peak, many large protein particles of different 
size were observed, showing that the majority of the protein in this sample is 
comprised of inhomogeneous oligomers and aggregates (Figure 3.6C). Protein 
samples taken from the tail of the peak looked more homogeneous. Therefore, 
isolating this part of the protein sample was intended to be achieved by modifying 
the purification protocol.  
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Figure 3.6: Purification and negative stain EM of MBP-NLRP1 
(A) Schematic of the MBP-NLRP1 construct. (B) Representative elution profile of 
a preparative SEC and SDS-PAGE analysis of MBP-NLRP1. MBP-NLRP1 was 
run on a Superose 6 (16/600) column at a flow rate of 0.2 mL/min. 10 µL of the 
eluting fractions were taken as samples for SDS-PAGE. The displayed 
Coomassie-stained gel covers the range of the peaks as marked by the black 
bracket. SDS samples were run on a 12 % acrylamide gel. (C) Negative stain 
electron microscopy of MBP-NLRP1. Samples were taken directly from fractions 
20 and 59 as highlighted in the chromatogram. Fraction 20 was diluted in SEC 
buffer to a concentration of 0.11 mg/mL. Fraction 59 had a concentration of 0.10 
mg/mL and was applied to an EM grid without further processing.  
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One approach to single out the homogeneous protein and prevent uncontrolled 
oligomer formation, is to add specific nanobodies that could potentially block 
interaction interfaces involved in oligomerization. The two nanobodies described 
in 3.3.5 are appropriate candidates to test in this context. However, in analytical 
SEC experiments, addition of either of the nanobodies did not result in a 
significant change in the elution behaviour of MBP-NLRP1 (Figure 3.7A). The 
main peak of the MBP-NLRP1 protein was slightly shifted towards a higher elution 
volume. Nevertheless, no new peak species could be observed when the 
nanobodies were added to MBP-NLRP1 in a 1:1 molar ratio. Thus, an 
accumulation of the homogeneous protein sample was not achieved. 
In addition to utilizing the nanobodies to separate the homogeneous protein 
from the inhomogeneous protein, alternative purification protocols were 
developed. One major change in the protocol was the usage of amylose resin 
following a gravity flow protocol instead of MBPTrap columns connected to an 
ÄKTA FPLC device. This change in the affinity chromatography step seemed to 
improve the elution behaviour of MBP-NLRP1. The more gentle batch method 
changed the elution behaviour of the protein, resulting in two distinct peaks and 
an accumulation of the homogenous part of the protein sample (Figure 3.7B). 
SDS-PAGE analysis of the different peaks showed that both, the first and the 
second peak, contained mainly MBP-NLRP1 (Figure 3.7B). A third peak species 
visible in the elution profile was shown to contain mainly contaminations or 
degradation products by SDS-PAGE (Figure 3.7B, SDS-PAGE not shown). 
Protein of the second peak was further analysed by mass spectrometry. Identity 
of the protein in the top two bands (Figure 3.7B) was confirmed to contain MBP-
NLRP1. Interestingly, the band observed just above the 25 kDa band of the 
marker, was shown to contain the C-terminal cleavage fragment of NLRP1 
(Appendix, Figure A2). Thus, the protein sample is comprised of a mixture of full-
length MBP-NLRP1 and MBP-NLRP1 that was autolytically cleaved within the 
FIIND domain. However, the cleaved protein makes up only a minor portion of 
the sample. The full-length proteins probably comprises more than 90 % of the 
protein present in the sample, as estimated from SDS-PAGE analysis. 
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Figure 3.7: Modification of MBP-NLRP1 purification protocol leads to 
improved elution behaviour 
(A) Analytical SEC of MBP-NLRP1 with a PYD-specific (AF-F08) and a CARD-
specific (Q2-G06) nanobody. Samples were run on a Superose 6 (3.2/300) 
column at a flow rate of 0.02 mL/min. Proteins were mixed in a 1:1 molar ratio 
and incubated at RT for 30 min before loading the samples into a 20 µL loop 
connected to an ÄKTA micro. (B) Elution profile of a preparative SEC and SDS-
PAGE of MBP-NLRP1 purified following the modified purification protocol. MBP-
NLRP1 was run on a Superose 6 (16/600) column at a flow rate of 0.2 mL/min. 
10 µL of the eluting fractions were taken as samples for SDS-PAGE. The 
displayed Coomassie-stained gel covers every second fraction within the range 
of the peaks as marked by the black bracket. Fractions had a volume of 0.5 mL. 
SDS samples were run on a 12 % acrylamide gel.  
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The MBP-NLRP1 peak 2 protein elutes at a volume significantly smaller than the 
peak corresponding to a molecular weight of 667 kDa of a molecular weight 
standard provided by the manufacturer of the column. This implies that MBP-
NLRP1 peak 2 protein forms an oligomer, as the SEC elution profile indicates a 
molecular weight significantly higher than the monomeric molecular weight of 
MBP-NLRP1 (207 kDa). Noteworthy, the second peak containing the 
homogeneous protein spans a wide range of the column. This might indicate that 
there are different assemblies of the oligomer present in this peak. The 
homogeneous sample was isolated by pooling the main fractions of the second 
peak and the protein was concentrated for further structural analysis. 
 
3.2.6 SEC-SAXS analysis suggests MBP-NLRP1 assembles into a 
hexamer 
 
Since full-length NLRP1 was unstable without the MBP-tag and only soluble at 
concentrations up to 3 mg/mL, protein crystallization for the generation of 
structural information was not feasible. To investigate the overall shape and 
oligomeric state of the protein we sought to analyse the second peak of MBP-
NLRP1 by size exclusion chromatography coupled Small Angle X-ray Scattering 
(SEC-SAXS). SEC-SAXS data was collected for two samples of MBP-NLRP1 
concentrated to 2.4 mg/mL and 1.8 mg/mL before loading the sample on the SEC 
column. A detailed analysis of recorded data is reported in Figure 3.8. The 
scattering data was indicative of a well behaved protein and was therefore further 
analysed for structural parameters (Figure 3.8A). Radius of gyration (Rg) values 
determined from Guinier analysis were 90.74 Å and 91.89 Å for the sample at 2.4 
mg/mL and 1.8 mg/mL, respectively (Figure 3.8B and E). The distance 
distribution revealed similar values for Rg with 94.46 Å and 93.62 Å (Figure 3.8C 
and E). The maximum dimension of the particle (Dmax) derived from the distance 
distribution function was 325 Å for both samples. Kratky analysis indicated that 
the sample is comprised of folded protein and has only minor flexible regions 
(Figure 3.8D).  
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Concentration 2.4 mg/ml 1.8 mg/ml 
Rg (Guinier) [Å] 90.74 ± 3.04 91.89 ± 5.93 
Rg (P(r)) [Å] 94.46 ± 0.09 93.62 ± 0.06 
Dmax [Å] 325 325 
Porod volume [Å3] 2050000 2010000 
Molecular mass 
monomer [kDa] 207 207 
Molecular mass 
(VPorod/1.66) [kDa] 1234.9 1210.8 
Molecular mass 
(SAXSMoW2) [kDa] 1284.3 1269.8 
Oligomeric state 6 6 
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Figure 3.8: SEC-SAXS analysis of MBP-NLRP1 Peak 2 reveals an 
oligomeric state of the protein particle 
(A) Scattering data recorded for samples at two different concentrations (2.4 
mg/mL and 1.8 mg/mL) of MBP-NLRP1. (B) Linear low-q regions used for the 
Guinier analysis of the scattering data shown in A. (C) Normalized pairwise 
distance distribution function (P(r)) derived from the scattering data shown in A. 
The distance distribution function revealed a maximum particle dimension of 315 
Å. (D): Kratky plot of the scattering data obtained from the two samples of MBP-
NLRP1, showing a distinct peak and thus indicating low intrinsic flexibility of the 
protein particle. (E) Overview of the parameters derived from the scattering data 
recorded for the two concentrations of MBP-NLRP1 including a calculation of the 
oligomeric state of the protein particle. 
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Two different methods were used to calculate an estimate for the molecular 
weight of the protein. One approach was to utilize the approximate Porod volume 
and divide it by 1.66 (Petoukhov et al., 2012). This approach resulted in a 
molecular weight of 1228.9 kDa and 1204.8 kDa for the 2.4 mg/mL and 1.8 
mg/mL sample, respectively. As a second method for molecular weight 
estimation, the raw scattering data was submitted for automated analysis by the 
SAXSMoW2 online tool (http://saxs.ifsc.usp.br/) (Fischer et al., 2010; Piiadov et 
al., 2019). This gave a molecular weight of 1284.3 kDa and 1269.8 kDa for the 
2.4 mg/mL and 1.8 mg/mL sample, respectively. Dividing the molecular weight 
determined from the SAXS data by the molecular weight of the monomeric MBP-
NLRP1 resulted in a factor between 5.8 and 6.2. This indicated that one protein 
particle consists of about six monomers of MBP-NLRP1. Thus, the oligomeric 
state of the protein was determined to be hexameric. 
The distance distribution function derived from the scattering data recorded for 
the 2.4 mg/mL sample was used to generate an ab initio bead model using the 
DAMMIF and DAMAVER tools of the ATSAS software. The bead model can be 
displayed as a molecular envelope and provide information about the overall 
shape of the protein particle. Such a molecular envelope for the MBP-NLRP1 
oligomer is visualized in Figure 3.9A. The overall shape can be described as an 
elongated, disc-like assembly with a triangular geometry. Dimensions of the 
particle were determined to be 316 Å in width, 342 Å in height and 112 Å in depth 
using the UCSF Chimera software (Pettersen et al., 2004). 
In a next step, a structure of NLRP1 was fitted into the molecular envelope, to 
investigate the nature of the oligomer assembly. Since there is no structure of 
full-length NLRP1 or any other full-length NLR protein available, a model of MBP-
NLRP1 was generated by submitting the entire amino acid sequence of 1851 
amino acids to the RaptorX secondary structure prediction tool (Wang et al., 
2016). The resulting model is visualized in Figure 3.9B and the different domains 
as well as the MBP-tag are depicted separately. A large linker region between 
the PYD and NACHT domain spanning amino acids 472-614 (corresponding to 
amino acids 94-236, the PYD-NACHT linker, in human NLRP1) was 
automatically excluded during the generation of this model. The fold of the overall 
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protein presented as an elongated molecule with the CARD folding back towards 
the NACHT domain. Apart from that, no intramolecular interactions and folds 
were found. It should be noted that the overall fold of the protein is a prediction 
and may not necessarily represent the true conformation of the full-length NLRP1 
protein. 
For a size comparison an overlay of the MBP-NLRP1 molecule and the 
molecular envelope generated from the SAXS data was produced (Figure 3.9C). 
The elongated model of MBP-NLRP1 fits to the length of the molecular envelope. 
The width of the particle could potentially fit two MBP-NLRP1 monomers next to 
each other. Hypothetically, the envelope could fit three dimers or two trimers, 
which could form a homotrimer or a homodimer, respectively. However, the 
overall conformation of the oligomer is difficult to predict without a high resolution 
structure of the oligomer or the monomer.  
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Figure 3.9: Ab initio model and molecular envelope of the MBP-NLRP1 
oligomer determined from SAXS data 
(A) Volume representation of the molecular envelope calculated from the SAXS 
data obtained for the 2.4 mg/mL sample of the MBP-NLRP1 oligomer. 
Dimensions were manually measured using Chimera software (Pettersen et al., 
2004). (B) Model of MBP-NLRP1. Different domains are highlighted and labelled 
in different colours. The model was generated using the RaptorX structure 
prediction tool (Wang et al., 2016). (C) Overlay of the MBP-NLRP1 model and 
the molecular envelope calculated from SAXS data shown in A. 
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3.3 Discussion 
 
Even though NLRP1 is – apart from NLRP3 – the most extensively studied NLR 
inflammasome, many questions about its mechanism of activation remain 
elusive. For other inflammasomes like NLRP3 and NLRC4, high resolution 
structural information has greatly contributed in improving the understanding of 
how these molecules are regulated (Hu et al., 2013; Diebolder et al., 2015; Zhang 
et al., 2015; Sharif et al., 2019). These structures helped to understand the 
mechanism by which certain mutations identified in patients lead to spontaneous 
activation of the according inflammasome (Sharif et al., 2019). The aim of this 
study was therefore to generate such structural data for NLRP1. However, 
problems with aggregation and oligomerization did not allow for the generation of 
high resolution structural information on the full-length protein. Similar problems 
with aggregation and degradation of recombinant NLRP1 protein have been 
reported in the literature previously (Martino et al., 2016). Making use of the MBP-
affinity tag helped resolving solubility issues for the NACHT, FIIND and CARD 
domain containing constructs as well as for the full-length protein. The resulting 
proteins were soluble and pure and were used for further biophysical 
characterization. The PYD and LRR constructs were stable without any affinity 
tag in solution and did not require an MBP-tag for solubilization. 
Structural analysis of NLRP1 PYD and LRR was not directly indicative of how 
these domains are involved in keeping NLRP1 autoinhibited. The absence of a3 
in NLRP1 PYD has been discussed previously. It was speculated that this helix 
cannot form in NLRP1 PYD due to a cis-trans isomerisation of a preceding 
peptide bond or the lack of a conserved lysine residue involved in inducing the 
formation of a3 (Hiller et al., 2003; Chu et al., 2015). A third reason for the 
absence of this helix in NLRP1 PYD could be the proline in position 45 (Chapter 
3.2.2). As shown by the interface analysis in Chapter 3.2.2, the absence of a3 by 
itself does not directly explain why NLRP1 PYD is autoinhibitory. Thus, it was 
hypothesized that the PYD contributes to autoinhibition by folding onto another 
domain in the full-length protein. No direct interaction between the PYD and the 
NACHT-LRR, LRR, FIIND, FIIND-CARD or CARD domain could be observed in 
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analytical SEC experiments. Interestingly, the MBP-CARD protein did also not 
interact with a nanobody which was supposed to be specific for NLRP1 CARD. 
Consequently, it is reasonable to consider that the MBP blocks important 
interfaces. Indeed, by doing so it could actively promote solubility of the fused 
construct in case of an otherwise exposed oligomerization interface. 
Recombinant PYD and LRR showed no interaction in an analytical SEC 
experiment despite not having any N-terminal affinity-tag, implying that these 
domains do not contribute to autoinhibition by interacting directly with each other 
intramolecularly. Additional repeats or a different approach to investigate 
intramolecular interactions of separate domains, like SPR, would be desirable to 
further support the findings described above. 
A biophysical characterization of full-length NLRP1 fused to MBP revealed that 
this protein forms oligomers in solution. It has to be considered that oligomer 
formation is induced by the MBP-tag. Nevertheless, oligomer formation is a well-
known feature of AAA+ ATPases and NACHT domain containing proteins and 
has been demonstrated previously by cryoelectron microscopy for the NLRC4 
inflammasome or the Apaf-1 apoptosome (Diebolder et al., 2015; Zhang et al., 
2015). In the case of NLRC4, one additional sensor molecule called NAIP 
(Neuronal Apoptosis Inhibitory Protein) is needed for the induction of oligomer 
formation. After induction by the NAIP protein, between nine and eleven NLRC4 
monomers assemble into a disk-like oligomer (Zhang et al., 2015). For NLRP1 
no nucleation factor, like NAIP for NLRC4, has been reported yet. In this study, 
the MBP-NLRP1 oligomer was found to be hexameric as calculated from the 
SAXS data. Since the domain architecture of the NLRC4 and NLRP1 proteins is 
considerably different (NLRC4 has an N-terminal CARD, a NACHT and an LRR 
domain), the oligomeric state of these two proteins might as well be different. 
Negative stain electron microscopy of full-length NLRP1 was found to also 
contain monomers and different oligomeric assemblies, the majority the 
oligomers being pentamers or heptamers (Faustin et al., 2007). Since the SAXS 
data is the result of the average of the scattering pattern of the protein particle in 
solution, the observations from the electron microscopy study do not directly 
support our finding that full-length MBP-NLRP1 may form a hexamer in solution 
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(Jacques and Trewhella, 2010). Technically, if heptamers were present in the 
sample analysed by SAXS, they should dominate in the scattering pattern, as 
they would be expected to form larger particles than hexamers. However, 
depending on the apparent fold of the oligomer and the required hydration radius, 
this must not necessarily be the case. Furthermore, the oligomeric state was 
determined by approximation of the molecular weight or more precisely the Porod 
volume. This approximation might have an intrinsic error, which could explain the 
difference between the present study and the previously reported insights into 
the NLRP1 oligomer (Faustin et al., 2007). Moreover, the manual fitting of an 
MBP-NLRP1 model showed that the molecular envelope calculated from the 
SAXS data could fit seven monomers of MBP-NLRP1. 
The overall shape of the particle could also be interpreted as a triangle. For a 
triangular shape, a hexameric assembly would be more likely than a pentameric 
or a heptameric assembly. From a mathematical point of view, the geometrical 
space of a triangle could be filled by a hexamer composed of three dimers (Figure 
3.9C) or two trimers. Other AAA+ ATPases have been shown to form hexameric 
assemblies as well, supporting our finding of a hexameric oligomer (Hanson and 
Whiteheart, 2005; Schumacher et al., 2008; Chen et al., 2010). In contrast to this, 
different proteins like apoptosomes harbouring a death domain have been 
reported to assemble into tetramers, heptamers or octamers (Yuan and Akey, 
2013; Oroz et al., 2016). The overall conformation described for a range of AAA+ 
ATPases, apoptosomes and inflammasomes is commonly disk-like, supporting 
the shape found for the envelope calculated from the SAXS data (Chen et al., 
2010; Yuan and Akey, 2013; Tenthorey et al., 2017). 
For NLRP1 to become active and bind to ASC, the C-terminal cleavage 
fragment has been shown to be sufficient (Zhong et al., 2016). In certain 
scenarios the N-terminal fragment has even been shown to be degraded during 
the activation process (Chui et al., 2019; Sandstrom et al., 2019). Thus, it can be 
speculated whether the N-terminal fragment comprised of the PYD, NACHT and 
LRR domain is actually required for the formation of the active oligomer. Since 
our study as well as the previously mentioned electron microscopy study suggest 
that the full-length protein forms oligomers, it can be further hypothesized that 
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NLRP1 might be oligomeric in its autoinhibited conformation. This could also 
explain, why no intramolecular interactions were found in analytical SEC 
experiments. PYD and LRR could contribute to autoinhibition by aiding in 
oligomer formation via homotypic interactions. However, purification and 
characterization of the PYD did not show dimer formation under the tested 
conditions, indicating that no homotypic interactions are present between the 
monomers of this domain. The LRR behaved as a dimer in solution and showed 
two molecules in the asymmetric unit. Nevertheless, the structure revealed that 
the dimer is asymmetric and did not unveil an interface that could be involved in 
dimer formation. These findings argue against an involvement of the PYD or LRR 
in forming the MBP-NLRP1 oligomer. Overall, it has to be considered that these 
experiments were carried out in an artificial environment not resembling 
physiological conditions. Homo- or heterotypic interactions of the aforementioned 
domains might depend on factors like the pH, the salt concentration, the 
temperature or the concentration of the protein itself. 
Collectively, the herein presented data demonstrate that full-length NLRP1 
fused to MBP forms oligomers in solution. These oligomers are potentially 
hexamers as determined by SEC-SAXS analysis. Further, analytical SEC 
experiments showed that PYD and LRR do not contribute to keeping NLRP1 
autoinhibited by interacting directly with each other and are unlikely to be involved 
in oligomer formation. The structural basis of PYD and LRR autoinhibitory 
functions as well as the physiological role of the full-length NLRP1 oligomer 
remain to be elucidated. 
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4. The role of nucleotides in regulating NLRP1 activity 
 
4.1 Introduction 
 
As described in Chapter 3.1, NLRP1 harbours a central NACHT domain. This 
domain is conserved throughout the entire family of NLRs (Proell et al., 2008). 
The NACHT domain is commonly described to be involved in nucleotide binding 
(Leipe et al., 2004; Maharana et al., 2018). The NACHT domain is commonly 
comprised of four subdomains, a nucleotide binding domain (NBD), a first helical 
domain (helical domain 1, HD1), a so-called winged helix domain (WHD), and a 
second helical domain (helical domain 2, HD2) (Bentham et al., 2017; Maharana 
et al., 2018). Conserved nucleotide binding motifs are located within these 
subdomains. These motifs are not only found in NACHT domain containing 
proteins but also in other members of the STAND (signal transduction ATPases 
with numerous domains) subfamily of the AAA+ ATPase (ATPases associated 
with diverse cellular activities) superfamily, to which the NLRs belong (Leipe et 
al., 2004; Ammelburg et al., 2006; Maharana et al., 2018). 
Commonly shared by all members of the AAA+ family are the Walker A motif, 
also referred to as the P-loop, and the Walker B motif. The Walker A motif is 
usually comprised of eight amino acids following the pattern GxxxxGK(T/S) 
(Hanson and Whiteheart, 2005; Wendler et al., 2012). Here, the x denotes any of 
the 20 proteinogenic amino acids. In the C-terminal position either a threonine or 
serine residue can be found. The positively charged side chain of the lysine 
residue is described to form contacts with the b- and g-phosphate of ATP (Saraste 
et al., 1990; Wendler et al., 2012). The polar residue at the end of Walker A 
(serine or threonine) is described to coordinate the magnesium ion with its side 
chain hydroxyl group (Saraste et al., 1990; Miller and Enemark, 2016). 
Consequently, mutations of these residues result in impaired nucleotide binding 
and hydrolysis (Matveeva et al., 1997; Babst et al., 1998). The Walker B motif 
typically consists of four hydrophobic residues followed by an aspartic acid and 
glutamic acid residue (hhhhDE, h = hydrophobic residue) (Hanson and 
Whiteheart, 2005; Wendler et al., 2012). Interestingly, for NLRs an altered Walker 
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B motif is found, with the glutamate of the terminal DE missing and an additional 
DE motif two amino acids downstream of the expected DE (hhhhDxxDE) (Proell 
et al., 2008). This variation of the Walker B motif is also found in NOD1 and NOD2 
and was termed “extended Walker B” (Zurek et al., 2012). The negatively charged 
residues of the Walker B motif are involved in coordination of the magnesium ion 
and priming of a water molecule for hydrolysis via a nucleophilic attack on the g-
phosphate of ATP (Story and Steitz, 1992). Moreover, the Walker B glutamate 
was also termed “glutamate switch”, as it is reported to be able to switch between 
an active and inactive state depending on the binding of cofactors and substrates 
(Wendler et al., 2012). Mutating the Walker B motif impairs hydrolysis but not 
nucleotide binding (Wendler et al., 2012). Further conserved motifs include the 
Sensor 1 motif containing a conserved arginine residue in NLRs and the Sensor 
2 motif which in NLRs contains a conserved histidine residue (Riedl et al., 2005; 
Proell et al., 2008). Sensor 1 is described to play a crucial role in coordinating the 
nucleotide by interacting with the g-phosphate of ATP, thereby making it 
susceptible to hydrolysis (Hanson and Whiteheart, 2005; Wendler et al., 2012). 
Sensor 2 is typically involved in nucleotide binding and mutations of this motif are 
known to impair nucleotide binding and hydrolysis (Ogura et al., 2004). 
NLRP3 is known to bind ATP and exhibit ATPase activity (Duncan et al., 2007). 
Functionally, ATP binding but not hydrolysis activity has been demonstrated to 
be required for activation of the NLRP3 inflammasome. The role of nucleotide 
binding of NLRP3 was investigated by mutating the GKT residues of the Walker 
A motif to three alanine residues (Duncan et al., 2007). More recent studies found 
that mutation of the Walker B motif results in constitutive activation of the NLRP3 
inflammasome (Coll et al., 2019; Tapia-Abellán et al., 2019). A similar mutational 
approach was taken to investigate the involvement of nucleotide binding and 
hydrolysis in NOD1 and NOD2 activity (Zurek et al., 2012). For the family of AAA+ 
ATPases it is described that the exchange of ADP for ATP and subsequent ATP 
hydrolysis are required to induce conformational changes to switch from the 
inactive to the active conformation and back (Iyer et al., 2004). This is also a 
proposed mechanism for the transformation of NLR family proteins from the 
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closed, inhibited conformation to the open, active conformation (Danot et al., 
2009). 
In contrast to NLRP3, a construct containing the NLRP1 NACHT and LRR domain 
has been shown to bind but not hydrolyse ATP (Liu et al., 2004; Martino et al., 
2016). Results from early studies suggested that NLRP1 requires ATP to form an 
active inflammasome (Liu et al. 2004; Faustin et al. 2007; Bruey et al. 2007; 
Faustin et al. 2009). Interestingly, no specific inhibitory effect of ATP competitive 
inhibitors designed for NLRP1 was found when tested on mouse NLRP1b 
activated with lethal toxin (Harris et al., 2015). Consistent with these results, more 
recent studies found that mutations within the Walker A motif of mouse NLRP1b 
or human NLRP1 lead to increased or constitutive inflammasome activity, 
respectively (Liao and Mogridge, 2013; Chavarría-Smith et al., 2016). Since 
these mutations were shown to impair nucleotide binding, it was concluded that 
NLRP1 does not require ATP to form an active inflammasome. 
For NLRP1, only mutations within the Walker A motif have been tested 
regarding their effect on inflammasome activation. Therefore, one aim of this 
work was to further elucidate the functional importance of the ATP binding site of 
NLRP1 by means of a mutagenesis study. To do so, conserved motifs and 
residues were identified using a sequence and structure based approach. 
Furthermore, a hydrolysis assay was designed and established using 
recombinant MBP-NLRP1 protein to test whether NLRP1 shows ATP hydrolysis 
activity. 
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4.2 Results 
 
4.2.1 MBP-NLRP1 exhibits ATP hydrolysis activity 
 
In previous studies, the hydrolysis activity of NLRP1 was investigated for 
recombinant protein containing the NACHT and LRR domains. Hydrolysis was 
measured as an increase in inorganic phosphate over time using a malachite-
green assay (Martino et al., 2016). Here, we investigated the ATPase activity of 
recombinant full-length MBP-NLRP1. A highly sensitive analytical assay based 
on the separation of different nucleotides by a Reversed-Phase High-
Performance Liquid Chromatography (RP-HPLC) based technique was 
established in our laboratory. RP-HPLC allows the separation of ATP, ADP, and 
AMP. Small changes of all three nucleotides can be monitored by measuring the 
absorbance of the eluate at 254 nm, which is the wavelength at which the 
nucleotides absorb light. 
For a measurement, 3 µM of the protein from the first peak described in 
Chapter 3.2.5 were incubated with 100 µM ATP and 5 mM MgCl2 for 60 minutes. 
Samples were incubated at 25 °C and analysed by RP-HLPC at the start of the 
experiment and every 10 min afterwards. A representative chromatogram of an 
experiment with WT MBP-NLRP1 protein is shown in Figure 4.1A. In contrast to 
what has been reported for the NACHT-LRR construct of NLRP1, full-length 
MBP-NLRP1 clearly showed hydrolysis activity. This is visible in the 
chromatogram in form of a reduction of the level of ATP over time. Quantification 
of the respective peak area and subsequent normalization allowed to calculate 
an approximate proportion of ATP, ADP and AMP in the sample at the measured 
time points. By this approach, it was calculated that ATP only comprised 52 % of 
the total nucleotide in the sample after 60 min of the time course measurement 
(Figure 4.1B). Based on linear regression the rate of hydrolysis was calculated to 
0.29 molecules of ATP per minute from the slope of the resulting curve. As a 
consequence of ATP hydrolysis, the ADP level in the sample increased over time, 
as ADP is a product of the hydrolysis reaction. The ADP level after 60 min was 
determined to be 34 % of the total amount of nucleotide in the sample.  
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Figure 4.1: MBP-NLRP1 exhibits ATP hydrolysis activity 
(A) Chromatogram of an RP-HPLC elution profile of an ATP hydrolysis 
measurement with MBP-NLRP1. 100 µM ATP and 5 mM MgCl2 were incubated 
in the presence of 3 µM MBP-NLRP1 protein (Peak1) at 25 °C for 60 min. Every 
10 min a sample was taken and analysed by RP-HPLC. Peaks for AMP, ADP 
and ATP are depicted by coloured lines and labelled accordingly. Data shown is 
from one experiment of two repeats. (B) Quantification of the data presented in 
A. Peak areas were integrated and normalised to 100 %.  
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Surprisingly, the level of AMP also increased in this measurement. After 60 min 
AMP made up 14 % of the entire nucleotide amount in the sample. This indicated 
that a second hydrolysis step is facilitated in which ADP is hydrolysed to AMP 
and inorganic phosphate. The observed increase in AMP did not go along with a 
decrease of the level of ADP, implying that the ADP hydrolysis reaction was 
slower than the ATP hydrolysis reaction. 
To further investigate this effect, a second experiment was performed in which 
100 µM ADP instead of ATP were added to the protein (Figure 4.2). If ADP 
hydrolysis occurs in the sample, a decrease in ADP should be observed as well 
as an increase in AMP. As expected, the level of ADP decreased in this 
experiment as the level of AMP increased over time, again indicating hydrolysis 
of ADP (Figure 4.2). However, at early stages of the measurement there was also 
an increase in ATP levels detected. This implies that apart from AMP, ATP is 
generated in the sample, which initially only contained ADP. Enzymatic activity 
facilitating the reaction of two molecules of ADP to ATP and AMP as well as the 
reverse reaction is commonly described for adenylate kinases (Abele and Schulz, 
1995). This class of enzymes monitors the cellular energy status by sensing 
nucleotide levels (Dzeja and Terzic, 2009). If required, they facilitate the alteration 
of nucleotide levels through the interconversion of ATP and AMP to two 
molecules of ADP as a well as the reverse reaction. The generated nucleotides 
can further serve as signalling molecules to stimulate metabolic pathways (Dzeja 
and Terzic, 2009). To date, adenylate kinase activity has not been reported for 
NLR proteins. 
Interestingly, ATP levels peaked after 12 min and then slowly decreased again. 
This might indicate that at this point of the measurement a concentration of ATP 
is reached at which hydrolysis of ATP is the preferred reaction. This is consistent 
with the observation of a drastically decreased reduction of ADP from this time 
point onwards. Similar to that, AMP increased at a much slower rate after this 
time point. To further evaluate NLRP1 ATP hydrolysis and adenylate kinase 
activity the amino acids involved in catalysing these reactions were identified by 
taking a sequence and structure based approach.  
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Figure 4.2: MBP-NLRP1 exhibits adenylate kinase activity 
(A) Chromatogram of an RP-HPLC elution profile of an ADP hydrolysis 
measurement with MBP-NLRP1. 100 µM ADP and 5 mM MgCl2 were incubated 
in the presence of 3 µM MBP-NLRP1 protein (Peak1) at 25 °C for 60 min. Every 
10 min a sample was taken and analysed by RP-HPLC. Peaks for AMP, ADP 
and ATP are depicted by coloured lines and labelled accordingly. Data is from 
one experiment. (B) Quantification of the HPLC data presented in A. Peak areas 
were integrated and normalised to 100 %. 
  
B 
0 10 20 30 40 50 60
0
20
40
60
80
Time [min]
Ab
so
rp
tio
n 
25
4 
nm
 [A
U
]
ATP 
ADP 
AMP 
A 
100 µM ADP 
0 10 20 30 40 50 60
0
20
40
60
80
100
Time [min]
Am
ou
nt
 o
f n
uc
le
ot
id
e 
[%
] 
ATP
ADP
AMP
100 µM ADP 
 Results 
113 
4.2.2 Identification of conserved nucleotide binding motifs in NLRP1 
 
To identify the conserved Walker A and B motifs as well as Sensor 1 and Sensor 
2 motif in NLRP1, a multiple sequence alignment of the amino acid sequences of 
all human NLRP proteins as well as NOD1 and NOD2 was performed (Figure 
4.3A). The online multiple sequence alignment tool Clustal Omega was used with 
default settings to align the sequences (Madeira et al., 2019). Conserved motifs 
were easily identified and are highlighted in a schematic of the NLRP1 NACHT 
domain in Figure 4.3B. The Walker A motif of NLRP1 (GAAGIGKS) follows the 
expected pattern of GxxxxGK(T/S). Besides NLRP5 and NLRP12, NLRP1 is one 
of only three members of the NLRP protein family having a serine residue instead 
of a threonine residue in the last position of the Walker A motif. NOD1 and NOD2 
both show a serine residue in that position. Similarly, the Walker B motif is 
conserved within the NLRP protein family. Most NLRPs, including NLRP1, 
contain the extended Walker B motif with the two negatively charged residues 
shifted three amino acids downstream. For NLRP1, these two negatively charged 
residues are aspartate and glutamate. Only NLRP9 and NLRP11 have an 
uncharged residue in the terminal position of the extended Walker B motif. 
Interestingly, NLRP11 contains both the classical Walker B motif with two 
negatively charged residues (ED) and the extended Walker B motif with only one 
negatively charged residue and one polar residue (DN). Within the sensor 1 motif 
the last residue presents with a conserved positive charge. An arginine residue 
is most prominent at this position in all proteins including NOD1 and NOD2. 
NLRP4 and NLRP13 contain a lysine residue instead of an arginine. Only NLRP9 
contains an uncharged but polar residue in sensor 1 (Q). The conserved histidine 
residue, shown to replace sensor 2, can be found in most NLRPs inclusive of 
NLRP1. NLRP8 shows a hydrophobic residue (L), whereas NLRP6 contains a 
negatively charged residue (D). 
In summary, NLRP1 contains all motifs known to be involved in nucleotide 
binding and hydrolysis. Since adenylate kinase activity is a newly discovered 
activity of NLRP1, identification of residues involved in catalysing the according 
reactions can simply achieved by aligning the amino acid sequences of NLR 
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proteins. It would either require a structure of a NACHT domain with bound 
nucleotide(s) or could be achieved by a mutagenesis approach elucidating the 
activity of different nucleotide binding site variants. In the next step, structural 
modelling of the nucleotide binding site of human NLRP1 was performed to 
confirm the residues identified from the sequence analysis to be directly involved 
in nucleotide binding and potentially hydrolysis.  
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NOD1    GETIFILGDAGVGKSMLLQRLQSLW 
NOD2    ADTVLVVGEAGSGKSTLLQRLHLLW 
NLRP2   SYTVVLYGPAGLGKTTLAQKLMLDW 
NLRP7   PYTVVLHGPAGVGKTTLAKKCMLDW 
NLRP11  NLNVFLMGERASGKTIVINLAVLRW 
NLRP5   PRTVVLHGKSGIGKSALARRIVLCW 
NLRP13  AQTIVLVGRAGVGKTTLAMQAMLHW 
NLRP8   PKTVAIQGAPGIGKTILAKKVMFEW 
NLRP14  PQIVVLQGAAGVGKTTLVRKAMLDW 
NLRP4   PRTVIIQGPQGIGKTTLLMKLMMAW 
NLRP9   RHTVVLEGPDGIGKTTLLRKVMLDW 
NLRP1   PRIVILQGAAGIGKSTLARQVKEAW 
NLRP6   PLTVVLQGPAGIGKTMAAKKILYDW 
NLRP10  PSLVVLQGSAGTGKTTLARKMVLDW 
NLRP3   VHTVVFQGAAGIGKTILARKMMLDW 
NLRP12  PRTVVMQGAAGIGKSMLAHKVMLDW 
           : . *  . **:         * 
Walker A 
LLRFPHVALFTFDGLDELH 
LLDHPDRVLLTFDGFDEFK 
ILAQARKILFVIDGFDELG 
ILAQAQRILFVVDGLDELK 
ILSDPKKLLFILEDLDNIR 
IMSRPERLLFIIDGFDDLG 
FMSQPEKLLFIIDGFEEII 
IMSKPDQLLLLLDGFEELT 
IMYQPSSLLFIIDSFDELN 
IVSQPERLLFVIDSFEELQ 
IFSQPERILFIMDGFEQLK 
ILSRPERLLFILDGVDEPG 
MLAQPQRLLFILDGADELP 
ILRQPERLLFILDGFDELQ 
IVRKPSRILFLMDGFDELQ 
LIRVPERLLFIIDGFDELK 
:.      *: .:. :: 
Walker B 
NOD1    KLLTARTGI 
NOD2    KVVTSRPAA 
NLRP2   LLVTTRPRA 
NLRP7   LLVTTRPRA 
NLRP11  FLISSRPTR 
NLRP5   LIVTVRDVG 
NLRP13  LLITIKTWF 
NLRP8   LLIMIRFTS 
NLRP14  LLVTTRLTT 
NLRP4   LLIAIKPVC 
NLRP9   LLIALGKLA 
NLRP1   FLITARTTA 
NLRP6   LLVTTRAAA 
NLRP10  LLITTRPLA 
NLRP3   LLITTRPVA 
NLRP12  LLITTRPTA 
         ::                      
Sensor 1 
YEFFHLTLQAFFTAFF 
LEFLHITFQCFFAAFY 
YSFIHLSFQQFLTALF 
YSFIHLSFQQFLTALF 
YKFIHLNVQEFCTAIA 
YTFFHLSLQDFCAALY 
TTFTHLSFQEFFAAMS 
YVFTLVTFQEFFAALF 
YVFTHLHVQEFFAAMF 
YVFLHVCIQEFCAALF 
FAFMHLCIQEFCAAMF 
YSFIHLCFQEFFAAMS 
YQFIDQSFQEFLAALS 
YSFRHISFQDFFHAMS 
YSFIHMTFQEFFAAMY 
YSFIHLSFQEFFAAMY 
  *    .* *  *:  
Sensor 2 
Walker B (406-414): LFILDGVDE  
800 200 300 400 500 600 700 
Walker A (334-341): GAAGIGKS  
Sensor 1 (457-459): TAR  
Conserved His (621-623): FIH  
A 
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Figure 4.3: Sequence alignment of human NLRP proteins and NOD1 and 
NOD2 reveals conserved nucleotide binding site motifs 
(A) Parts of a sequence alignment of all human NLRP proteins as well as NOD1 
and NOD2. The shown parts include motifs identified to be involved in nucleotide 
binding or hydrolysis. The alignment was performed using the Clustal omega 
online tool (Madeira et al., 2019). Protein sequences were obtained from the 
Uniprot database. Major differences in the described motifs are highlighted in 
cyan. Conserved motifs identified in NLRP1 are highlighted in their respective 
colour in the schematic in B. Stars below the sequences indicate identical 
residues for all sequences at the respective position. Dots indicate conserved 
charge, hydrophobicity or polarity of the residue at the respective position. (B) 
Schematic of NLRP1 NACHT domain with the conserved nucleotide binding and 
hydrolysis motifs highlighted in different colours. Numbers indicate the number of 
the amino acids in the sequence of NLRP1.  
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4.2.3 Structural model of the NLRP1 NACHT domain 
 
As mentioned above, no high resolution structural information is available for the 
NLRP1 NACHT domain. Therefore, to facilitate a structural assessment of the 
nucleotide binding site, a homology model was generated. Among all matches 
identified from a sequence alignment, the crystal structure of a rabbit NOD2 
NACHT-LRR construct (PDB: 5IRL) produced the best fit with 26 % sequence 
identity, when aligned to the NLRP1 NACHT-LRR amino acid sequence within 
the range 230-990. The Swiss Model Template Search was used for this 
alignment and to build the according model (Waterhouse et al., 2018). In Figure 
4.4A a superposition of the NACHT domains of the NOD2 crystal structure with 
bound ADP and the NLRP1 homology model is displayed. Both structures align 
well, allowing to identify subdomains within the NLRP1 NACHT domain (Figure 
4.4B). From the homology model the NBD subdomain of NLRP1 NACHT was 
found to span residues 309 to 479. HD1 spans residues 480 to 544 and the WHD 
is located within residues 545 to 642. This is comparable with previous findings 
(Maharana et al., 2018). HD2 was estimated to span amino acid residues 643 to 
758. However, the HD2 LRR module is described to be variable among NLRs 
and therefore more difficult to clearly identify (Sharif et al., 2019). Especially the 
transition between the NACHT and LRR domain is highly variable when 
comparing the known structures of NLRP3, NLRC4 and NOD2 (Hu et al., 2013; 
Maekawa et al., 2016; Sharif et al., 2019). Thus, predicting this region in NLRP1 
is particularly difficult. 
Presence of the ADP molecule in the NOD2 structure in combination with the 
superposition of the NOD2 crystal structure and the NLRP1 NACHT homology 
model allowed for the identification of residues which are likely to be in proximity 
of the nucleotide in NLRP1. A magnified view from two different perspectives of 
the nucleotide binding site of the NLRP1 homology model is shown in Figure 
4.4C. In the Walker A motif the conserved lysine residue and the polar serine 
residue are in direct vicinity of the b-phosphate of ADP, indicating an important 
role in coordinating the nucleotide for hydrolysis. The same holds for sensor 2 
(Figure 4.4C, left panel). The glutamate of the extended Walker B motif as well 
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as the arginine of Sensor 1 are not forming direct contacts with the ADP molecule 
according to the homology model (Figure 4.4C, right panel). Noteworthy, the 
presented model only has an ADP molecule and not an ATP and no water 
molecules are included in this model. Furthermore, it is based on the structure of 
an NLR in the closed, inactive conformation.  
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Figure 4.4: Homology model of NLRP1 NACHT domain 
(A) Superposition of the NOD2 NACHT crystal structure (PDB: 5IRL) and the 
NLRP1 NACHT homology model generated here. The model was built using 
Swiss Model (Waterhouse et al., 2018). Amino acids 230-990 of human NLRP1 
were fed into the Swiss Model Template Finder tool. (B) Homology modelling of 
NLRP1 NACHT with the subdomains NBD, HD1, WHD and HD2 depicted in 
different colours. (C) Two different views of the NLRP1 nucleotide binding site 
with ADP from superposition with NOD2 crystal structure. Side chains of certain 
amino acids of the Walker A, Walker B, Sensor 1 and Sensor 2 are shown in stick 
representation. Colours of side chain atoms represent certain elements (Blue: 
Nitrogen, Red: Oxygen). Hydrogen atoms were excluded in these images. 
Residues are labelled with their respective amino acid (one letter code) and the 
number according to the primary sequence of human NLRP1. Numbers between 
residues and ADP indicate distances measured between atoms connected by 
dashed yellow lines. All images and distance measurements were generated in 
PyMOL. 
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4.2.4 Effect of mutations in the nucleotide binding site of MBP-NLRP1 on 
its hydrolysis activity 
 
In Chapters 4.2.2 and 4.2.3 motifs and residues important for nucleotide binding 
and potentially hydrolysis were identified within the NACHT domain of human 
NLRP1. Using a mutational approach, the functional relevance of these residues 
for NLRP1 ATP hydrolysis activity was investigated. First, the effect of 
modifications of the respective residues on ATP hydrolysis was tested by 
introducing point mutations into the MBP-NLRP1 construct for recombinant 
protein production. Conserved residues of the Walker A motif (K340, S341), the 
Walker B motif (E414) as well as the Sensor 1 arginine (R459) and the Sensor 2 
histidine (H623) of NLRP1 were analysed by mutagenesis. The following 
mutations were separately introduced into the WT MBP-NLRP1 expression 
construct: K340A, S341A, E414Q, R459A and H623A. Thus, the charge or 
polarity of the respective residues is replaced by a hydrophobic side chain in the 
case of alanine or a polar side chain in the case of glutamine. These mutations 
are thought to impair nucleotide binding or hydrolysis and reduce the ATP 
hydrolysis rate in RP-HPLC experiments. The proteins containing the mutations 
were purified and eluted in a single peak in the void volume and behaved similar 
to the WT protein described in Chapter 3.2.5 (Nucleotide binding site variants of 
NLRP1 purified and measured by Dr. David Fußhöller). To test ATP hydrolysis 
activity of the different variants designed for the nucleotide binding site, 3 µM 
MBP-NLRP1 Peak 1 protein harbouring one of the introduced mutations was 
incubated with 100 µM ATP and 5 mM MgCl2 at 25 °C for 60 min and a sample 
was analysed by RP-HPLC every 10 min. 
First, the consistency of the hydrolysis rate between measurements of the WT 
protein was tested (Figure 4.5A). The second measurement of the WT protein 
exhibited a slower hydrolysis rate of 0.19 molecules per min. This indicates a 
variability in the measurements that has to be considered when interpreting the 
results obtained for nucleotide binding site variants of MBP-NLRP1. The above 
mentioned variants were tested for their ability to hydrolyse ATP in RP-HPLC 
measurements as well (Figure 4.5B). When compared to the first WT 
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measurement all nucleotide binding site variants of MBP-NLRP1 exhibit slightly 
reduced hydrolysis activity. This would be consistent with the effects described 
for these mutations, which is to prevent nucleotide binding and impair hydrolysis 
(Hanson and Whiteheart, 2005). The most significant reduction in hydrolysis 
activity was observed for the Sensor 2 histidine variant (H623A). The Walker B 
mutation E414Q did not seem to impair hydrolysis as it exhibited similar activity 
as the WT protein. In contrast, when comparing the hydrolysis activity of the 
nucleotide binding site variants with the second measurement of the WT protein, 
most mutations show a slightly increased hydrolysis activity. Here, the Walker B 
mutation seemed to increase hydrolysis activity. Only the hydrolysis activity of 
H623A is still slightly lower compared to the second measurement of the WT 
protein. Taking the variation between measurements of the WT protein into 
account, effects seen for nucleotide binding site variants of NLRP1 might simply 
be due to the variability of the measurement. To make a clear statement on how 
these mutations affect nucleotide binding and hydrolysis of NLRP1, more 
experiments have to be conducted to generate statistically significant data.  
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Figure 4.5: Effect of mutations in the nucleotide binding site on ATP 
hydrolysis 
(A) Comparison of two measurements of ATP hydrolysis activity of MBP-NLRP1 
Peak1 depicted by the reduction of ATP over time. Measurements were carried 
out with 3 µM protein, 100 µM ATP and 5 mM MgCl2 at 25 °C for 60 min. Proteins 
for the different measurements were expressed, purified and measured 
separately. (B) Comparison of ATP hydrolysis measured for two samples of WT 
MBP-NLRP1 and nucleotide binding site variants (K340A, S341A, E414Q, 
R459A, H623A) of MBP-NLRP1. Measurements were carried out with 3 µM 
protein, 100 µM ATP and 5 mM MgCl2 at 25 °C for 60 min. Data shown is from 
one experiment. 
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4.2.5 Nucleotide binding site variants exhibit increased NLRP1 activation 
 
For a functional investigation of nucleotide binding site variants of NLRP1 on 
inflammasome activation, an in vitro assay was performed. In this assay, ASC 
speck formation is used as a measure for NLRP1 inflammasome activation. 
Activation of NLRP1 leads to binding of the adaptor protein ASC and induces 
speck formation. ASC speck formation can be quantified by flow cytometry 
(Sester et al., 2015). Activation of NLRP1 was recorded at two time points, 24 h 
and 48 h post transfection. 
The same mutations described in Chapter 4.2.4 were introduced into an 
NLRP1 construct for expression in mammalian cells. All mutations located within 
the nucleotide binding site led to increased activation of NLRP1 as indicated by 
an increased level of ASC specks when compared to the WT (Figure 4.6A and 
B). The frequency of ASC specks was similar for the Walker A (K340A, S341A), 
Walker B (E414Q) and Sensor 1 (R459A) mutations. Hence, the level of NLRP1 
activation was comparable for these mutations. This was also consistent for both 
timepoints measured. Interestingly, mutation of the Sensor 2 histidine (H623A) 
exhibited only a slight increase in ASC specks compared to all other mutations. 
This was consistent between measurements 24 h post transfection and 42 h post 
transfection. Combining the Sensor 2 H623A mutation with the Walker A mutation 
K340A resulted in an increased amount of ASC specks, reaching a level 
comparable to that of the Walker A mutation by itself. This implies that either the 
Walker A mutation masks the effect of the Sensor 2 mutation or that NLRP1 
activation by mutations of the nucleotide binding site reaches a maximum. 
Altogether, nucleotide binding site variants of NLRP1 lead to hyperactivation 
of the protein, as determined by measuring ASC speck formation. The level of 
ASC specks is comparable for all variants except for the Sensor 2 variant, which 
showed lower hyperactivation than the other variants. Noteworthy, mutation of 
the conserved histidine also led to the most significant reduction in ATP 
hydrolysis activity (Chapter 4.2.4). 
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Figure 4.6: Effect of mutations in the nucleotide binding site on NLRP1 
activation 
ASC speck assay of WT and nucleotide binding site mutants of human NLRP1. 
HEK293T cells stably expressing ASC-RFP were transfected with the respective 
construct encoding for NLRP1 or a GFP control vector. Cells were harvested and 
analysed for ASC speck formation 24 h post transfection (A) or 42 h post 
transfection by flow cytometry (B). Graphs present pooled data of three individual 
experiments and are shown as mean ± SEM. All values were compared to the 
WT measurement for statistical analysis using an ordinary one-way ANOVA. 
****p < 0.0001. Representative flow cytometry plots are shown in Fig. A3. 
  
 Results 
127 
4.2.6 Clones of THP1s harbouring the E414Q Walker B mutation show no 
significant spontaneous activation 
 
To confirm the results observed in the ASC speck assay described in the previous 
Chapter (4.2.5), we sought to test one of the nucleotide binding site mutations in 
a more physiological setting. In the ASC speck assays, NLRP1 is overexpressed, 
therefore not mimicking a physiological cellular level of NLRP1 protein. THP1s 
are a human monocyte cell line that harbours endogenous NLRP1. To introduce 
the desired mutation a CRISPR-Cas9 based approach was taken. Single cell 
clones of THP1s were generated that harbour a homozygous mutation of the 
Walker B motif (E414Q) in their NLRP1 gene. This mutation was identified as a 
particularly interesting variant for two reasons. First, it is the most conservative 
mutation tested in this approach. Second, as mentioned above, the Walker B 
glutamate is described to be able to switch between an active and inactive 
conformation. Thus it might be directly involved in changing the overall 
conformation of the NLRP1 protein, affecting its activation state. As described in 
Chapter 4.2.5 the E414Q mutation resulted in hyperactivation of the NLRP1 
protein in speck assays and is described to impair nucleotide hydrolysis but not 
nucleotide binding. As spontaneous activation of NLRP1 would result in activation 
of caspase-1 and thus in the release of mature IL-1b and IL-18 as well as cell 
death, the clones were analysed for these parameters after stimulation with 
Pam3CSK4 or Talabostat. Talabostat is a DPP9 inhibitor that has been shown to 
induce NLRP1 activation (Zhong et al., 2018). Pam3CSK4 directly binds TLR2 
and is a known agonist, commonly used to induce expression of NLRs through 
activation of the NF-kB pathway (M. S. Jin et al., 2007). Treatment with DMSO 
served as a negative control. A combination of Pam3CSK4 and Nigericin served 
as a positive control to induce NLRP3 inflammasome activation. Nigericin is an 
ionophore that facilitates rapid exchange of potassium ions and protons through 
membranes and has been described as a potent activator of NLRP3 
(Mariathasan et al., 2006).  
In Figure 4.7 (Experiment conducted by Pawat Laohamonthonkul) the effects 
of the different stimuli on NLRP1 WT, NLRP1 E414Q or NLRP1 KO clones are 
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summarized. For both, cell death (Figure 4.7A) and IL-18 cytokine release (Figure 
4.7B), no clear trend can be observed for the E414Q clones. Clone E414Q#2 as 
well as clone E414Q+Pam#2 showed slightly increased levels of cell death and 
IL-18 when compared to the WT clones. However, the remaining two clones of 
the E414Q variant showed similar levels as the WT clones. This clonal variation 
makes a clear interpretation difficult. Furthermore, the cells did not respond to 
Talabostat, as all clones exhibit similar levels of cell death and IL-18 when treated 
with DMSO or Talabostat. The NLRP1 KO clones also show similar levels of cell 
death when stimulated with Pam3CSK4, with some clonal variation. IL-18 levels 
are slightly reduced for the NLRP1 KO clones compared to the WT. Taken 
together, the results do not indicate a role for the E414Q mutation of the Walker 
B motif to induce spontaneous NLRP1 activation in THP1 cells. However, clonal 
variation makes drawing clear conclusions from the herein presented results 
difficult. Additionally, supernatant IL-1b levels were checked by ELISA. The 
overall results look similar to the IL-18 data and did not reveal a specific 
phenotype for the E414Q variant (Figure A4).  
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Figure 4.7: THP1 clones harbouring E414Q exhibit no spontaneous 
activation 
(A) Clones of THP1s were treated with the indicated chemicals and analysed for 
cell death by PI staining. (B) The supernatant of the cells described in A was 
analysed for proinflammatory cytokines IL-18 by ELISA. Data is representative 
from two individual experiments and displayed as mean ± SEM.  
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4.2.7 Mutations of the nucleotide binding site do not affect FIIND 
cleavage or the interaction of N- and C-terminal fragments 
 
FIIND domain cleavage has been shown to be required for the activation of 
NLRP1 (Finger et al., 2012). Since mutations of the nucleotide binding site led to 
increased activation of NLRP1 in ASC speck assays (Chapter 4.2.5), we aimed 
at examining whether this effect was due to a change in FIIND domain cleavage. 
Furthermore, the interaction of the N- and C-terminal cleavage fragments was 
investigated. To this end, a C-terminally FLAG-tagged NLRP1 was subjected to 
immunoprecipitation (IP) after overexpression in HEK293T cells (Figure 4.8A). 
Immunoblot of the IP samples allows both, testing the effect of mutations on 
FIIND domain cleavage as well as the interaction of N- and C-terminal cleavage 
fragments. The latter is possible as only the full-length protein or the C-terminal 
cleavage fragment can bind in the FLAG-IP. Therefore, the N-terminal fragment 
can only be detected in an immunoblot when associated with the C-terminal 
fragment. Using an NLRP1 antibody that binds within the N-terminal cleavage 
fragment, the full-length protein as well as the N-terminal fragment can be 
detected by immunoblotting. A FLAG antibody is used to detect the C-terminal 
fragment. In Figure 4.8B a representative immunoblot is shown. In this 
experiment a mutation identified from patients was used as a control for an 
activating mutation (A66V). In addition, a known variant of NLRP1, M1184V, was 
used as a control for a mutation inducing increased FIIND cleavage. Another 
mutation, S1213A, was used as a control for a mutation that abrogates FIIND 
cleavage. The nucleotide binding site variants of NLRP1 show similar amounts 
of full-length protein as well as N- and C-terminal cleavage fragments relative to 
the WT sample on the immunoblot. Thus, alterations of the nucleotide binding 
site do not affect FIIND domain cleavage or the interaction of the two cleavage 
fragments. Therefore, increased activity through alterations in the nucleotide 
binding site of NLRP1 is not caused by a change in FIIND domain cleavage or by 
disrupting the interaction of the cleavage fragments. 
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Figure 4.8: Effect of nucleotide binding site variants on FIIND cleavage 
(A) Schematic of autolytic cleavage within the FIIND domain and the resulting N-
terminal fragment and C-terminal fragment with the C-terminally linked FLAG-tag 
for immunoprecipitation. (B) Immunoblot of NLRP1-FLAG IP overexpressed in 
HEK293T cells. Different variants of NLRP1 were transfected as indicated in the 
blot. Cells were harvested for immunoprecipitation 24 h after transfection. NLRP1 
full-length and N-terminal cleavage fragment were detected using an anti-NLRP1 
antibody. C-terminal fragment was detected using an anti-FLAG antibody. The 
displayed blot is a representative of two individual experiments. Uncropped blots 
can be found in the appendix (Figure A5) 
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4.3 Discussion 
 
As all NLRs, NLRP1 harbours a central NACHT domain which is described to be 
involved in nucleotide binding and hydrolysis as well as oligomer formation (Proell 
et al., 2008). To date, a construct containing the NACHT and LRR domain of 
NLRP1 was described to bind but not hydrolyse ATP (Martino et al., 2016). Using 
recombinant MBP-NLRP1 we were able to show for the first time that NLRP1 
exhibits ATP hydrolysis activity. To further investigate the physiological relevance 
of this activity we first sought to identify conserved motifs required for nucleotide 
binding and the hydrolysis reaction. A combination of sequence alignments and 
structural analysis resulted in the identification of important residues within the 
conserved Walker A (K340, S341), Walker B (E414) and Sensor 1 (R459) motifs 
as well as the Sensor 2 histidine (H623). These residues were mutated in order 
to investigate their functional role in ATP hydrolysis and NLRP1 activity. 
Most of these mutations had only minor effects on the hydrolysis activity of 
NLRP1. Unfortunately though, variations between measurements make it difficult 
to draw conclusions, as to which of these amino acids are directly involved in 
binding and hydrolysing ATP. Recombinant full-length MBP-NLRP1 protein was 
prone to unspecific oligomerization and aggregation as described in Chapter 
3.2.5. This made it difficult to keep the results reproducible between different 
batches of protein. Variation in the ATP hydrolysis activity measured could be a 
result of these differences between protein batches. Therefore, further 
experiments comparing the activity of WT NLRP1 and nucleotide binding site 
variants of NLRP1 are required, to generate statistically significant data. 
Additionally, a high resolution structure of the full-length NLRP1 protein or the 
NACHT domain bound to ADP or ATP together with water molecules and a bound 
magnesium ion might further improve the understanding of the hydrolysis 
mechanism. Residues which are involved in nucleotide binding and hydrolysis 
could be identified and more importantly their respective role in nucleotide binding 
and hydrolysis could be determined. 
Apart from ATP hydrolysis, a second reaction was observed in RP-HPLC 
experiments with MBP-NLRP1. When incubated with ADP instead of ATP, the 
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generation of both, AMP and ATP was detected. The interconversion of two ADP 
molecules to ATP and AMP as well as the reverse reaction is described for 
adenylate kinases. To date, now such activity is described for NLR proteins. 
Thus, the functional relevance of this catalytic activity is unclear and can only be 
speculated about. Thus far, ATP hydrolysis was described to induce a 
conformational change from an active, open conformation to an inactive, closed 
conformation (Maharana et al., 2018). For instance, it could serve as a regulatory 
mechanism to convert from an active to an inactive state and the reverse. Since 
adenylate kinase activity has not been described previously for NLR proteins, a 
prediction of the residues involved in catalysing this reaction is difficult. 
Nevertheless, the residues identified to be involved in ATP binding and 
hydrolysis were investigated regarding their role in NLRP1 inflammasome 
activation. ATP-dependent activity has been described for multiple NLR proteins 
including NLRP3, NLRP7, NLRP10 and NLRP12 (Duncan et al., 2007; Ye et al., 
2008; Su et al., 2013; Radian et al., 2015). Formation of the active Apaf-1 
apoptosome was also shown to require ATP binding (Yuanming et al., 1999). 
Controversial findings have been reported in the literature regarding the role of 
nucleotides in regulating NLRP1 inflammasome activity. While some studies 
found that NLRP1 activity is dependent on ATP, other more recent studies found 
that loss of ATP binding by mutation of the Walker A motif results in constitutive 
or increased inflammasome activity (Faustin et al. 2007; Liao and Mogridge 2013; 
Chavarría-Smith et al. 2016). Furthermore, a reduction in cytosolic ATP levels 
was identified as an activating trigger for the mouse variant NLRP1b (Liao and 
Mogridge, 2013). Consistent with the more recent studies, mutation of the 
conserved residues within Walker A, Walker B, Sensor 1 or Sensor 2 resulted in 
increased activation of NLRP1 when overexpressed in HEK293T cells. One 
conclusion regarding the autoactivating effect of Walker A mutations stated in the 
literature is that NLRP1 does not require an intact Walker A motif to be activated 
(Chavarría-Smith et al., 2016). This conclusion could now be extended to include 
the Walker B and Sensor 1 motif as well as the Sensor 2 histidine (H623). 
Furthermore, it could be assumed that a loss of ATP hydrolysis activity by 
mutating the nucleotide binding site leads to an activation of NLRP1. Thus, 
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hydrolysis activity and conformational changes depending on hydrolysis might be 
required for NLRP1 to adapt an autoinhibited conformation. However, the 
assumed loss of ATP hydrolysis by nucleotide binding site mutations was not 
observed in RP-HPLC based hydrolysis assays with recombinant NLRP1 and 
remains to be confirmed by additional hydrolysis experiments as discussed 
above. Also, changes in nucleotide binding and hydrolysis might not be directly 
linked to functionality of the protein. 
Interestingly, the mutation of the Sensor 2 histidine (H623) to alanine resulted 
in a significantly lower increase of NLRP1 activation compared to all other 
mutations. Firstly, this excludes the option that any mutation within the NACHT 
domain has the same effect and may therefore serve as a control. Second, this 
result might imply a different function of this residue compared to the other 
residues mutated in this approach. NLRC4 also harbours a conserved histidine 
at the respective position. An examination of the structure of NLRC4 in its 
inhibited and active conformations reveals that this histidine residue is shifted 
away from the nucleotide binding site, probably through conformational changes 
in the NACHT domain (Hu et al., 2013; Tenthorey et al., 2017). Such 
conformational changes have been described for other members of the 
superfamily of AAA+ ATPases as well as for NLRs (Chen et al., 2010; Zhang et 
al., 2015). All other residues investigated in the mutagenesis approach reside in 
the nucleotide binding site in both NLRC4 structures. Thus, the conserved 
histidine might form a contact with ADP after ATP hydrolysis and thereby support 
the integrity of the autoinhibited conformation. 
Moreover, it is compelling that NLRP1 NACHT seems to have a different 
function compared to other NLRs. As mentioned previously, formation of the 
NLRP3 inflammasome is dependent on ATP binding. In contrast, for NLRP1 a 
loss of ATP binding induced by nucleotide binding site mutations leads to 
activation of the inflammasome. One possible explanation could be the different 
domain architecture of NLRP1 compared to other members of the NLR protein 
family. Most importantly, the C-terminal CARD is the effector domain in NLRP1. 
In all other members of the NLRP family the effector domain is located at the N-
terminus (Meunier and Broz, 2017). Additionally, NLRP1 undergoes autolytic 
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cleavage within its FIIND domain and the resulting C-terminal cleavage fragment 
has been shown to be sufficient for inducing ASC speck formation and IL-1b 
release (Zhong et al., 2016). IP and subsequent western blot analysis revealed 
that mutations of the nucleotide binding site do not affect FIIND domain cleavage 
or the interaction of the N- and C-terminal cleavage fragments (Chapter 4.2.6). 
Thus, the NLRP1 NACHT domain might be primarily involved in mediating the 
adaptation of an autoinhibited fold through conformational changes. Loss of ATP 
binding would prevent the NACHT domain from mediating these conformational 
changes and potentially destabilise the autoinhibited conformation, ultimately 
resulting in activation. Consistent with the finding that mutations supposed to 
impair ATP hydrolysis result in autoactivation of NLRP1, recently an 
autoactivating effect of Walker B mutations was described for NLRP3 (Coll et al., 
2019; Tapia-Abellán et al., 2019). A similar mechanism was proposed for the 
plant R protein I-2, for which mutations impairing ATP hydrolysis were shown to 
induce autoactivation as well (Tameling et al., 2006). 
In the THP1 experiments, the E414Q variant of NLRP1 did not clearly show 
increased cell death and cytokine levels. Surprisingly, treatment with Talabostat 
did also not induce an increase in cell death and cytokine levels, suggesting that 
the THP1 system might not be suitable for NLRP1 activation assays. It should 
also be noted that the increase in cell death from treatment with Pam3CSK4 alone 
cannot be explained by TLR1/TLR2 activation. Thus, this experiment might need 
to be optimized in regards to the concentration of Pam3CSK4 used or the 
incubation time, if it was to be repeated. Since the experiments in THP1s could 
not confirm the findings observed in the ASC speck assay in HEK 293T cells, 
additional experiments are required to confirm the above stated hypothesis. A 
system employing cleaved IL-1b and cleaved IL18 would be particularly helpful 
for this. Although, according to the manufacturer, the IL-1b kit has a higher 
specificity for the mature, bioactive protein, ELISA kits are often able to detect 
unprocessed, inactive IL proteins. Thus, it should also be considered to do a 
western blot analysis to distinguish between cleaved and total IL-1b/IL18. 
Taken together, the results presented within this chapter show that 
recombinant NLRP1 exhibits ATP hydrolysis activity. Mutagenesis of the Walker 
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A, Walker B, Sensor 1 and Sensor 2 motifs led to increased inflammasome 
activation. Therefore, hydrolysis activity is potentially physiologically important in 
mediating conformational changes required for NLRP1 to adapt an autoinhibited 
conformation. However, in which way these mutations affect nucleotide binding 
and hydrolysis activity of NLRP1 remains to be elucidated in detail. 
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5. NLRP1 inflammasome activity is tightly regulated 
through diverse molecular mechanisms 
 
5.1 Introduction 
 
It is well described that protein activity is regulated through a large number of 
molecular mechanisms, including epigenetics and post-translational 
modifications (PTMs). For instance, modifications of histones, also referred to as 
the histone code, were intensively studied and the role of PTMs like acetylation, 
phosphorylation, methylation and ubiquitination in histone functionality has been 
extensively discussed in the literature (Strahl and Allis, 2000; Jenuwein and Allis, 
2001). PTMs can be grouped into reversible and irreversible modifications. The 
addition of a chemical group (e.g. phosphorylation, acetylation) or a more 
complex molecule (e.g. glycosylation) to the side chain of an amino acids are 
usually reversible modifications. Irreversible modifications include deamidation of 
amino acids or proteolytic cleavage (Seo and Lee, 2004). Phosphorylation has 
been reported to be the most frequent PTM and can occur on serine, threonine 
and tyrosine residues (Khoury et al., 2011). Another common PTM not as 
frequent as phosphorylation is proteolytic cleavage. Many proteins, especially 
proteases, are known to be expressed and translated as inactive zymogens and 
require proteolytic cleavage by another protein to become active (Khan and 
James, 2008). The pro-inflammatory caspase-1 is also expressed as a zymogen, 
Procaspase-1 (Elliott et al., 2009). As a special case of proteolytic activation, so 
called autolysis, has been reported for a significant number of proteins (Perler et 
al., 1997). Here, autolysis means that the proteolytic cleavage is catalysed 
through residues within the molecule itself. A well-studied example for this rare 
case of a PTM is p53-induced protein with a death domain (PIDD). PIDD 
undergoes autolytic cleavage at two different sites and the occurrence of 
autolysis determines the outcome of its signalling activity, ultimately resulting in 
cell survival or apoptosis. A non-cleavable variant of PIDD has been shown to be 
unable to become active (Tinel et al., 2007). 
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NLRP1 was the first NLR protein described to form an inflammasome 
(Martinon et al., 2001). To date, autoproteolysis within the FIIND domain of 
NLRP1 is the only post-translational mechanism regulating NLRP1 activity (Baker 
et al., 2017). Autolytic cleavage was identified as a major modification of the 
mature NLRP1 protein and is a strict requirement for activation (D’Osualdo et al., 
2011; Finger et al., 2012). However, cleavage does not result in activation by 
itself but requires an additional activating stimulus. Furthermore, the N- and C-
terminal fragments remain associated after processing of the FIIND domain 
(Finger et al., 2012). Apart from the residues comprising the cleavage site 
(S1211, F1212 and S1213) a conserved histidine residue was identified to be 
essential for proteolysis (Finger et al., 2012). H1186 is described to initiate 
cleavage by deprotonating the hydroxyl group of S1213. Substituting any of these 
residues individually for an alanine results in loss of autolytic cleavage and 
consequently loss of NLRP1 inflammasome activity (Finger et al., 2012). A 
common polymorphism of human NLRP1, M1184V (rs11651270), has been 
shown to be associated with multiple diseases, like vitiligo associated 
autoimmunity, asthma and breast cancer (Gao et al., 2012; Levandowski et al., 
2013; Leal et al., 2018). Interestingly, this polymorphism has been described to 
increase proteolysis within the FIIND domain and was linked to increased NLRP1 
activity (Finger et al., 2012). 
Another proteolytic mechanism was described to activate rodent versions of 
NLRP1 (Hellmich et al., 2012; Levinsohn et al., 2012). For instance, murine 
NLRP1b can be cleaved by anthrax lethal toxin within the N-terminal part of the 
protein leading to activation of the inflammasome (Hellmich et al., 2012; 
Chavarría-Smith and Vance, 2013). Anthrax lethal toxin does not activate human 
NLRP1. However, proteolytic cleavage of a human NLRP1 variant modified to 
contain a TEV cleavage site between its PYD and NACHT domain was also 
shown to be activated by proteolytic cleavage at the inserted TEV site (Chavarría-
Smith et al., 2016). Consistent with that finding, several mutations identified from 
patients with NLRP1 associated autoimmune syndromes are located within the 
PYD and have been shown to destabilize the six helix bundle fold of the PYD. 
This conformational destabilization of the N-terminus also results in 
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hyperactivation of human NLRP1 (Zhong et al., 2016). In accordance with this, a 
recent study investigated if N-terminal degradation could be a general 
mechanism for the activation of NLRP1 (Sandstrom et al., 2019). Indeed it was 
reported that IpaH7.8, an E3 ubiquitin ligase of the pathogenic bacterium Shigella 
flexneri, induces activation of mouse NLRP1b by degradation of the N-terminal 
cleavage fragment and subsequent release of the active C-terminal fragment 
(Sandstrom et al., 2019). A different study described that inhibition of dipeptidyl 
peptidase 9 (DPP9) by Talabostat resulted in degradation of NLRP1b as well. 
Dipeptidyl peptidases are a class of regulatory proteins that is described to cleave 
off dipeptides from the N-terminus of proteins. The DPP9 protein had previously 
been identified to negatively regulate NLRP1 activity in both humans and mice 
by binding to the FIIND domain. Inhibition of DPP9 with various inhibitors like 
Talabostat was described to induce activation of NLRP1 (Okondo et al., 2018; 
Zhong et al., 2018). Further, three N-end rule proteins, UBR2, UBR4 and UBA6 
were shown to be involved in directing NLRP1b to the proteasome (Chui et al., 
2019). The activating effect of anthrax lethal toxin and Talabostat was 
successfully reversed by proteasome inhibitors (Chui et al., 2019; Sandstrom et 
al., 2019). 
Apart from the two mechanisms described above, no other PTMs have been 
described for NLRP1. Since NLRP1 is a large multidomain protein it is likely that 
it is regulated by other PTMs like phosphorylation. Such regulating mechanisms 
have been described for other NLR proteins like NLRP3. Here a phosphorylation 
within the PYD was described to regulate inflammasome activity by blocking 
PYD-PYD interactions (Stutz et al., 2017). Other phosphorylation sites (S198, 
S295, Y861) located in the NACHT and LRR domains of NLRP3 were shown to 
be involved in regulating inflammasome activity as well (Song and Li, 2018). 
Phosphorylation was further shown to be involved in ASC speck formation. Loss 
of phosphorylation at residue Y146 in the CARD domain of the human ASC 
protein has been described to impair speck formation and thus caspase-1 
activation (Hara et al., 2013; Chung et al., 2016). More recently, the 
phosphorylation status of two other tyrosine residues (Y60, Y137) of human ASC 
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has been reported to play an important role for ASC function (Mambwe et al., 
2019). 
This part of the project aimed to further investigate how autolytic cleavage in 
the FIIND domain as a crucial PTM regulates NLRP1 activity. To this end, the 
polymorphism M1184V was tested regarding its effect on different activating 
stimuli for NLRP1. Furthermore, a potential phosphorylation site was identified in 
the NLRP1 CARD domain and investigated by a mutagenesis approach. 
Additionally, a screening of inhibitors targeting different tyrosine kinases was 
performed in BMDMs to potentially identify kinases regulating NLRP1 activity. 
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5.2 Results 
 
5.2.1 Computational analysis of the NLRP1 polymorphism M1184V 
 
The polymorphism M1184V has been described to be associated with multiple 
autoimmune syndromes (Levandowski et al., 2013). To investigate how 
conserved this residue is in different species, a multiple sequence alignment was 
performed using the Clustal Omega online tool (Madeira et al., 2019). In Figure 
5.1A the part of this alignment containing the residue of interest is shown. 
Interestingly, it was found that only in the human version of NLRP1 a methionine 
residue is present in position 1184. In other primates and rodents the according 
residue was found to be a valine. In Ophiophagus Hannah, a lizard species, the 
valine residue is also conserved. Only in Danio rerio, a zebrafish species, the 
valine is not present and instead a leucine residue is found in the corresponding 
position. Of note, Danio rerio is also the only species in this alignment in which 
the histidine residue shown to initiate autolytic cleavage (H1186 in human 
NLRP1) is not conserved (Finger et al., 2012). This raises the question, why 
human NLRP1 has evolved to contain a methionine instead of a valine in position 
1184. To further investigate this, a computational structural assessment of the 
FIIND cleavage site was carried out and functional assays were performed in 
vitro (Chapter 5.2.2). 
The presence of a valine in position 1184 has been reported to increase the 
autolytic cleavage in human NLRP1 (Finger et al., 2012). To investigate the 
molecular basis for that increase in cleavage, a structural assessment of the 
cleavage site was performed. Since there is no structure available of the FIIND 
domain, a homology model was generated using a SWISS Model approach 
(Waterhouse et al., 2018). In the according alignment the best match was found 
with the structure of the cytoplasmic domain of Unc5b, which showed 15 % 
sequence identity with NLRP1 (residues 1081-1380). The cytoplasmic domain of 
Unc5b consists of a ZU5-UPA domain tandem similar to the NLRP1 FIIND 
domain and was therefore an appropriate candidate for the generation of a 
homology model. The resulting structural model contains the entire ZU5 domain 
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including the cleavage site and only part of the UPA domain. The ZU5 domain 
forms a b-sheet sandwich with the cleavage site located in a loop between two 
b-sheets. The side chain of histidine 1186 is only 4.6 Å away from the reactive 
oxygen of serine 1213 (Figure 5.1B, bottom panel). This could support the 
proposed involvement of this histidine residue in deprotonating serine 1213 to 
initiate the cleavage. Furthermore, the side chain of methionine 1184 is located 
in close proximity to histidine 1186. However, it is not obstructing the interaction 
of histidine 1186 and serine 1213 structurally, as it is located on the opposite side 
of H1186. An exchange of methionine for valine in position 1184 would not 
introduce a significant change in electrostatics, since the side chain of both amino 
acids is aliphatic. Nevertheless, such an exchange would remove the S-methyl 
thioether present in the side chain of methionine and not in valine. The S-methyl 
thioether of methionine has been reported to be involved in cation-p interactions 
(Imai et al., 2007). If such an interaction occurs between M1184 and H1186 it 
could affect the potential of the histidine to deprotonate S1213 and thereby inhibit 
autolytic cleavage in the FIIND domain. Moreover, a change from methionine to 
valine could open up space for water molecules potentially involved in catalysing 
autoproteolysis. However, these hypotheses are solely based on a homology 
model and the exact mechanism by which M1184 reduces cleavage of the FIIND 
domain remains to be clarified. 
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Figure 5.1: Computational analysis of the human NLRP1 FIIND domain 
(A) Sequence alignment of the amino acid sequence of NLRP1 from different 
organisms. Sequences were taken from NCBI. Multiple sequence alignment was 
performed using the Clustal Omega online tool with default settings (Madeira et 
al., 2019). Only part of the alignment is shown. Methionine 1184 in human NLRP1 
and corresponding residues in other species are highlighted. (B) Homology 
modelling of the NLRP1 FIIND domain (residues 1084-1278). The homology 
model was generated using Swiss Model (Waterhouse et al., 2018). Images and 
distance measurements were generated using PyMOL. 
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5.2.2 Effect of increased FIIND cleavage on NLRP1 activation 
 
To investigate the effect of the M1184V polymorphism and the resulting increase 
in FIIND domain cleavage on NLRP1 activation, the in vitro ASC speck assay in 
HEK293T cells was utilised. First, the effect of the polymorphism was 
investigated in the context of NLRP1 activation by destabilization of the N-
terminus. This stimulus for activation was mimicked by introducing the A66V 
mutation, which was found in patients presenting with NLRP1-associated 
autoimmunity and which has been described to induce spontaneous activation of 
NLRP1 (Zhong et al., 2016). 
ASC speck formation was measured 24 h and 42 h post transfection by flow 
cytometry. Consistent with previous findings, the A66V patient mutation induced 
increased activation of NLRP1, as reflected in the increased frequency of ASC 
specks (Figure 5.2). In contrast, the M1184V polymorphism does not induce 
spontaneous activation of NLRP1. Instead, it displays a similar frequency of ASC 
specks as WT NLRP1 after 24 h (Figure 5.2A). For the 42 h timepoint, a slightly 
lower frequency of ASC specks can be observed for M1184V compared to WT 
NLRP1 (Figure 5.2B). This might indicate an inhibitory effect of M1184V on 
spontaneous activation of NLRP1. Of note, this is in conflict with a study that 
described M1184V to not only induce increased cleavage in the FIIND domain 
but also increased NLRP1 activity, as determined by measuring IL-1b levels in a 
reconstituted overexpression system in HEK293T cells (Finger et al., 2012). 
Interestingly, when NLRP1 was activated by a destabilised N-terminus (A66V), 
the polymorphism significantly increased the amount of ASC specks. This 
suggested a synergistic effect for the combination of a destabilised N-terminus 
and an increase in FIIND domain cleavage (M1184V). Although significantly less 
pronounced, this effect was still observed after 42 h (Figure 5.2B).  
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Figure 5.2: Effect of M1184V on NLRP1 activation by destabilization of 
the N-terminus 
HEK293T cells stably expressing ASC-RFP were transfected with WT or mutant 
NLRP1 or a vector control (EV) and analysed for ASC formation 24 h (A) and 42 
h (B) post transfection by flow cytometry. Samples were recorded in triplicates. 
Data was analysed in FlowJo and graphed in Prism. Data shown is a 
representative of two individual experiments and is graphed as mean ± SEM. 
Representative flow cytometry plots are shown in Fig. A6.  
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To further investigate whether M1184V leads to increased speck formation upon 
activation of NLRP1 in the context of other activating stimuli, activation of NLRP1 
by Talabostat was also investigated (Figure 5.3). Talabostat leads to activation 
of NLRP1 by inhibiting the negative regulator DPP9. DPP9 has been described 
to bind NLRP1 within its FIIND domain, assisting in keeping it in an autoinhibited 
conformation (Zhong et al., 2018). Therefore, it was assumed that activation 
through Talabostat is a different mechanism than activation through destabilizing 
the N-terminus. This was also reflected in the results of the according ASC speck 
assay. Incubation of NLRP1 WT with Talabostat for 6 h (Figure 5.3A) or 24 h 
(Figure 5.3B) lead to a significant increase in the frequency of ASC specks 
recorded. Compellingly, M1184V seemed to have an inhibitory effect on NLRP1 
activity, when stimulated only with Talabostat, as this variant shows a lower 
frequency of ASC specks compared to WT NLRP1 stimulated with Talabostat 
(Figure 5.3A). These results further supported the hypothesis that a 
destabilisation of the N-terminus (A66V) and loss of DPP9 binding (Talabostat) 
are two different mechanisms of NLRP1 activation. Destabilising the N-terminus 
synergises with increased FIIND cleavage induced by the M1184V 
polymorphism, while a loss of DPP9 binding does not. This effect was also 
observed for the later timepoint although being significantly less pronounced 
(Figure 5.3B). Even though the difference between the two samples is only 
marginal, it was consistent between experiments for the 24 h timepoint. 
The S1213A mutation is located within the FIIND domain cleavage site. This 
variant served as a control for a non-cleavable and thus non-activatable variant 
of NLRP1. Indeed, this variant was not activated when stimulated with Talabostat 
for 6 h or 24 h (Figure 5.3A and B).  
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Figure 5.3: Activation of NLRP1 by Talabostat is delayed by M1184V 
HEK293T cells stably expressing ASC-RFP were transfected with WT or mutant 
NLRP1 or a vector control (EV) and analysed for ASC formation 24 h (A) and 42 
h (B) post transfection by flow cytometry. Cells were treated with 2 µM Talabostat 
18 h post transfection. Samples were recorded in triplicates. Data was analysed 
in FlowJo and graphed in Prism. Data shown is a representative of two individual 
experiments and is graphed as mean ± SEM. Representative flow cytometry plots 
are shown in Fig. A7.  
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To confirm the inhibitory effect that M1184V had on NLRP1 activation in the 
context of DPP9 inhibition, a different NLRP1 variant, the P1214R patient 
mutation, was introduced into the NLRP1 expression vector. The mutation 
P1214R was reported to trigger spontaneous activation of NLRP1 by inhibiting 
DPP9 binding (Grandemange et al., 2017; Zhong et al., 2018). Thus, we 
hypothesized that P1214R activates NLRP1 by a mechanism comparable to 
Talabostat. 
Again, the effect of P1214R on NLRP1 activation in the context of increased 
FIIND cleavage was investigated in regards to ASC speck formation 24 h and 42 
h post transfection (Figure 5.4). As expected, P1214R mutation of NLRP1 led to 
strong spontaneous activation as reflected in the increased frequency of ASC 
specks. Strikingly, activation of NLRP1 by P1214R was inhibited when combined 
with the M1184V polymorphism, reflected in a reduced frequency of ASC specks 
compared to P1214R alone. In contrast to activation with Talabostat (Figure 
5.3B), the inhibitory effect of M1184V on NLRP1 activation by P1214R was still 
clearly observable for the later timepoint (Figure 5.4B). Furthermore, treating cells 
transiently expressing the P1214R variant with Talabostat did not lead to an 
additional increase in the level of ASC specks. In contrast, treatment of cells 
expressing the A66V variant with Talabostat resulted in an additional significant 
increase in ASC specks (Appendix, Figure A8). This further supports the 
hypothesis that destabilization of the N-terminus (A66V mutation) and inhibition 
of DPP9 (Talabostat, P1214R) are two different mechanisms of NLRP1 
activation. 
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Figure 5.4: P1214R induces NLRP1 activation similar to Talabostat 
HEK293T cells stably expressing ASC-RFP were transfected with WT or mutant 
NLRP1 or a vector control (EV) and analysed for ASC formation 24 h (A) and 42 
h (B) post transfection by flow cytometry. Cells were treated with 2 µM Talabostat 
18 h post transfection. Samples were recorded in triplicate. Data was analysed 
in FlowJo and graphed in Prism. Data shown is pooled from three individual 
experiments (24 h) or from one individual experiment (42h). Graphs show the 
mean ± SEM. All values were compared to the WT measurement for statistical 
analysis using an ordinary one-way ANOVA. ns: non-significant; * p < 0.05; *** p 
< 0.001; **** p < 0.0001 (C) Expression levels of different NLRP1 variants were 
monitored by immunoblot. The full-length protein as well as N-terminal cleavage 
fragment were probed by using an NLRP1 antibody specifically binding to the N-
terminal part of the protein. The C-terminal fragment was probed for with a FLAG 
antibody. (Experiments were carried out by Pawat Laohamonthonkul) 
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Similar expression levels were confirmed by western blot of the different variants 
of NLRP1, as reported in Figure 5.4C. Only expression of the M1184V variant 
was slightly increased compared to WT NLRP1. Although baseline levels were 
increased, the western blot indicated increased FIIND cleavage for the M1184V 
variant. Interestingly, P1214R showed higher levels of the C-terminal cleavage 
fragment compared to the WT protein even without M1184V. Increased FIIND 
processing was observed for the M1184V/P1214R variant when probing for the 
full-length and N-terminal cleavage fragment. However, the level of C-terminal 
fragment remained unchanged when combining M1184V and P1214R. For the 
A66V/M1184V double mutation both, the N- and C-terminal fragment is increased 
compared to A66V alone. 
 
5.2.3 Investigation of a potential phosphorylation site in NLRP1 CARD 
 
As described above, thus far FIIND domain cleavage is the only PTM described 
to regulate NLRP1 activity. However, in a manuscript uploaded to the preprint 
server BioRxiv (https://biorxiv.org/) a conserved tyrosine residue within the 
NLRP1 CARD was described to be potentially phosphorylated (Boyle and Monie, 
2016). The conserved amino acid motif follows the pattern EQYE in the NLRP1 
CARD. Similar motifs with a tyrosine residue were identified in the inflammasome 
adaptor ASC and the receptor-interacting protein kinase 2 (RIPK2). Of note, 
tyrosine phosphorylation in this position was described to be essential for the 
effector function of both ASC and RIPK2 (Tigno-Aranjuez et al., 2010; Chung et 
al., 2016). To investigate whether the respective tyrosine residue, Y1413, is of 
importance for NLRP1 activity, an ASC speck assay was carried out. The activity 
of NLRP1 WT upon activation by Talabostat or an autoactivating mutation 
(E414Q, Chapter 4.2.5) was compared to NLRP1 with tyrosine 1413 substituted 
for phenylalanine (Y1413F). Tyrosine and phenylalanine have very similar side 
chains, with the latter only lacking the hydroxyl group compared to tyrosine, which 
is why this substitution was considered the most conservative alternative. 
Compellingly, a substitution of Y1413 resulted in a complete loss of NLRP1 
activity, as determined by the frequency of ASC specks (Figure 5.5A and B).  
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Figure 5.5: Substitution of Y1413 impairs NLRP1 activity 
HEK293T cells stably expressing ASC-RFP were transfected with WT or mutant 
NLRP1 or a vector control (EV) and analysed for ASC speck formation 24 h (A, 
C) and 42 h (B) post transfection by flow cytometry. Cells were treated with 2 µM 
Talabostat 18 h post transfection. Samples were recorded in triplicate. Data was 
analysed in FlowJo and graphed in Prism. For A and B graphs present pooled 
data of three individual experiments and are shown as mean ± SEM. All values 
were compared to the WT measurement for statistical analysis using an ordinary 
one-way ANOVA. ns: non-significant; * p < 0.05; *** p < 0.001; **** p < 0.0001. 
Data shown in C is from one experiment. (D) Expression of NLRP1 WT and 
NLRP1 Y1413F was monitored by immunoblot. The full-length protein as well as 
N-terminal cleavage fragment were probed by using an NLRP1 antibody 
specifically binding to the N-terminal part of the protein. Samples were taken from 
lysates prepared from cells treated similar to cells used in the ASC speck assay. 
Representative flow cytometry plots and uncropped blots can be found in the 
appendix (Fig. A9 and A10).  
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Similar expression of the NLRP1 WT and NLRP1 Y1413F was confirmed by 
western blot (Figure 5.5D). Even when combining both activating stimuli the 
amount of ASC specks did not increase. This was consistent for both timepoints 
measured. The S1213A mutation abrogating FIIND domain processing served as 
a negative control for NLRP1 activation. As expected this variant was also not 
activated by Talabostat, the E414Q autoactivating mutation or the combination of 
both. 
To ensure that the impairment of the NLRP1-ASC interaction is not just due to 
the hydrophobicity of the phenylalanine, Y1413 was also substituted for 
glutamate (Y1413E) or glutamine (Y1413Q). Y1413E was chosen as a 
substitution to potentially mimic phosphorylation by adding a negative charge. 
Y1413Q was chosen as the equivalent substitution to Y1413E but without the 
negative charge. Interestingly, both variants could not be activated with 
Talabostat. 
Assuming that NLRP1 activation is directly dependent on Y1413 
phosphorylation and that the Y1413E mutation is effectively mimicking this 
phosphorylation, increased ASC speck formation would be expected for this 
variant. To further investigate this, the structure of the NLRP1 CARD (PDB: 
3KAT, Figure 5.6A) was analysed by implementing Y1413 phosphorylation and 
Y1413E substitution using PyMOL (Figure 5.6B and C). The structure itself 
reveals that Y1413 is surrounded by residues forming a negatively charged 
surface (E1397, D1401, E1414). When comparing the unphosphorylated with the 
phosphorylated state, it became evident that by phosphorylation not only two 
negative charges were added to the surface of the CARD domain, but also that 
the surface of the CARD domain was expanded (Figure 5.6A and B). This 
illustrates how a phosphorylation of Y1413 could be involved in facilitating an 
interaction with ASC. Furthermore, the insertion of Y1413E substitution into the 
NLRP1 CARD structure revealed that the glutamate cannot effectively mimic 
phosphorylation (Figure 5.6C). Although it introduced a negative charge similar 
to a phosphorylation, it does not reach out and expand the surface of the CARD 
as phosphorylation of the tyrosine would (Figure 5.6B and C). Implementing all 
the above mentioned substitutions also revealed that these amino acids should 
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not impair the conformation of NLRP1 CARD. Mutagenesis in PyMOL resulted in 
well suited rotamers without any steric hindrance. Still, this modelling is no 
evidence for the NLRP1 CARD folding correctly when containing either of the 
three different substitutions (F, E ,Q) at position 1413. 
Overall, the data herein suggest that Y1413 is important in mediating the 
interaction of NLRP1 CARD and ASC CARD. Further structural assessment of 
recombinant NLRP1 CARD harbouring the aforementioned substitutions is 
required to reveal, whether the structural integrity of the domain is compromised 
by introducing different amino acids in this position. 
Since phosphorylation of NLRP1 cannot be effectively mimicked by an amino 
acid substitution, a different approach was taken to investigate the hypothesis of 
Y1413 phosphorylation. In this approach, an array of tyrosine protein kinase 
inhibitors was tested in combination with Talabostat on BMDMs. If 
phosphorylation of tyrosine 1413 is required for the interaction with ASC and 
therefore NLRP1 activity, inhibition of the kinase responsible for phosphorylating 
this residue should also inhibit NLRP1 activity. As a readout, IL-1b release into 
the cell culture supernatant was measured by ELISA 24 h after LPS stimulation 
and subsequent treatment with Talabostat and a tyrosine protein kinase inhibitor. 
The results are visualized in Figure 5.7. For some of the inhibitors measured, 
large error bars indicate a strong variation in the duplicates measured in this 
experiment. However, it is still clear that most of them have either no effect or 
even increase cytokine levels. Only one of the tested inhibitors significantly 
decreased the amount of IL-1b to the level of the LPS and DMSO control. Inhibitor 
number 15 (TAK165 or Mubritinib) is an inhibitor for the protein kinase human 
epidermal growth factor receptor 2 (HER2). 
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Figure 5.6: Structural analysis of Y1413 in NLRP1 CARD 
Structure of the NLRP1 CARD in cartoon and surface representation. Side chains 
of residues E1397, D1401, E1414 and Y1413 (A) phospho-Y1413 (B) or E1413 
(C) are shown in stick representation. The PTM was added using the Pytms 
plugin of PyMOL. The Y1413E substitution was generated using the mutagenesis 
wizard in PyMOL. Red colour in stick representation indicates oxygen atoms and 
orange colour represents phosphorus atoms. 
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To confirm that this protein tyrosine kinase is involved in regulating NLRP1 
activity, another ASC speck assay was carried out. NLRP1 was activated by 
treatment with 2 µM Talabostat or destabilisation of the N-terminus (A66V). 
Additionally, the medium was supplemented with different concentrations of 
TAK165 to inhibit HER2. Unfortunately, no inhibitory effect of the HER2 inhibitor 
was observed in this experiment (Figure 5.7B), indicating that this kinase might 
not directly phosphorylate the NLRP1 CARD domain. Thus, the question whether 
NLRP1 Y1413 is directly phosphorylated remains yet to be elucidated. Still, the 
herein presented data demonstrate that Y1413 is of importance for the interaction 
with ASC, since substitution of this residue for phenylalanine, glutamine or 
glutamate resulted in a complete loss of ASC speck formation. 
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Figure 5.7: Screening for tyrosine kinase inhibitors of NLRP1 activity 
(A) Screening of tyrosine protein kinase inhibitors and their effect on IL-1b 
production upon activation of NLRP1. BMDMs were stimulated with LPS (200 
ng/µL) for 3 h. Afterwards BMDMs were treated with Talabostat (2.5 µM) and 
different inhibitors (5 µM) for 24 h before analysing the supernatant for IL-1b. 
Dashed line indicates level of activation in positive control. Data shown is from 
one experiment. (B): ASC speck assay with NLRP1 WT. Cells were treated 18 h 
post transfection with Talabostat (2 µM) for 1 h before supplementation with 
TAK165 at different concentrations. Cells were incubated for 6 h before analysis 
for ASC speck formation by flow cytometry. Data shown is representative from 
two individual experiments (repeat performed by Pawat Laohamonthonkul). 
Representative flow cytometry plots are shown in Fig. A11.  
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5.3 Discussion 
 
The activity of several inflammasomal proteins such as NLRP3, NLRC4 and ASC 
is regulated by a multitude of PTMs (Yang et al., 2017). For instance, the activity 
of NLRP3 depends on both phosphorylation and deubiquitination (Py et al., 2013; 
Stutz et al., 2017). Therefore, it is likely that the activity of NLRP1 is regulated 
through multiple PTMs as well. 
The first PTM reported for NLRP1 was proteolytic cleavage within the FIIND 
domain (Finger et al., 2012). This processing was described to be essential for 
NLRP1 to be activated and allow downstream signalling through ASC and 
Caspase-1 (Finger et al., 2012). However, other additional signals are required 
to trigger NLRP1 activation. To further investigate how NLRP1 activity is 
regulated by cleavage within the FIIND domain, we utilised the common 
polymorphism M1184V. This SNP was reported to increase cleavage in the FIIND 
domain and is reportedly involved in multiple autoimmune syndromes such as 
asthma and vitiligo-associated autoimmunity (Finger et al., 2012; Levandowski et 
al., 2013; Leal et al., 2018). We were able to show by western blot that the 
M1884V polymorphism indeed increases FIIND cleavage. However, an additional 
densitometry approach might be useful to confirm this, since baseline expression 
of this variant was also slightly increased. Surprisingly, aligning the amino acid 
sequence of NLRP1 from different primates, rodents and a lizard species, we 
found that all sequences except human NLRP1 harbour a valine in position 1184. 
This raised the question why human NLRP1 has evolved to contain a methionine 
in this position and how it might be related to NLRP1-associated infection and 
autoimmunity. In the case of NLRP1 activation through a destabilisation of the N-
terminus (A66V), NLRP1 with a valine in position 1184 showed increased ASC 
specks compared to NLRP1 containing methionine at this position. In contrast, a 
reduced frequency of ASC specks was measured for the M1184V variant when 
NLRP1 was activated by impairing DPP9 binding (Talabostat, P1214R). When 
activated with Talabostat, the M1184V variant showed lower levels of ASC 
specks after 6 h of treatment. This effect was significantly less pronounced for 
the later timepoint after 24 h of treatment. In contrast, inhibition of DPP9 binding 
by introduction of the P1214R mutation resulted in significantly lower ASC speck 
 Results 
161 
levels for both timepoints when combined with the M1184V polymorphism. A 
possible explanation for this difference could be the nature of the delivery of the 
activating stimulus. Talabostat has to cross the plasma membrane to reach the 
cytoplasm and fulfil its inhibitory function. Introducing a mutation is an intrinsic 
stimulus, that is constantly affecting the activity of every molecule of NLRP1 that 
is expressed in the cell. Furthermore, Talabostat is likely to induce cell stress by 
off-target effects. 
Given the different effects observed depending on the activating stimulus, it is 
conceivable that humans have adopted a methionine at position 1184 as 
protection against certain pathogens. However, this variant might in turn 
predispose to other types of infection or have a pleiotropic impact on 
autoimmunity, depending on the way in which NLRP1 is activated. 
To compare the role of M1184V (SNP rs11651270) in different diseases it is 
associated with, a table was generated listing the Odds Ratio, the respective p 
value and whether M1184V and IL-1b/IL-18 contribute to or protect from the 
according disease (Table 5.1). Interestingly, this comparison revealed that 
M1184V indeed protects from some diseases and contributes or predisposes to 
developing others. For instance, individuals carrying the rs11651270 
polymorphism are more protected from developing Type I diabetes, but more 
susceptible to acquiring asthma (Leal et al., 2018; Sun et al., 2019). This supports 
the above stated hypothesis of the M1184V variant having evolutionary emerged 
in humans as a protection from some disease. However, the role of 
inflammasome activation in the development of the respective disease, here 
reviewed as the involvement of IL-1b/IL-18, is not always clear. In some cases 
these proinflammatory cytokines play a protective role and in others they 
contribute to the severity of the disease. In some diseases the role of one or both 
cytokines is not entirely clear. Thus, conclusions regarding the mechanism of 
activation of NLRP1 in the disease based on the presence of M1184V remains 
speculative. Moreover, it is very likely that other factors play a role in development 
and outcome of each of the diseases associated with the M1184V polymorphism. 
It is furthermore difficult, to transfer the results observed in this analysis to 
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protection from pathogenic stimuli, due to the lack of data on pathogenic ligands 
for human NLRP1. 
Finally, additional repeats of experiments with less than three repeats would have 
been preferable, since this would allow for statistical analysis and thus strengthen 
the findings described in this chapter.  
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Table 5.1: Disease associated with the M1184V polymorphism 
 
Disease 
Odds 
Ratio 
P value 
M1184V (rs11651270) 
contributes/protects 
to/from disease 
(Reference) + (PMID) 
Inflammasome 
contributes/protects 
to/from disease 
(Reference) + (PMID) 
Vitiligo and 
associated 
autoimmunity 
1.6 n/a 
Contributes together 
with L155H/V1059M1 
(23382179) 
IL-1b contributes2,3 
(28082234, 25221996) 
Asthma 3.4 0.013 
Contributes4 
(29154202) 
 
IL-1b contributes5,6,7 
(16210060, 23837489, 
8527954) 
 
IL-18 protects8,9,10 
(12006423, 10629451, 
11972614) 
Breast Cancer n/a 0.013 
Potentially 
contributes11 
(23107584) 
 
IL-1b contributes12 
(30545915) 
 
IL-18 protects13 
(29725393) 
HPV infection 
and associated 
cervical cancer 
0.43 0.003 
Protects14 
(26945813) 
IL-1b contributes to 
cancer15 (19904560) 
 
IL-18 protects from 
infection16 (11470273) 
Crohn’s disease 1.35 0.02 
Contributes to 
inflammatory 
phenotype17 
(20403135) 
 
IL-1b contributes18,19 
(22891275, 7817982) 
 
IL-18 contributes20,21 
(10352304, 10384110) 
Chagas 
cardiomyopathy 
n/a 0.036 
Contributes22 
(29438387) 
 
IL-1b involvement 
unclear23 (30354432) 
 
IL-18 involvement 
unclear24 (25743241) 
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Type 1 Diabetes 0.643 0.002 
Protects25 (31396539) 
 
IL-1b unclear26,27 
(23562090, 21518168) 
 
IL-18 contributes28,29 
(25576800, 18359638) 
Diabetic Kidney 
Disease 
0.36 0.01 
Protects30 (29031829) 
 
IL-1b contributes31,32 
(27516236, 31191559) 
 
IL-18 contributes33,34,35 
(12759891, 16306550, 
17425653) 
Malaria 
(Plasmodium 
vivax) 
n/a n/a 
Potentially 
contributes36 
(26946405) 
IL-1b potentially 
contributes to severity37 
(29602073) 
 
IL-18 reduces severity 
(with IL-12)38 (28615061) 
Bacterial 
meningitis 
2.32 0.023 
Potentially 
contributes39 
(23053059) 
 
IL-1b protects40 
(12707352) 
 
IL-18 contributes to 
inflammation41 (12742650) 
 
List of references: 
 
Vitiligo: 1: (Levandowski et al., 2013); 2: (Bhardwaj et al., 2017); 3: (Laddha et al., 2014); 
Asthma: 4: (Leal et al., 2018); 5: (Johnson et al., 2005); 6: (Johnson et al., 2005); 7: (Konno et 
al., 1996); 8: (Ho et al., 2002); 9: (Kodama et al., 2000); 10: (Kuribayashi et al., 2002); Breast 
cancer: 11: (Gao et al., 2012); 12: (Kaplanov et al., 2019); 13: (Liu et al., 2018); HPV 
infection/cervical cancer: 14: (Pontillo et al., 2016); 15: (Qian et al., 2010); 16: (Cho et al., 
2001); Crohn’s disease: 17: (Cummings et al., 2010); 18: (Coccia et al., 2012); 19: (Sher et al., 
1995); 20: (Monteleone et al., 1999); 21: (Pizarro et al., 1998); Chagas cardiomyopathy: 22: 
(Clipman et al., 2018); 23: (Nunes et al., 2018); 24: (Nogueira et al., 2015); Type I Diabetes: 25: 
(Sun et al., 2019); 26: (Moran et al., 2013); 27: (Sumpter et al., 2011); 28: (Altinova et al., 2008); 
29: (Harms et al., 2015); Diabetic kidney disease: 30: (Soares et al., 2018); 31: (Anders, 2016); 
32: (Lei et al., 2019); 33: (Moriwaki et al., 2003); 34: (Nakamura et al., 2005); 35: (Wong et al., 
2007); Malaria (Plasmodium vivax): 36: (Santos et al., 2016); 37: (Singh et al., 2018); 38: 
(Schofield et al., 2017); Bacterial meningitis: 39: (Geldhoff et al., 2013); 40: (Petra J. G. 
Zwijnenburg et al., 2003); 41: (Petra J.G. Zwijnenburg et al., 2003) 
 
n/a: not available/not stated 
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Apart from autolytic cleavage in the FIIND domain, proteolytic degradation of the 
N-terminus was described to be involved in activating NLRP1 (Chui et al., 2019; 
Sandstrom et al., 2019). However, no PTMs like phosphorylation have been 
described to be involved in NLRP1 regulation. We investigated the role of a 
previously identified conserved tyrosine within the NLRP1 CARD, which is 
potentially phosphorylated (Boyle and Monie, 2016). NLRP1, in contrast to other 
NLRP proteins, interacts with the adaptor protein ASC via its CARD domain 
(Zhong et al., 2016). Thus, we hypothesized that the interaction of NLRP1 and 
ASC is regulated by phosphorylation of the NLRP1 CARD. Indeed, we found that 
substituting tyrosine 1413 for phenylalanine, glutamine or glutamate results in a 
complete loss of NLRP1 activity, as determined by ASC speck formation. This 
implies, that this residue has a crucial role for the interaction with ASC. 
Phosphorylation of amino acid side chains is well described to add two 
negative (net) charges to the protein surface. Interestingly, other negatively 
charged residues are found in this part of the CARD (E1397, D1401, E1414). 
Hence, an additional negative charge might increase the affinity to a positively 
charged interface of an interacting protein. More importantly, comparison of the 
phosphorylated and unphosphorylated structure revealed that phosphorylation 
also expanded the surface of the NLRP1 CARD. Phosphorylation of Y1413 was 
achieved by in silico modification of the available structure of NLRP1 CARD 
(PDB: 3KAT) using the Pytms plugin for PyMOL. Computational modelling of the 
Y1413E substitution further revealed that the negative charge of the glutamate 
cannot effectively mimic the phosphorylation of Y1413, since the side chain of 
glutamate is not large enough. This problem of mimicking tyrosine 
phosphorylation is also well documented in the literature (Anthis et al., 2009). 
The surface area of NLRP1 CARD harbouring the respective tyrosine residue 
has been discussed to form an interface for the interaction with procaspase-1 (Jin 
et al., 2013). A comparison of the Apaf-1/Procaspase-9 complex revealed similar 
interfaces, which could be involved in mediating the interaction (Jin et al., 2013). 
However, phosphorylation of Y1413 was not taken into account and the interface 
in this model was comprised of only three negative charges without 
phosphorylation. Additional negative charges in this surface might contribute to 
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the interaction with procaspase-1. Alternatively, phosphorylation might be 
involved in regulating specific binding of either NLRP1 CARD ASC or 
procaspase-1 directly. 
As mentioned previously, phosphorylation of conserved tyrosine residues in 
CARD domains has been reported to be essential for protein activity by mediating 
protein-protein interactions. For the human and murine version of the 
inflammasome adaptor protein ASC, phosphorylation of Y146 (Y144 in mice) was 
described to be crucial for speck formation (Hara et al., 2013; Chung et al., 2016). 
Furthermore, RIPK2 was reported to auto-phosphorylate tyrosine residues within 
its CARD, which was shown to be a crucial event for the interaction of RIPK2 with 
NOD2 (Tigno-Aranjuez et al., 2010). These findings support the hypothesis of 
NLRP1 activity being dependent on phosphorylation of Y1413. 
From an initial screening of protein tyrosine kinase inhibitors we identified 
Mubritinib (TAK165) as a potential inhibitor of NLRP1 activity in BMDMs when 
activated with Talabostat. Mubritinib specifically inhibits HER2, a member of the 
epidermal growth factor receptor family of receptor tyrosine kinases. HER2 was 
described to be involved in multiple regulatory pathways, such as the mitogen-
activated protein kinase (MAPK) pathway (Roy and Perez, 2009). Interestingly, 
NLRP1 expression was shown to be induced by activation of the MAPK pathway 
in neurons (Fann et al., 2018). However, the inhibiting effect of Mubritinib on 
NLRP1 activity could not be confirmed for human NLRP1 in ASC speck assays. 
Since the initial screening was performed in mouse macrophages and the 
following experiment was performed in a human cell line (HEK293T), it has to be 
considered that differences in these cells are the reason for the different results 
obtained. Moreover, HER2 might not be the proximal kinase responsible for 
phosphorylation of Y1413 in the NLRP1 CARD, or the Mubritinib could have off-
target effects. These alternate pathways could operate differently in the two 
systems used for studying the effect of Mubritinib. Finally, only IL-1b and not IL-
18 was used as a readout, since a stronger response in the IL-1b signal was 
expected. An ELISA looking at IL-18 levels might reveal additional compounds 
that act on the NLRP1 activation pathway. 
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Altogether, the data presented herein demonstrate that different molecular 
mechanisms play a role in regulating NLRP1 inflammasome activity. As shown 
by utilising the M1184V polymorphism, regulation of autolytic cleavage is a major 
determinant of NLRP1 activity depending on the activating stimulus. Further, a 
potential phosphorylation site in NLRP1 CARD was described to be essential for 
the interaction with the inflammasome adaptor ASC. For now, phosphorylation of 
this residue remains to be confirmed. However, if confirmed, identification of the 
kinase responsible for phosphorylation might pose a new target for the treatment 
of NLRP1-associated autoinflammatory disease. The same holds for the 
identification and characterisation of other PTMs involved in regulating NLRP1 
activity. 
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6. Overall Discussion 
 
6.1 Key findings 
 
NLRP1 is well-known to form an inflammasome and to potently induce an 
inflammatory immune response by activating caspase-1, ultimately leading to the 
release of mature IL-1b/IL-18 and pyroptosis. It is often highlighted as the first 
inflammasome forming NLR described in the literature (Martinon et al., 2002). As 
sensor component of the NLRP1 inflammasome, NLRP1 is described to respond 
to different pathogenic and non-pathogenic stimuli, like Toxoplasma gondii 
infection or inhibition of the negative regulator DPP9, respectively (Ewald et al., 
2014; Gorfu et al., 2014; Okondo et al., 2018; Zhong et al., 2018). Several 
missense mutations were found to cause autoinflammatory diseases in patients 
presenting with different skin and systemic inflammatory symptoms. Identification 
and functional characterization of these mutations improved the understanding of 
the physiological role of NLRP1 and the molecular mechanisms regulating the 
activity of this inflammasome (Zhong et al., 2016; Grandemange et al., 2017). 
Functional degradation of the N-terminal cleavage fragment was recently 
identified as the molecular basis of different activating stimuli for mouse NLRP1b 
and could pose a unified mechanism for NLRP1 activation (Chui et al., 2019; 
Sandstrom et al., 2019). 
Despite these advances in the understanding of NLRP1 biology, many 
questions regarding the molecular mechanisms regulating the activity of the 
NLRP1 inflammasome as well as its physiological role remain unclear. Work 
presented in this thesis therefore aimed at advancing the understanding of the 
molecular basis of molecular mechanisms regulating NLRP1 activity. To clarify 
how NLRP1 is maintained in an autoinhibited conformation, recombinant protein 
was produced and analysed biochemically and structurally. Results of the 
biochemical analysis of separate domains of NLRP1 revealed that the PYD and 
LRR domains do not contribute to autoinhibition by direct intramolecular 
interaction. NLRP1 PYD also showed no significant interaction with recombinant 
MBP fusion proteins containing the NACHT, FIIND or CARD domains. 
 Overall Discussion 
169 
Furthermore, recombinant full-length NLRP1 fused to MBP was shown to form 
oligomers in solution. SAXS analysis of the NLRP1 oligomer further allowed for 
the calculation of a low resolution molecular envelope of the oligomer. The 
oligomeric state was estimated to be hexameric, based on a particle volume 
approximation. 
Moreover, the requirement of ATP as a cofactor for NLRP1 activity was 
explored by biochemical and functional means. Using an RP-HPLC based 
approach, the herein presented results demonstrated for the first time that 
recombinant NLRP1 exhibits ATP hydrolysis activity. Conserved motifs involved 
in nucleotide binding and hydrolysis previously described for NLRs were 
identified for NLRP1 by computational sequence and structure analysis. The 
identified residues were mutated to investigate how ATP hydrolysis regulates 
NLRP1 activity. An in vitro overexpression assay utilising ASC speck formation 
as a measure for NLRP1 activation unveiled a potential involvement in 
autoinhibitory mechanisms for ATP hydrolysis. 
Apart from the role of ATP as a cofactor for NLRP1 activity, the involvement of 
direct modifications of the NLRP1 protein was examined as well. Differential 
FIIND domain cleavage and its effect on NLRP1 activity was investigated by 
applying the common NLRP1 polymorphism M1184V in functional assays. 
Differential FIIND domain cleavage was thereby shown to either increase or 
decrease inflammasome activation, depending on the activating stimulus. 
Destabilising the N-terminus by introducing a patient mutation in the PYD of 
NLRP1 synergised with increased FIIND domain cleavage in regards to 
inflammasome activation. In contrast, increased cleavage led to retarded NLRP1 
activation when stimulated by inhibition of DPP9. 
A potential phosphorylation of a conserved tyrosine motif within the NLRP1 
CARD domain was identified as another mechanism regulating NLRP1 activity 
by direct modification of the protein. Substitution of the respective tyrosine 
residue completely abrogated NLRP1 activation in the ASC speck assay. 
  
 Overall Discussion 
170 
6.2 Physiological implications of NLRP1 self-assembly 
 
Structural information on inflammasome sensor proteins has greatly improved 
the understanding of regulatory mechanisms underlying the activation of the 
respective inflammasome (Diebolder et al., 2015; Zhang et al., 2015; Maekawa 
et al., 2016; Tenthorey et al., 2017; Sharif et al., 2019). So far, only separate 
domains of NLRP1 have been structurally characterised including the calculation 
of high resolution structures of the PYD (Solution NMR), LRR and CARD (both 
X-ray crystallography) domains, and a low resolution SAXS-derived envelope for 
a NACHT-LRR construct (Hiller et al., 2003; Jin et al., 2013; Reubold et al., 2014; 
Martino et al., 2016). However, this data does not give any insight into the overall 
fold of the NLRP1 protein. 
The SAXS data presented in this work suggests that the full-length MBP-
NLRP1 protein self assembles into a hexamer. The majority of purified 
recombinant MBP-NLRP1 protein sample contained the uncleaved full-length 
protein, as shown by SDS-PAGE. Thus, the protein particle analysed by SAXS is 
likely to contain uncleaved MBP-NLRP1 as well. Cleavage in the FIIND domain 
has been described to be essential for NLRP1 activation (Finger et al., 2012). 
This result was also confirmed in the ASC speck assays with the uncleavable 
NLRP1 variant S1213A presented in Chapter 5. Therefore, the protein in the 
oligomer analysed by SAXS was most likely inactive. Consequently, it can be 
concluded that the full-length MBP-NLRP1 oligomer represents the inactive form 
of NLRP1. Oligomeric conformations in both the inactive and active state have 
been described for different members of the AAA+ ATPase superfamily, like 
NtrC1 and p97 (Chen et al., 2010; Hänzelmann and Schindelin, 2016). Moreover, 
all NLRs are described to form functional oligomers upon activation (Danot et al., 
2009; Maharana et al., 2018). Structures of the active NLRC4 inflammasome 
provided direct evidence for this model (Diebolder et al., 2015; Zhang et al., 2015; 
Tenthorey et al., 2017). However there is no experimental evidence for NLRs 
forming oligomers in their inactive state. 
In the above described model, FIIND domain cleavage would occur in the 
oligomer for two reasons. First, the protein particle characterized in SAXS 
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contained the full-length protein. Second, the cleavage within the FIIND domain 
is not sufficient for activation of NLRP1, meaning that the protein remains 
autoinhibited even after the autoproteolysis event in the FIIND domain. 
Interaction of the N- and C-terminal cleavage fragments has been reported for 
NLRP1 (Finger et al., 2012). In the case of an oligomeric conformation in the 
autoinhibited state, the N- and C-terminal cleavage fragments of NLRP1 could 
be retained in the oligomer by intermolecular interactions. Additionally, the 
negative regulator DPP9 could be involved in maintaining an oligomeric 
conformation. Regulation of protein activity by autoproteolytic cleavage has been 
reported for other proteins, like the nuclear pore protein Nup98 (nucleoporin 98) 
and the apoptosis inducing protein PIDD (p53-induced protein with a death 
domain) (Hodel et al., 2002; Hänzelmann and Schindelin, 2016). PIDD has 
further been described to form oligomers upon activation to form a signalling 
platform termed the PIDDosome (Park, Logette, et al., 2007). However, there is 
no evidence that autoproteolysis occurs in the oligomeric state of PIDD. In 
contrast, the C-terminal PIDD death domain was shown to form an oligomer 
together with the death domain of the adapter protein RAIDD, without the need 
for N-terminal domains, including two ZU-5 domains and an LRR domain (Park, 
Logette, et al., 2007). In the context of NLRP1, this would argue more for the 
ability of the C-terminal cleavage fragment to oligomerize together with ASC 
without need for the NACHT or any other domain of the N-terminal fragment. 
However, this does not completely exclude the possibility of an oligomeric 
conformation in the autoinhibited state. It should be mentioned that the above 
described model is only a speculation about the potential physiological role of the 
MBP-NLRP1 oligomer characterized in Chapter 3.2. 
 
6.3 The role of ATP hydrolysis in NLRP1 oligomerisation 
 
Different members of the family of STAND proteins, like Apaf-1 or MalT, have 
also been reported to form functional oligomers upon activation. Both proteins 
were described to require a ligand and ATP as a cofactor for activation and 
oligomer formation (Larquet et al., 2004; Zhou et al., 2015). While Apaf-1 requires 
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ATP hydrolysis for binding of its ligand Cytochrome C and subsequent 
oligomerisation, MalT only binds ATP together with its ligand maltotriose to 
oligomerise. MalT does not require hydrolysis of ATP for oligomerisation 
(Yuanming et al., 1999; Larquet et al., 2004). For NLRP1 no activating ligand, as 
Cytochrome C for Apaf-1 or maltotriose for MalT, is known. An overarching 
hypothesis for NLRs is that ATP binding and hydrolysis is involved in mediating 
conformational changes that allow oligomer formation (Danot et al., 2009; 
Maharana et al., 2018). 
The herein presented data showed that NLRP1 has ATP hydrolysis activity. 
Substitution of residues located in the conserved ATP binding and hydrolysis site 
of NLRP1 resulted in constitutive activation, indicating that ATP hydrolysis might 
have autoinhibitory functions in the regulation of NLRP1. This is consistent with 
the constitutively active Walker B mutants found for NLRP3 and the plant R 
protein I-2 (Tameling et al., 2006; Coll et al., 2019; Tapia-Abellán et al., 2019). 
ATP hydrolysis might thus be required to adapt the oligomeric autoinhibited 
conformation (Chapter 6.2) upon translation of the NLRP1 protein. For NLRP1, 
the oligomeric conformation could provide protection from N-terminal 
degradation, which would result in activation of the NLRP1 inflammasome. It 
would further pose a possible explanation for how the PYD and LRR contribute 
to maintaining NLRP1 in an autoinhibited conformation - they are involved in 
oligomer formation. Although no homotypic interactions were found for both 
domains, they could still support the oligomeric state by binding to another 
domain or a linker region between domains. 
Assuming that NLRP1 does require ATP hydrolysis for oligomer formation and 
to adapt an inhibited conformation, impairing ATP hydrolysis by substituting 
residues involved in nucleotide binding or hydrolysis would consequently inhibit 
oligomer formation and result in constitutive activation of NLRP1. Monomeric 
NLRP1 could be more prone to N-terminal degradation, resulting in the liberation 
of the C-terminal cleavage fragment and formation of the NLRP1 inflammasome. 
The C-terminal fragment of NLRP1 has been described to be sufficient to form 
an active inflammasome (Zhong et al., 2016). An autoinhibitory or at least 
regulatory function of the NACHT domain and the nucleotide binding site within 
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this domain is further indicated by the N-terminal degradation model of activation. 
This model implies that all domains located N-terminal of the FIIND cleavage site, 
including the NACHT domain, are dispensable for inflammasome activity. In turn, 
this would also mean that ATP hydrolysis is not required for the activity of NLRP1, 
as previously concluded in the literature (Chavarría-Smith et al., 2016). 
 
6.4 The mechanisms and role of PTMs and DPP9 in NLRP1 regulation 
 
As discussed previously (Chapter 5.3), PTMs are directly involved in regulating 
NLRP1 activity. Oligomer formation of NLRP1 in an autoinhibited state as 
discussed above could serve as an explanation for the differential effects 
observed in experiments with the M1184V variant of NLRP1. Cleavage within the 
oligomeric form of NLRP1 would likely induce conformational changes in the 
oligomer. These could expose the PYD and thus make it more susceptible to 
interaction with a protein able to induce N-terminal degradation, ultimately 
resulting in activation of NLRP1. In contrast to predisposition to N-terminal 
degradation, DPP9 binding and its function could become redundant in this 
conformation. Consequently, more cleavage would lead to increased activation 
of NLRP1 by N-terminal destabilisation (A66V). However, loss of DPP9 binding 
(Talabostat, P1214R) would not result in activation, since the oligomer would 
remain autoinhibited even without DPP9 directly bound. 
Conformational changes induced by FIIND cleavage could also occur in the 
case of NLRP1 being monomeric in its autoinhibited state. Thus, the differential 
effects of increased FIIND domain cleavage induced by the variant M1184V could 
be explained by an autoinhibitory interaction between the PYD and the cleaved 
FIIND domain. A similar mechanism of the PYD folding back onto another domain 
to mediate an inhibitory conformation has been proposed previously (Zhong et 
al., 2016). However, intramolecular binding of the PYD was never discussed in 
the context of FIIND domain cleavage. Disturbing the fold of the PYD, as induced 
by the A66V disease mutation, would abrogate the interaction with the FIIND 
domain. Thus, increased cleavage would induce increased binding between the 
two domains in the WT protein. For the A66V variant however, increased 
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cleavage would consequently result in increased cleavage, since the PYD cannot 
mediate autoinhibition through FIIND domain interaction. An interaction was not 
observed in experiments with recombinant protein of the PYD and MBP-FIIND 
domains. As discussed earlier, this does not exclude the possibility of an 
interaction between these two domains. Particularly since the MBP-tag could 
block interaction surfaces as shown for the MBP-CARD protein and a CARD-
specific nanobody. Furthermore, the MBP-FIIND fusion did not appear as two 
cleavage products in SDS-PAGE analysis. 
Considering the role of DPP9, the evaluation of the role of PTMs in regulating 
NLRP1 activity becomes more complex. It is possible that DPP9 directly modifies 
NLRP1 by cleaving a dipeptide off the N-terminus of the C-terminal cleavage 
fragment. Thereby it could regulate protein turnover of this fragment and 
consequently NLRP1 activity. A similar model has been discussed previously in 
the literature (Zhong et al., 2018). It poses a logical explanation for the molecular 
mechanism underlying hyperactivation of the NLRP1 disease mutation P1214R. 
In the context of an interaction of the PYD and FIIND domains, DPP9 could 
regulate turnover of the C-terminal cleavage fragment upon release of the C-
terminal fragment from the N-terminal fragment. Since DPP9 cleavage requires 
a proline or an alanine residue in position 2, the P1214R disease variant could 
not be recognized by DPP9 and would thus accumulate and induce 
inflammasome formation. This is consistent with the finding that the activity of the 
A66V disease variant can be further increased by DPP9 inhibition. The contrary 
is the case for the P1214R mutation. However, a substrate screening of 
peptidases showed that DPP8/9 does not directly cleave mouse NLRP1b 
(Griswold et al., 2019). As for the others models described above, the reason for 
the differential effects seen for increased FIIND cleavage on NLRP1 activity 
induced by diverse activating stimuli remains a matter of speculation. 
As described above, NLRP1b was not found to be a direct target of DPP9. This 
suggests that this peptidase is indirectly involved in regulating NLRP1 activity. A 
possible way of indirectly regulating NLRP1 could be the regulation of 
phosphorylation of the NLRP1 CARD domain. DPP9 has been reported to directly 
cleave off a dipeptide of the N-terminus of spleen tyrosine kinase (SYK) and 
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thereby regulate the protein turnover of SYK. Cleavage of SYK at its N-terminus 
directs it to the N-terminal degradation pathway (Justa-Schuch et al., 2016). 
Assuming DPP9 has a similar function in regulating protein turnover of the kinase 
phosphorylating Y1413 in the NLRP1 CARD domain, inhibition of DPP9 would 
increase the level of intracellular kinase and likely result in increased 
phosphorylation of NLRP1 CARD. This way, phosphorylation could be a control 
mechanism regulating NLRP1 activity. However, this would be in conflict with 
DPP9 being required to directly bind to NLRP1 to maintain NLRP1 autoinhibition 
(Zhong et al., 2018). 
Taken together, FIIND domain cleavage, DPP9 binding and CARD 
phosphorylation all regulate NLRP1 activity. However, the exact mechanisms and 
the order in which they occur remain elusive. In the context of an autoinhibited 
NLRP1 oligomer all three regulatory events would likely occur post self-assembly 
of the protein. In contrast, for a monomeric autoinhibited NLRP1, DPP9 binding 
and FIIND domain cleavage would precede oligomerisation of the C-terminal 
cleavage fragment. Phosphorylation could serve as a check-point mechanism 
independent of self-assembly and could thus occur before and after 
oligomerisation. 
The different mechanisms regulating NLRP1 activity arising from the results 
presented in this work will be summarised in Chapter 6.5 together with existing 
models of NLRP1 activation. 
 
6.5 Model of NLRP1 activation 
 
The current model of inflammasome activation includes two steps. In a first 
priming step, expression of the inflammasome sensor molecules is induced 
through NF-kB upon activation by TLR signalling (Bauernfeind et al., 2010; 
Schroder and Tschopp, 2010; Walsh et al., 2014). The second step is the direct 
activation of the inflammasome sensor protein, for example the binding of 
bacterial flagellin to NAIP5 (Tenthorey et al., 2017). 
Although multiple pathogens and disease mutations are described to activate 
NLRP1, no direct ligand has been reported. This makes the investigation of the 
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sequence in which molecular events required for NLRP1 activity occur difficult. 
However, taking recent advances in the understanding of NLRP1 activation into 
account, I will try to summarise and order the molecular mechanisms underlying 
NLRP1 regulation and activation. A graphical summary can be found in Figure 
6.1. 
A first step after transcription and translation would be the adaptation of an 
autoinhibited conformation. To this end, NLRP1 could oligomerize in an ATP 
hydrolysis dependent manner. Subsequently, autolytic cleavage and DPP9 
binding would occur successively or simultaneously. DPP9 binding is unlikely to 
precede autolytic cleavage, since uncleavable variants of NLRP1 were shown to 
be unable to bind DPP9 (Zhong et al., 2018). Activation of NLRP1 by inhibition of 
DPP9 or a destabilized N-terminus result in impaired oligomer formation and 
consequently activation of the NLRP1 inflammasome by degradation of the N-
terminal cleavage fragment. Finally, tyrosine 1413 in the NLRP1 CARD domain 
is phosphorylated to allow interaction with ASC and full activation of the NLRP1 
inflammasome. 
The inhibitory role of nucleotide binding and hydrolysis could also be to 
facilitate conformational changes or the stabilization of a monomeric NLRP1 in 
its autoinhibited conformation. The sequence of events in this monomeric model 
would be similar to the above described model of an oligomeric inhibited 
conformation. An exception would be that oligomerisation occurs after activation, 
N-terminal degradation and release of the C-terminal fragment of NLRP1. 
These models and the sequence of events are still speculative. For instance, 
phosphorylation could also occur earlier in the sequence and the interaction 
surface for the CARD could simply be blocked sterically. More research is 
required to completely reveal the molecular mechanisms regulating NLRP1 
activity and the order in which they occur.  
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Figure 6.1: Sequence of molecular events required for NLRP1 activation 
(1) Upon transcription and translation NLRP1 adapts an inhibited conformation in 
an ATP hydrolysis dependent manner. The inhibited conformation might be 
oligomeric or monomeric, but definitely requires the N-terminus of NLRP1. (2) 
After adapting its correct conformation, the cleavage event in the FIIND domain 
occurs. This allows the negative regulator DPP9 to bind to the inhibited NLRP1 
protein. (3) Activation of NLRP1 by different mechanisms exposes the N-terminus 
for degradation. This results in liberation of the C-terminal fragment, (4) which 
can be phosphorylated. (5) The phosphorylated oligomeric C-terminus provides 
a platform for the recruitment of ASC and procaspase-1 to form an active 
inflammasome. 
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6.3 Future directions 
 
As mentioned in previous chapters, many of the conclusions described above are 
speculative. To further improve the understanding of how NLRP1 is regulated, 
generation of a high resolution structure of the MBP-NLRP1 oligomer would 
provide valuable information. Cryo-EM is probably the most feasible approach to 
obtain that information. Since it was not possible to keep the full-length NLRP1 
protein in solution at high concentrations, X-ray crystallography analysis is 
restricted to separate domains of NLRP1. Additionally, a screening of other 
expression and solubility tags could improve the stability of the protein, to make 
structural analysis more achievable. Expressing full-length NLRP1 only with a 
His6-tag resulted in an extremely low protein yield, emphasizing the requirement 
for a tag that improves expression of the protein. Alternatively, a change of the 
expression system might improve solubility of the protein. Insect cells are able to 
perform posttranslational modifications like phosphorylation and glycosylation. 
However, the respective pattern is usually different between mammalian cells 
and insect cells (Owczarek et al., 2019). Thus, a mammalian cell line would be 
more likely to modify human NLRP1 in a native way, ensuring biological activity 
of the recombinant protein. 
A high resolution structure could also provide insight into the nucleotide 
binding site of NLRP1 and confirm the residues important for ATP binding and 
hydrolysis identified in this work. Additional hydrolysis assays could further 
confirm the involvement of these residues in ATP hydrolysis. 
Moreover, testing the nucleotide binding site variants of NLRP1 in a different 
assay measuring inflammasome activation at the level of IL-1b and IL-18 
secretion as well as cell deaths is required to support the findings from the ASC 
speck assay. The THP-1 monocyte cell line proved to be unsuitable, since no 
specific activation of NLRP1 was achieved in viral transduction experiments (not 
shown) as well as in a CRISPR-Cas9 based approach (Chapter 4.3.6). 
Immortalized keratinocytes have been shown to be a suitable system for the 
investigation of NLRP1 biology (Zhong et al., 2016; Zhong et al., 2018). Basic 
transfection experiments could already reveal, if the effects seen in the ASC 
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speck assay can be reproduced in a different system in regards to IL-1b and IL-
18 secretion as well as cell death. However, the ELISA kit used to detect IL-18 in 
this work can potentially detect unprocessed (inactive) IL-18. Thus, a western blot 
analysis of cell culture supernatants looking at total and cleaved IL-18 should be 
considered to additionally support the findings from ELISA experiments. The kit 
used to detect IL-1b has a high specificity for the processed (active) protein. An 
additional analysis by western blot would still be beneficial, as it could support 
the findings found in the ELISA analysis. 
A system employing release of cleaved IL-1b and IL-18 as a measure for 
inflammasome activation could also be useful to support the results described on 
the effects of differential FIIND domain cleavage. As for the nucleotide binding 
site variants, immortalized keratinocytes might be a suitable system to test this. 
Additionally, other activating stimuli could be tested, like UV-B irradiation or 
depletion of intracellular ATP, to further explore the effects of differential FIIND 
cleavage on NLRP1 inflammasome activation. Infection with different strains of 
Toxoplasma gondii was attempted to be employed as an activating stimulus in 
the ASC speck assay. However, no specific activation of NLRP1 could be 
observed in these experiments (not shown). Again, using a different cell line or 
an alternative readout for inflammasome activation might resolve this problem. 
To confirm phosphorylation of Y1413 in the NLRP1 CARD, different 
approaches could be taken. Transiently expressed protein could be purified by 
immunoprecipitation and subsequently analysed by SDS-PAGE and mass 
spectrometry. Alternatively, the protein could be analysed by immunoblotting 
using a phospho-tyrosine antibody. NLRP1 WT and Y1413F could be compared 
in the immunoblot-based approach, to specifically show Y1413 phosphorylation. 
If phosphorylation of this residue can be confirmed, identification of the kinase 
would be the next step. However, this would be more difficult to achieve. The 
inhibitor screen described in Chapter 5.3 did not reveal a kinase. A problem of 
this approach is of course, that inhibition of a kinase will inevitably result in the 
alteration of multiple pathways, since kinases usually have more than one target. 
Thus, a screening of tyrosine kinase inhibitors would always require follow-up 
experiments to confirm direct phosphorylation of NLRP1 by the identified kinase. 
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This could for example be achieved using recombinant protein and radiolabelled 
ATP in an in vitro kinase assay (Hastie et al., 2006). Assuming that CARD 
phosphorylation proves to be essential for NLRP1 activity, identification of the 
respective kinase might pose a possible target for the treatment of NLRP1-
associated autoinflammatory diseases. 
 
Research on NLRP1 is still emerging and becoming more and more of a focus 
in inflammasome biology. Together with recently published studies, the data 
presented herein highlight the complexity of NLRP1 biology and challenges 
arising when investigating regulatory mechanisms underlying NLRP1 activity. 
Collectively, the results of this work contribute to improving our current 
understanding of molecular mechanisms governing the regulation of the NLRP1 
inflammasome. 
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Figure A1: Sequence alignment of PYDs of all NLRPs and ASC 
Sequence alignment of the first 120 amino acids of all human NLRP proteins as 
well as human ASC. Only part of the sequence alignment is shown, to highlight 
the presence of a proline only in NLRP1 within the sequence expected to form -
helix 3 in the PYD. The alignment was preformed using the Clustal Omega 
sequence alignment tool (Madeira et al., 2019). Amino acid sequences were 
obtained from the UniProt database. The sequence described as canonical 
isoform 1 of all proteins was used in the alignment. 
  
NLRP8   ----ENGVMLYMRNVSHEELQRFKQLLLTEL--------STGTMPITWDQVETASWAEVV 85 
NLRP2   M---GFNLQALLEQLSQDELSKFKYLITTFSL-------AHELQKIPHKEVDKADGKQLV 56 
NLRP7   L---EWTLQTLLEQLNEDELKSFKSLLWAFPL-------EDVLQKTPWSEVEEADGKKLA 55 
NLRP5   LTFSSYGLQWCLYELDKEEFQTFKELLKKKSS-------ESTTCSIPQFEIENANVECLA 110 
NLRP3   -ASTRCKLARYLEDLEDVDLKKFKMHLEDYPP-------QKGCIPLPRGQTEKADHVDLA 55 
NLRP10  ARKPREALLWALSDLEENDFKKLKFYLRDMTL-------SEGQPPLARGELEGLIPVDLA 58 
ASC     MGRARDAILDALENLTAEELKKFKLKLLSVPL-------REGYGRIPRGALLSMDALDLT 53 
NLRP13  ----NQGLLPYLMALDQYQLEEFKLCLEPQQLMDFWSAPQGHFPRIPWANLRAADPLNLS 69 
NLRP6   LAVARELLLAALEELSQEQLKRFRHKLRDV---------GPDGRSIPWGRLERADAVDLA 65 
NLRP1   -AWG--RLACYLEFLKKEELKEFQLLLANKAH-------SRSSSGETPAQPEKTSGMEVA 54 
NLRP12  -RDGLCRLSTYLEELEAVELKKFKLYLGTAT--------ELGEGKIPWGSMEKAGPLEMA 57 
NLRP11  -DSTDFDLLWYLENLSDKEFQSFKKYLARKIL-------DFKLPQFPLIQ---MTKEELA 53 
NLRP14  -FFPDFGLLLYLEELNKEELNTFKLFLKETM--------EPEHGLTPWNEVKKARREDLA 59 
NLRP4   -FFSDFGLMWYLEELKKEEFRKFKEHLKQMTL-------QLELKQIPWTEVKKASREELA 56 
NLRP9   -FFSDFGLLWYLKELRKEEFWKFKELLKQPLE-------KFELKPIPWAELKKASKEDVA 56 
               :   :  :   ::  ::  :                               :  
𝛼3 
 Appendix 
228 
 
Figure A2: Mass spectrometry analysis of MBP-NLRP1 
Peptide coverage as determined by mass spectrometry of band 1 (A) band 2 (B) 
and band 3 (C) observed from SDS-PAGE analysis of MBP-NLRP1 Peak 2 
(Figure 3.7). The Log2 intensity measured for the different peptides is plotted on 
the y-axis. The x-axis represents the primary sequence of the MBP-NLRP1 
protein, which is comprised of 1851 amino acids. MS analysis was performed at 
the WEHI mass spectrometry facility. 
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Figure A3: Representative FACS plots of ASC speck assay (Fig 4.6) 
Shown are dot plots of each variant tested in the respective ASC speck assay 
displayed in Figure 4.6. A and B correspond with panel A and B in Figure 4.6. 
The width of the RFP signal (YG585-15) is plotted over the area of the RFP 
signal. 
  
A 
EV WT K340A S341A 
E414Q R459A H623A K340A/H623A 
B 
EV WT K340A S341A 
E414Q R459A H623A K340A/H623A 
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Figure A4: Effect of Talabostat on NLRP1 A66V and P1214R variants 
The supernatant of the cells described in A was analysed for the proinflammatory 
cytokine IL-1b by ELISA. Data is pooled from two experiments and displayed as 
mean ± SEM. 
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Figure A5: Uncropped blots (Fig. 4.8) 
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A EV WT A66V 
M1184V A66V/M1184V 
B EV WT A66V 
M1184V A66V/M1184V 
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Figure A6: Representative FACS plots of ASC speck assay (Fig 5.2) 
Shown are dot plots of each variant tested in the respective ASC speck assay 
displayed in Figure 5.2. A and B correspond with panel A and B in Figure 4.6. 
The width of the RFP signal (YG585-15) is plotted over the area of the RFP 
signal. 
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Figure A7: Representative FACS plots of ASC speck assay (Fig 5.3) 
Shown are dot plots of each variant tested in the respective ASC speck assay 
displayed in Figure 5.3. A and B correspond with panel A and B in Figure 5.3. 
The width of the RFP signal (YG585-15) is plotted over the area of the RFP 
signal. 
  
A 
EV (Tal) WT (Tal) M1184V (Tal) S1213A (Tal) 
B 
EV (Tal) WT (Tal) M1184V (Tal) S1213A (Tal) 
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Figure A8: Effect of Talabostat on NLRP1 A66V and P1214R variants 
HEK293T cells stably expressing ASC-RFP were transfected with WT or mutant 
NLRP1 or a vector control (EV) and analysed for ASC formation 24 h (A) and 42 
h (B) post transfection by flow cytometry. Cells were treated with 2 µM Talabostat 
18 h post transfection. Samples were recorded in triplicates. Data was analysed 
in FlowJo and graphed in Prism. Data shown is a representative of two individual 
experiments and is graphed as mean ± SEM. 
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Figure A9: Representative FACS plots of ASC speck assay (Fig 5.5) 
Shown are dot plots of each variant tested in the respective ASC speck assay 
displayed in Figure 5.5. A and B correspond with panel A and B in Figure 5.5. 
The width of the RFP signal (YG585-15) is plotted over the area of the RFP 
signal. 
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Figure A10: Uncropped blots (Fig. 5.5) 
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Figure A11: Representative FACS plots of ASC speck assay (Fig. 5.7) 
Shown are dot plots of each variant tested in the respective ASC speck assay 
displayed in Figure 5.7. A and B correspond with panel A and B in Figure 5.7. 
The width of the RFP signal (YG585-15) is plotted over the area of the RFP 
signal. 
DMSO TAK Ctrl Tal Ctrl TAK (2.5 µM) 
TAK (1 µM) TAK (0.5 µM) TAK (0.25 µM) TAK (0.01 µM) 
